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Abstract 
 
Langerhans Cell Histiocytosis (LCH) is a rare disease of the immune system which, in 
children, is treated mainly by oncologists. It has several forms ranging from 
spontaneously regressing localised bony disease to life-threatening multi-organ failure. 
Mortality is low but children may be left with long-term sequelae. LCH is inconsistently 
registered by cancer registries and although the Children‟s Cancer and Leukaemia 
Group (CCLG) records cases, its incidence in the UK and Republic of Ireland was 
previously unknown, prompting this national survey to describe the epidemiology of 
LCH in children. 
 
Three sources of case ascertainment were used: the British Paediatric Surveillance Unit, 
a Newcastle-based postal survey of other clinicians, and the CCLG.  National deaths 
data were also obtained. Questionnaires were sent to reporting clinicians to obtain 
further information and to follow up cases one and two years after diagnosis. The 
completeness of ascertainment was estimated by capture-recapture methods; the 
spectrum of disease was described; possible associations, event-free survival and 
mortality were assessed.  
 
Each source uniquely ascertained cases and completeness was estimated at 93%. 94 
children were identified giving an incidence rate, comparable with other European 
reports, of 4.1 per million per year (aged 0-14 years). 67% of cases had SS bone disease 
and 26% had multi-system disease. More cases than expected were diagnosed in spring 
(p=0.04) and there was a higher than expected proportion of mixed/other ethnicity 
children than in the general population (p=0.027). At the end of the study, 91% had no 
active disease and 18% had sequelae. Mortality was 3.2%. 
 
This is the first national study to use a well-established prospective method of case 
identification.  The importance of multiple sources of ascertainment was demonstrated.  
Although the data and number of cases were limited, the results above, and other 
observations, indicate the need for further follow up and larger studies. 
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Chapter 1. Introduction 
 
1.1 Why study Langerhans cell histiocytosis? 
Langerhans cell histiocytosis (LCH) is a rare disorder of the immune system that has 
multiple patterns of presentation ranging from spontaneously regressing lesions to a 
multi-system form with organ failure. The cause of the disease is unknown. Although 
there have been a few international and regional studies of geographically defined 
populations, most publications on LCH have been of case reports or studies of hospital 
series and the epidemiology of LCH is under-researched [1-3].  Clinical studies of LCH 
in children had been carried out for many years in the UK and Republic of Ireland but 
the incidence of the disease was not known.  As well as describing occurrence, an 
observational epidemiological study is the first step in countering the lack of 
information about a disease, and it may explain the pattern of the disease by identifying 
possible aetiological factors. The rarity of disorders such as LCH makes them difficult 
to study and identification of cases from a large population is required to give a 
sufficient number of cases to obtain meaningful data.  A national study was therefore 
initiated and an epidemiological survey of LCH in children in the UK and Republic of 
Ireland began in 2003.  The aims of the study, which are described further in section 1.8, 
were to establish the incidence of LCH over two years, describe the spectrum of disease 
and assess the outcome.  
 
The approach taken to carry out the study was informed by the nature of the disease 
itself  its various forms, the clinicians who treat it, how it is classified, diagnosed and 
registered and the possible methods of ascertaining cases in the UK. These are described 
in the remainder of this chapter.   The rationale and objectives of the study are stated 
and an outline of this thesis is presented.  A more detailed description of the disease, 
including its symptoms and characteristics and treatment and outcome, are given in 
Chapter 2 with a review of epidemiological studies. 
 
1.2  Langerhans cells and LCH  
Langerhans cells were first described by Paul Langerhans in 1868 as neuronal cells but 
it was not until the 1970s that they were demonstrated to form part of the immune 
2 
 
 
system [4].  They are dendritic cells, originating in the bone marrow, and are normally 
found in the skin, lymph nodes and main airways [5, 6]. They present various antigens 
and are involved in stimulating the immune response.  LCH cells appear to be an 
immature form of Langerhans cells with a more rounded shape (figure 1.1) [7]. LCH is 
commonly found in skin, bone and the pituitary gland, and may also affect the lungs, 
intestines, liver, spleen, bone marrow, lymph and brain – in tissues where Langerhans 
cells are not normally found. The features of disease are accumulation and proliferation 
of LCH and other immune cells and overproduction of cytokines, causing tissue damage 
and inflammation resulting in fibrosis and scarring [7, 8]. Identification of the LCH cell 
is important in diagnosing the disease (see section 1.4 below).  It is not known how the 
various organs described above can be affected by LCH when Langerhans cells are 
normally restricted to the epithelium. However, there has been a recent suggestion, 
based on animal studies, that LCH cells and Langerhans cells may develop from 
different subsets of mesenchymal cells, the subset giving rise to LCH being present in 
most tissues affected by the disease [9]. 
 
Although LCH is a disorder of the immune system, it is treated mainly by paediatric 
oncologists and haematologists. However, since a variety of organs may be affected, a 
child may present with a wide range of symptoms and referral may be either to a general 
paediatrician or one or more of a number of specialists.  There is world-wide 
collaboration in the treatment of LCH because of its rarity, heterogeneous forms and 
response to treatment, and international protocols have been established for many years. 
Treatments range from observation through localised surgery to chemotherapy and 
immunotherapy. 
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(b) 
Figure 1.1 Langerhans cell and LCH cells (from Laman et al [7]) 
 
 
 
 
Figure 1.2 Birbeck granules within Langerhans cells [10] 
 
 
      
      
  
LCH skin stained for CD1a, showing (a) normal Langerhans cells with 
dendritic morphology in epithelium, and (b) an accumulation of rounded LCH 
cells.  
 
Electron microscopy (a) and schematic (b) showing Birbeck granules with 
characteristic tennis-racket shape which may appear rod-shaped in certain planes.  
 
(a) 
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1.3 Types and classification of LCH 
The disease has several different forms ranging from spontaneously healing bone 
lesions to a progressive multi-system disorder which may be fatal [2, 11].  In the late 
19
th
 and early 20
th
 century clinicians in the US and Europe noted similarities in cases 
leading to the recognition and naming of the condition and its different forms as shown 
below.   
 
 eosinophilic granuloma (bone)  
 Hand-Schuller-Christian disease (multifocal bone, diabetes insipidus, proptosis) 
 Letterer-Siwe disease (disseminated) 
 
The history of LCH has been described in detail by Coppes-Zantinga and Egeler [12].  
In the 1950s the term Histiocytosis X was introduced to include the different forms of 
LCH based on common pathology – all types having Birbeck granules which are found 
in Langerhans cells (figure 1.2). The disease is also known as infantile acute 
reticuloendotheliosis, Hashimoto–Pritzker disease (a self-healing skin variant) and 
Langerhans cell granulomatosis. The various forms are not exclusive and may overlap 
with progression between types. However, since all variants of LCH have Langerhans-
like cells in common, the Histiocyte Society proposed the term Langerhans cell 
histiocytosis and it has been in use since 1985 [13].  LCH is the most common of a 
group of histiocytic disorders. They were classified by the Histiocyte Society and 
revised by Favara et al in 1997 [14, 15]. The classification is given in table 1.1 showing 
their relationship to malignancies. 
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Table 1.1 Classification of histiocytic disorders (adapted from Favara et al 
[14, 15])  
 
 
Langerhans Cell Histiocytosis 
 
non-Langerhans Cell Histiocytoses 
 Juvenile Xanthogranuloma Family 
  Cutaneous – Juvenile xanthogranuloma 
  Cutaneous and systemic – Xanthoma disseminatum 
Systemic – Erdheim-Chester disease 
 non-Juvenile Xanthogranuloma Family 
  Cutaneous – Solitary reticulohistiocytoma 
  Cutaneous and systemic – Multicentric reticulohistiocytosis 
Systemic – Rosai-Dorfman disease 
 
Haemophagocytic Lymphohistiocytosis 
 Familial (congenital) 
 Secondary (reactive) 
 
Histiocyte Lineage-related Malignancies 
 Leukaemias 
  Acute myelomonocytic and monocytic 
  Chronic myelomonocytic/juvenile myelomonocytic leukaemia 
 Monocytic and histiocytic sarcomas 
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To put LCH in a wider context, the classification used by the World Health 
Organisation (WHO) in the latest version of their International Classification of 
Diseases (ICD) series (Version 10 (ICD-10)) is shown in Appendix A [16].  The 
classification takes into account the severity of the different forms of the disease. 
Letterer-Siwe disease, a disseminated form of LCH, is found among the group of 
“Malignant neoplasms of lymphoid, haematopoietic and related tissue” while the other 
forms are found among “Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism”.    
 
The current version of the International Classification of Diseases for Oncology (ICD-
O-3), a specialty-based adaptation of the ICD series which is used mainly in cancer 
registries, includes one form of LCH (disseminated) as a malignant neoplasm.  ICD-O-3 
is based on ICD-10 but provides greater detail for neoplasms since it includes an 
additional code for the histological type [17]. The site (topography) and the histology 
(morphology) are coded from information usually obtained from a pathology report. 
The fifth digit (after /) in the morphology code is a behaviour code which indicates 
whether a tumour is malignant, benign, in situ, or uncertain whether benign or 
malignant.  Those with /1 are usually considered of uncertain borderline behaviour.  The 
ICD-O-3 morphology codes for LCH are as follows. 
 
9751/1 Langerhans cell histiocytosis NOS  
9752/1 Langerhans cell histiocytosis Unifocal  
9753/1 Langerhans cell histiocytosis Multifocal  
9754/3 Langerhans cell histiocytosis Disseminated 
 
This coding system is particularly useful for children‟s cancers which have more 
heterogeneous histological sites and types than adult cancers which are generally 
classified by the primary site of the tumour [18].  However, if registration of LCH cases 
by cancer registries is based on whether the disease is coded as a malignancy, then only 
cases of disseminated LCH (Letterer-Siwe disease) are likely to have been included.  
 
Children‟s cancers have been grouped, using these oncology codes, into twelve 
categories of childhood cancers – the International Classification of Childhood Cancers 
(ICCC). This was designed to be used in international, population-based, 
epidemiological studies and cancer registries where the use of an international grouping 
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system is important in ensuring data comparability. Since the inclusion of LCH is 
controversial, it is not in the ICCC classification and data on an international scale are 
not available [19]. Some registries such as the German Cancer Registry have, however, 
adopted the Birch and Marsden classification, on which ICCC was originally based, and 
which includes LCH in the group of reticuloendothelial neoplasms [2, 20]. The version 
used by the UK Children‟s Cancer and Leukaemia Group (CCLG) also includes an 
extra group (XIII) for non-malignancies including all LCH variants and 
haemophagocytic lymphohistiocytosis (HLH) [21]. 
 
1.4 Diagnosis  
Eligibility of cases in a disease registry or epidemiological study depends on well-
defined diagnostic criteria.  The variety of forms of LCH and its rarity may increase the 
possibility of it being mistaken for other diseases such as osteomyelitis, seborrheic 
dermatitis or juvenile xanthogranuloma.  Histological diagnosis of LCH is therefore 
important for confirmation of disease although clinical judgement may be used in some 
cases. 
 
LCH can be diagnosed definitively by characteristic histology, positive staining for 
antigen CD1a and the presence of Birbeck granules (figure 1.2) [13, 14]. Since positive 
staining can occur in normal Langerhans cells it is important to examine lesional cells 
only. Two or more other positive stains (S-100 protein, adenosinetriphosphatase (ADP), 
D-mannoxidase or peanut lectin, in addition to conventional histology (staining with 
Hematoxylin and Eosin (H&E)), and clinical findings may be sufficient for a 
presumptive diagnosis of LCH [22]. Although desirable, a biopsy may be unfeasible 
because of the location of the lesion or because clinical features suggest possible 
resolution. In the case of LCH of the pituitary gland and some bone lesions, diagnosis 
may be made by characteristic appearances on X-rays or CT scans (with additional tests 
for pituitary dysfunction).   
 
Diagnosis may be made accidentally in some cases, particularly of isolated disease. For 
example, Leavey et al reported that 6/22 unisystem cases in a hospital series in Dublin 
were diagnosed from X-rays for an unrelated condition [23]. 
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1.5 Sources of LCH cases  
Disease-based registers, of which there are reported to be over 250 in England, collect 
data on all cases of a particular condition for a defined geographic population [24]. 
Registries rely on the cooperation of clinicians to report cases although eligible cases 
may be actively sought. Case registration is based on defined classification and 
diagnostic criteria. Additional sources may be used to ascertain cases, such as death 
certificates, or data may be cross-checked with other registries or study groups [2, 25].  
Registries and other potential sources of LCH cases are discussed below. 
 
1.5.1 National and regional studies 
In both national and regional incidence studies of LCH most authors obtained data from 
malignancy registers [1-3].  Three reports from France, Hungary and Germany 
(described in section 2.3.1) used data from national registries which have consistently 
recorded cases of LCH [3, 26, 27]. In other studies, sources of data were paediatric 
oncology or haematology centres with additional cases identified from paediatric or 
other specialties [1, 28]. Approaching other specialists optimised the identification of 
cases, for example, of bone LCH which may only have been seen by orthopaedic 
surgeons. Estimations of the completeness of ascertainment of LCH and cancer cases 
using several sources were reported to be 95% and 90% in the children‟s cancer 
registries in Germany and Switzerland respectively and 97% for LCH cases in France 
[3, 20, 29].   
 
1.5.2 UK and Republic of Ireland registries 
There are 11 regional cancer registries in the UK which provide a standard set of data 
for the Office for National Statistics (ONS) in England and its equivalents in Wales, 
Scotland and Northern Ireland. There is also an Irish National Cancer Registry which 
began registering cancers in 1994. Registries provide information for estimating cancer 
incidence, assessing the outcome of screening programmes and treatments and 
monitoring of national health policies aimed at improving patient care and survival.  
Although treated by oncologists, LCH is not a mandatory registerable condition (due to 
the fact that not all forms of disease are recognised as a malignancy) and cases have not 
been collected consistently by all cancer registries in the UK [30].  Cancer registries in 
other countries also vary in their registration of LCH cases. For example, the Pediatric 
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Oncology Group of Ontario registers cases but the Ontario Cancer Registry does not 
[31].   
 
With regard to sources of information in the UK there is a national children‟s cancer 
registry and there are several regional children‟s cancer registries.  Children‟s cancer 
registries are believed to be more accurate and up-to-date than general cancer registries 
as there are fewer delays in registrations, more accurate data capture and more complete 
ascertainment; most carry out pathological reviews of cases [32].  However, there is only 
published data on the incidence of LCH from three regional children‟s registries 
although a fourth has reported the number of cases registered [2, 21, 25, 33] – see 
section 2.3.2.  Cases ascertained by the National Registry of Childhood Tumours (NRCT) 
have been mainly via the Children‟s Cancer and Leukaemia Group (CCLG) with very few 
additional cases notified by regional and national cancer registries in recent years [30]. The 
NRCT does not engage in active case-finding.  Numbers of cases have been included in 
their annual report but LCH has not been included in NRCT incidence and survival 
statistics because many cases are non-malignant and registration was thought to be 
incomplete.  In addition, the NRCT only registers LCH cases up to the age of 15 years and 
it was of interest to investigate the upper age range for LCH in children. 
 
 
1.5.3 Children’s Cancer and Leukaemia Group (CCLG) 
The CCLG co-ordinates clinical trials for all the major types of childhood cancers and 
LCH, and estimates that it registers 90-95% of all cases [34, 35].  In particular, cases of 
LCH requiring therapy (multifocal bone and multi-system cases) should be registered. 
However, those needing little treatment, for example, uncomplicated bone disease, may 
not have been registered. Children diagnosed before their 15
th
 birthday are included in 
clinical trials although since registration has been extended up to 24 years, the upper 
limit for some tumours may be higher [36]. However,  referral patterns vary between the 
22 paediatric oncology treatment centres and some register few older children [21, 34]. 
The total number of cases recorded between 1993 and 2003 is shown in figure 1.4. The 
average number of cases per year over this eleven-year period was 37. The numbers 
include those notified by clinicians in the Republic of Ireland since Dublin is one of the 
CCLG treatment centres.   
 
 
10 
 
 
Figure 1.3 CCLG LCH registrations in the UK and Ireland 1993-2003  
 
 
 
1.5.4 Death registrations 
Death registrations are available from the General Registry Offices at the Office for 
National Statistics in the UK and Central Statistics Office in the Republic of Ireland [37, 
38].  The causes of deaths registered are coded using ICD coding systems (ICD-9 and 
ICD-10). Searches for deaths from LCH using the appropriate codes may therefore identify 
cases.  However, there is potential for miscoding where histological type codes have not 
been used.  A death may also be misreported since disorders other than LCH may be 
classified in the group of “Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism“. 
 
1.5.5 British Paediatric Surveillance Unit (BPSU) 
The BPSU undertakes active (prospective) national surveys of rare conditions affecting 
children by contacting paediatric consultant members of the Royal College of Paediatrics 
and Child Health (RCPCH) [39].  The BPSU had previously undertaken a survey of 
another histiocytic disorder (haemophagocytic lymphohistiocytosis (HLH)) in 1991, for a 
period of three years, and use of the same method was therefore attractive.  LCH fulfilled 
the criteria for participation in their surveillance programme as it was thought to have an 
incidence of less than 300 cases per year (based on CCLG numbers and other European 
incidence rates); the majority of cases would be seen by a paediatrician and it is diagnosed 
by a definitive method (section 1.4). However, it is a requirement of the BPSU that other 
31
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sources should be used when participating in one of their surveys, particularly when 
investigating incidence. Although the CCLG may be one of the sources, cases would be 
contributed mainly by paediatricians, many of whom would be members of the RCPCH.  
Other sources were therefore desirable. BPSU does not undertake surveillance studies 
solely for the purposes of establishing the incidence of a disease, and consideration was 
also given to the data that could be collected.   
 
1.5.6 Other potential sources 
Other sources used for epidemiological (incidence) studies in the UK include Hospital 
Episode Statistics (HES), the General Practice Research Databases (GPRD) and the 
Doctors‟  Independent Network (DIN) [40-42].  The GP databases record face-to-face 
contacts and are patient-oriented; HES records episodes of hospitalisation and was not 
designed to count the number of individuals treated.  Patients with particular conditions 
can be identified by ICD codes and incidences of various conditions have been reported 
[42, 43]. Although data are anonymised it is possible to identify individual cases. 
However, data manipulation would be time-consuming. In addition, GP databases 
would not give complete UK coverage and would be inappropriate given the rarity of 
LCH.  There may also be a delay in the diagnosis of LCH being registered on GP 
databases, while HES only records those treated as in-patients.  
 
1.6. Types of epidemiological study 
The main uses of epidemiological studies in medicine have been to investigate the 
distribution, causes and natural history of diseases in the population with the aim of 
controlling and preventing disease, and providing information for health services. 
Experimental studies (interventional) largely measure the effects of preventative 
treatments; observational studies (descriptive and analytic) may describe the occurrence of 
disease in a population or cohort, explain the pattern of disease and identify causal or other 
risk factors.  Descriptive studies usually involve estimating incidence, prevalence and 
mortality rates in a population, and examining patterns of disease by different subgroups, 
for example, sex, age or ethnicity.  Observations linking the disease to basic 
characteristics in a population are valuable in informing clinicians of those most at risk 
of disease and in health service planning. Analytic studies further examine the 
relationship between health status and particular variables, i.e. investigate risk factors for a 
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disease, although the two types of study may overlap.  As well as describing symptoms, 
characteristics and natural history, an observational study of LCH may also provide clues 
to the aetiology of disease.  
 
Data for an observational epidemiological study may be collected retrospectively or 
prospectively. Prospective studies collect case data after the investigation has started and 
retrospective studies use cases recorded prior to the study starting.  A combination of both 
methods of collection may be used [44]. Retrospective studies may be quicker to carry out 
than prospective ones. However, diagnosis or classification of the disease may have 
changed in the interim and case notes made in the past may be unreliable or unsuitable for 
the current study. The main advantage of prospective studies (such as those employed via 
the BPSU) is that the method of recording cases can be controlled from the outset rather 
than relying on data collected previously for other purposes.  A major disadvantage is that 
they may take many years to collect cases and produce results, especially if the disease is 
rare.   
 
1.7 A national survey of LCH 
1.7.1 Approach and methods 
In order to estimate the incidence of LCH and to identify sufficient numbers of cases to 
obtain meaningful data, a national study was required. The estimates of completeness of 
ascertainment described above lead to the conclusion that no individual source was 
likely to identify all LCH cases and that multiple sources of data would be required to 
ascertain as many as possible. A publication on the National Register of Childhood 
Tumours (NRCT) reported that cases were ascertained using four sources of notifications 
including children‟s cancer registries, clinical trials data and death certificates [18].  The 
importance of using multiple sources, particularly for rare diseases, has been discussed 
by Knowles et al. They described the reporting sources of 59/71 studies of rare 
paediatric disorders conducted through the BPSU [45]. They found that 38 studies used 
additional sources of ascertainment which they concluded were essential to improve 
ascertainment, to define the denominator for the study and to assess the level of 
ascertainment in order to adjust incidence.   
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Although UK and Republic of Ireland (RoI) cancer registries do not record cases of 
LCH consistently, the CCLG has registered cases from both countries for many years. 
However, most of these cases have been reported by paediatric oncologists and it is 
possible that only more severe cases will have been notified.  In addition, only cases up 
to the age of 15 years may have been registered.  Therefore although many cases will 
have been recorded by the CCLG it is likely that not all will have been registered. This 
is corroborated by CCLG‟s own assessment of their ascertainment of LCH and cancer 
cases (90-95%) [34, 35]. 
 
As described, the heterogeneity of LCH makes it challenging to diagnose and treat.  The 
wide range of organs affected, and age at diagnosis, may mean that clinicians from a 
number of specialties other than oncology are involved and identification of cases on a 
national scale may also be challenging.  In addition to cases registered by CCLG, active 
methods of ascertaining cases were considered, to cover as many relevant clinical 
specialties as possible.  The BPSU was thus approached to include LCH in its 
surveillance programme. 
 
To fulfil BPSU participation criteria and complement the BPSU survey and CCLG 
register, a survey of non-members of the RCPCH was devised. This aimed to include those 
involved in diagnosing cases – pathologists and radiologists – and those who may treat less 
severe cases – orthopaedic surgeons and dermatologists – who would not necessarily 
register patients with the CCLG. 
 
For completeness of ascertainment, a fourth source – death registrations – was included in 
the study methods. 
 
1.7.2 Summary 
Taking into account the different forms of the disease and presentation to different 
specialists, the limitations of CCLG registration, cancer and deaths registry data, BPSU 
requirements and human and financial resources, a national survey was designed to 
establish the incidence of LCH.  A prospective study was carried out to actively identify 
cases via as wide a range of clinicians and specialists as possible using four sources of 
ascertainment: BPSU, CCLG, death registrations and a survey carried out from 
Newcastle of non-members of RCPCH.  The methods employed are described in detail 
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in Chapter 3.  As well as assessing incidence, the study collected data from 
questionnaires sent to reporting clinicians, with the aim of describing the disease and 
looking for evidence of possible causal and other risk factors.  In addition, since the 
disease may result in permanent consequences, patterns of presentation, treatment and 
outcome were analysed. 
 
1.8 Objectives 
The aims of this study as set out in the protocol were to describe the epidemiology of LCH 
in children in the UK and RoI, to assess the presenting features and referral patterns for the 
disease and eventually to contribute to a wider investigation also involving Canada and 
the Netherlands.  A study in Canada began in 2009 [46]. 
 
1)  In particular the study aimed to 
a) describe the incidence of LCH in boys and girls by age and the extent of 
disease at diagnosis,  
b) study variation between ethnic groups 
c) describe regional differences in incidence rate to assess geographic variation 
e.g. north/south or urban/rural. (There would be too few cases and too short a 
timescale of ascertainment for cluster analysis.) 
d) assess the frequency of familial LCH. 
 
2) It also aimed to 
a) document patterns of presentation,  
b) describe the interval between the onset of symptoms and diagnosis, 
c) describe the treatment and outcome for the disease.   
 
In carrying out a national survey among paediatricians it was also hoped to publicise the 
disease and to increase the index of suspicion in those who might see children with 
LCH. 
 
1.9 Author‟s contribution 
Discussion and preparations for the study began as early as 2001 although my 
participation did not begin until the end of 2002.  I became fully involved at the time a 
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second-phase application was being made to the British Paediatric Surveillance Unit 
(BPSU) to include LCH in their programme.  The Histiocytosis Research Trust agreed 
to fund the study.  Following acceptance of the study by the BPSU, I was involved in 
the preparation of the protocol, study questionnaires and accompanying documentation 
for clinicians, and the compilation of the mailing lists. I prepared and obtained multi-
centre research ethical approval and subsequently, approval for a further follow-up of 
cases (two years after diagnosis) plus approvals from the CCLG and national statistics 
offices for data. 
 
Since that time I have run the study on a day-to-day basis, prepared annual and quarterly 
reports for the BPSU and kept the funders up-to-date. Poster and oral presentations have 
been made at several conferences including international meetings of the Histiocyte 
Society.  A paper based on this study, of which I am first author, was published in 2009 
[47].  Other LCH publications include abstracts written for Histiocyte Society Meetings, 
a „Highlight‟ of another national LCH epidemiology study and a contribution to a paper 
on adults with LCH [48-52]. A separate list of publications can be found after the 
Appendixes.  In addition, I have become a member of the Histiocyte Society and have 
attended meetings of the Epidemiology Sub-committee and, when appropriate, meetings 
of the CCLG LCH Sub-committee. 
 
1.10 Outline of this thesis 
The following chapter summarises what is known about LCH from a review of the 
literature on studies of its clinical characteristics and epidemiology.  
 
Chapter 3 describes the sources and methods used to identify LCH cases in this study 
and the questionnaires used.  Methods used to analyse the data collected can be found in 
Chapter 4.   
 
Results of case ascertainment, the incidence of LCH and capture-recapture analysis are 
presented in Chapter 5.  Chapter 6 begins with descriptive epidemiology of cases 
followed by disease-free and sequelae-free survival analysis of one and two year follow-
up data, and mortality.  
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Finally, the study is discussed and evaluated in Chapter 7; recommendations for future 
studies and conclusions are made in Chapter 8. 
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Chapter 2. Literature review  
 
A literature review was carried out before the study commenced and was subsequently 
extended.  The literature research strategy is described in Appendix B; search terms 
included all named forms of the disease mentioned in the Introduction.  This chapter 
gives a detailed description of the features of LCH for comparison with the study cohort 
and outlines past UK and RoI studies. It also reviews national and regional reports of 
LCH incidence by age, sex and type of disease. Aetiological studies are described, as 
are studies of potential risk factors for the development of the disease and associations 
with other conditions. Mortality and survival studies are reviewed including risk factors 
for survival and permanent consequences.   
 
2.1 Description of disease 
2.1.1 Symptoms and presentation 
LCH can occur at all ages [53-55].  The peak in incidence in children occurs between 
one and four years of age and it is slightly more common in boys than girls [1, 26, 56].  
LCH may occur in a single organ (single system disease (SS)) in one or more locations 
(unifocal or multifocal). Multi-system disease (MS), which refers to LCH in at least two 
different organs, is more common in children under two years of age. Multifocal SS 
disease usually affects two to five year olds while 50% of unifocal bone disease affects 
children over five years old [57]. The variously reported incidence of the disease by age, 
sex and type is detailed in section 2.3. 
 
Almost any part of the body may be affected and a summary of the main sites is given 
in table 2.1. SS disease is more common than MS disease and occurs in around 60% of 
cases, predominantly in bone, skin and lymph nodes [3, 58].  Bone is by far the most 
frequently reported site of disease and it is estimated to occur in over 70% of cases of 
LCH [3, 59, 60]. Bone disease may occur at one or more sites and in combination with 
LCH in other organs. Approximately 15-30% of bone cases are multifocal and it has 
been found in over 50% of those with MS disease [3, 59, 61]. Almost any bone may be 
affected, particularly the long bones and skull, although lesions in the extremities are 
rare [57]. Figure 2.1 shows an X-ray of bone lesions of the humerus. Skull lesions, more 
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common in younger children, may also affect the eyes, ears or teeth [62]. The main 
symptoms are pain, limp and swelling or lumps. However, in a study in Dublin, 6/22 
cases of SS bone disease were found incidentally [23]. Painful swellings may be 
mistaken for trauma [63].  SS bone involvement is most frequently seen in older children 
whose skeletons are still growing, and is more common in boys [64-66]. This may be due to 
pubertal growth starting later in boys and continuing longer than in girls.  
 
Table 2.1 Main sites of disease 
Site Description 
Bone Although any bone may be affected the skull, femur, 
tibia and fibula, and spine, pelvis, mandible and ribs are 
most often involved.   
Skin It occurs as SS disease and is more prevalent in MS 
disease.   
Ears, lymph nodes, 
thymus 
These sites are often associated with neighbouring skin 
or bone disease. 
Lungs, liver, spleen, bone 
marrow 
These (risk) organs are usually only affected in MS 
disease (disseminated disease).  
Endocrine system 
(pituitary) 
Diabetes insipidus (DI) is the most common 
presentation of pituitary disease and it may occur 
singly, with or after other lesions, most commonly of the 
skull.  
Central nervous system 
(CNS) 
 
Apart from the pituitary, all other parts of the CNS may 
be affected, the cerebellum being the second most 
affected site.  
Gastrointestinal tract The mouth or gut may be affected and it is more 
frequent as part of MS disease. 
 
 
The skin is also commonly affected. It is estimated to occur in 10% of those with SS 
disease and in over 50% of those with MS disease [67-69]. The first symptoms of LCH 
may be a skin rash which is seen in up to 50% of cases [67, 68].  Young children are 
most often affected. Lau et al found that 22/26 cases with skin disease were under 12 
months old at the onset, and progression to MS disease occurred in 40% of cases [68]. 
One form of skin LCH is congenital Hashimoto-Pritzker disease which mainly occurs in 
early life, regresses spontaneously within 1-3 months and is generally described as self-
healing [53, 70, 71].  However, some cases of skin-only LCH have been found to 
regress initially and recur in the same site or progress to other organs, sometimes 
several years later.  In a study by Minkov et al, the disease progressed in 4/9 non-treated 
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neonates with cutaneous disease [54]. Stein et al described 19 neonates presenting with 
skin lesions, 18 of whom were diagnosed with LCH by skin biopsy at a mean age of 3.5 
months. At diagnosis a comprehensive workup of each patient was carried out and 
multi-organ involvement was found in 14 cases. At follow up (mean 3.2 years after 
diagnosis) two patients had died and 12/19 had MS disease, four patients having 
developed DI between 2-3 years of age [72].  Given that the course of skin disease may 
be unpredictable authors have advised careful assessment of patients for systemic 
disease and monitoring for disease progression [70, 72]. Typical skin lesions described 
by Stein et al were red and pustular and often crusted although morphological traits 
varied and could not be used to predict the course of the disease. Rashes may be 
mistaken for common conditions such as eczema, dermatitis, nappy rash or prolonged 
„cradle cap‟ (figure 2.2) and thus a diagnosis of LCH may be missed [63, 72].   
 
Other organs are affected less frequently affected in SS disease.   
 
In MS disease the most common sites are bone, skin and pituitary [61, 73]. The liver, 
spleen, lungs and bone marrow are referred to as „risk organs‟ because they are 
associated with a poorer prognosis, especially in infants – see section 2.1.4 [74]. 
Symptoms of MS disease include rash, jaundice, ear discharge, diabetes insipidus and 
lymphadenopathy. 
 
Symptom-less or spontaneously regressing bone disease and mild forms of skin disease 
may go unreported or undiagnosed. It is thought that gastrointestinal disease may also 
be underestimated since symptoms, such as failure to thrive and diarrhoea, are 
nonspecific [63, 75].  
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Figure 2.1 Plain X-ray of lytic bone lesion 
 
 
Figure 2.2 LCH presenting as „cradle cap‟ 
 
Both images from Nanduri 2002 [63] 
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2.1.2 Adults 
Although some cases may be referred from childhood, adult cases of LCH are also 
diagnosed. Adults tend to be treated by an individual specialist, e.g. a dermatologist or 
respiratory specialist, rather than an LCH specialist, and therefore the incidence has 
been more difficult to estimate. There have been a few large studies of hospital series 
but adult disease may be more common than was previously thought. The incidence of 
LCH in adults is discussed in more detail in section 2.3.4. The most common sites of 
LCH differ in adults and children. Genital disease (mainly vulval disease) and isolated 
pulmonary LCH, which are rare in children, are frequent sites in adults [76]. The 
aetiology of pulmonary LCH is associated with smoking and is discussed further in 
section 2.4. In adults,  lung disease is a major risk factor for both morbidity and 
mortality;  patients are more likely to have a comorbidity such as lymphoma or lung 
cancer [77, 78].  
 
The different sites in adults and children, and their frequency, where published, are 
shown in table 2.2.  The various sources of frequency of site involvement in children are 
referenced in the second column. All the frequencies of site involvement in adults 
(shown in the fourth column) are taken from two papers by Arico et al and Howarth et 
al [55, 76].  Frequencies from Howarth et al are marked with †. As can be seen, there is 
a very wide range in pituitary LCH reported by Grois et al [73]. 
 
Arico et al reported that 68% of 274 adults aged over 18 years in the International 
Histiocyte Society Adult Registry had MS disease. Of those with SS LCH, over 50% 
had lung disease with 38% having bone and 7% having skin disease; the frequencies 
were much higher in MS disease cases (61%, 66% and 50% respectively) [76]. The 
numbers with isolated lung disease were slightly lower (40%) in a US study by Howarth 
et al and 22% in a report from the LCH-Belgian Survey [44, 55]. In another US adult 
group of 211 orthopaedic cases, Islinger reported that 75% were male [79]. Although 
smoking is more prevalent in men [80] the reported frequency of pulmonary LCH 
among men and women varies.  In a review by Vassallo et al, some studies reported a 
male predominance although more recent studies reported an equal incidence or slight 
predominance among women.  The authors suggested that this may reflect the 
“increased prevalence of smoking among women in recent years” [81]. The ratio of 
males to females with pulmonary disease in Howarth‟s study was 1:2.2.  In the German 
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National Database of Adult LCH Patients, data on 121 adults (35% male, 65% female) 
were collected between 2002-2008. Patients had a mean age of 44 years at diagnosis 
and 86% were smokers or ex-smokers [77].  
 
Table 2.2 Most common sites of LCH in children and adults with 
frequency, where reported (adapted from Tatevossian [55]) 
Children Frequency  Adults Frequency 
Bone 70-80%  [59, 82]  Lungs 51% SS, 61% MS  
40% SS, 43% MS†  
Skin 10% SS [83], 
50% MS [68] 
 Bone 38% SS, 66% MS  
52% SS, 77% MS† 
Ears, Nose 
Throat 
>15% [84]  Skin and muco-
cutaneous 
junctions 
7% SS, 50% MS 
6% SS, 65% MS† 
 
Pituitary 5-50% [73]  Pituitary 43% MS 
0.9% SS, 44% MS†  
Orbits Up to 20% [85]  Dental  
Mouth 6% [86]  Genital (mainly 
vulval) 
 
Gastrointestinal 
tract 
2-13% [87]   Liver 1.2% SS, 23% MS 
5% MS† 
Lungs <5% SS [61] 
12% MS [56] 
 Spleen  
Liver 4% [82]  Thyroid 9% MS 
Spleen   Other rare sites  
Lymph nodes <10% [82]  All adult figures from Arico et al [76], and 
Howarth et al† [55] 
Thyroid    
Other rare sites     
 
 
2.1.3 Time from symptoms to diagnosis 
Since the early stages of the disease are variable and milder forms may be mistaken for 
other disorders there may be a long delay between the first symptoms and diagnosis. 
Lack of timely treatment may allow the disease to progress and increase the possibility 
of permanent consequences. Stein et al in a study of 19 neonatal cases of cutaneous 
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LCH reported misdiagnoses such as psoriasis and dermatitis prior to presentation at 
their hospital in Chicago. Over 70% of cases had skin lesions at birth but the mean age 
at diagnosis was 3.5 months (range 2 days to 20 months) [72]. More recently one 
national study has estimated the elapsed time between symptoms and diagnosis for 352 
children aged <15 years, diagnosed in France over a six year period [88].  For SS 
(unifocal) LCH the median time from symptoms to diagnosis was 33 days increasing 
from 30 days for bone to 77 days for skin and 119 days for endocrine disease. For those 
with multifocal or MS disease the median elapsed time was 48 days.  
 
 
2.1.4 Treatment 
Treatment depends on the site of disease and, if MS, whether children are at risk of 
dying. Those with two or more organs including a risk organ – liver, lung, spleen or 
bone marrow – are most at risk [89]. Surgery or chemotherapy may be required but 
since the disease may regress spontaneously for many patients treatment is simply 
„waiting and seeing‟.  Conservative treatment has been advocated and, in a recent 
French study of 258 children, 43% underwent observation only [3, 90]. Radiotherapy is 
now avoided because of its possible role in the subsequent development of malignancies 
in these patients – see section 2.5.5 [91].   
 
For many years children have been treated on internationally agreed protocols 
developed by the Histiocyte Society, based on classification of the type of disease [74].  
Clinical trials of these treatments have been conducted in the UK and Ireland under the 
auspices of the CCLG. In the French study, mentioned above, Guyot et al reported that 
36% of children had been treated on LCH II or LCH III protocols [3].  The criteria for 
eligibility for current treatment (on LCH III protocol) are given below (table 2.3).  A 
new protocol (LCH IV) is in the process of being established based on the results of 
previous clinical trials.  It has been reported, that lung, if the only risk organ involved, 
does not confer a higher risk of death and it will be removed from the list of risk organs 
in future studies [92].  
 
Unfortunately, owing to the rarity of LCH and the current nature of EU regulations for 
new clinical trials in children, it is possible that UK patients will not be able to be 
entered into the upcoming LCH IV study [93]. Clinical trials units may have to reduce 
the number of trials they can offer as increasing amounts of time and resources are 
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being taken up by audits and the requirements of the EU Clinical Trials Directive. Other 
recent changes have meant that children‟s cancer and LCH trials are no longer being 
conducted by CCLG at Leicester University. However, much of the CCLG‟s work is 
being transferred to Birmingham Clinical Trials Unit.  
 
Table 2.3 Treatment - LCH III protocol eligibility [74] 
Protocol group Eligibility – site of disease 
Group 1 - MS “risk” patients  
 
MS patients with involvement of one or more 
“RISK” organs i.e. hematopoietic system 
(with or without bone marrow involvement), 
liver, spleen or lungs 
Patients with SS lung involvement are not 
eligible for randomisation 
Group 2 - MS “low risk” patients 
 
MS patients with multiple organs involved but 
WITHOUT involvement of “RISK” organs. 
Group 3 - SS “multifocal bone 
disease” and localised “special site” 
involvement 
 
Patients with multifocal bone disease, i.e. 
lesions in two or more different bones. 
Patients with localised special site 
involvement, like “CNS-RISK” lesions with 
intracranial soft tissue extension or vertebral 
lesions with intraspinal soft tissue extension 
(CNS RISK” lesions - lesions in the orbital, 
temporal/mastoid, sphenoidal, zygomatical, 
ethmoidal bones, maxilla, sinuses or anterior or 
middle cranial fossa, with intracranial soft tissue 
extension demonstrated on magnetic resonance 
imaging (MRI). Vault lesions are not regarded as 
“CNS Risk” lesions.) 
 
 
2.1.5 Reactivation and progression 
The disease may recur or reactivate after treatment, particularly in those with MS 
disease, sometimes many years after diagnosis [56, 94-97].  It may reactivate at the 
original site of disease or progress to new sites. For example, SS bone disease may 
reactivate at the original site or become multi-focal, or may progress to MS disease; 
disease in MS cases previously at low risk may progress to risk organs. In a study of 
300 children in Buenos Aires, LCH recurred in 30% of cases overall – 21% of cases of 
SS disease and 48% of those with MS disease [96]. The proportion of cases with 
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recurrence reported by Jubran et al in a study of 122 cases was 17% and 50% for SS and 
MS disease respectively [94].  In a study using data from the International LCH 
Registry, of 335 MS patients, complete resolution of disease was documented in 64% of 
cases after a median observation time of 1.5 years. However, reactivation occurred in 
134 cases (40%), mostly within two years of disease resolution (88%). The probability 
of first reactivation was 46%, and 44% for a second reactivation at five years after 
disease resolution.  The most frequent site of first reactivation was of the skeleton with 
only 10% of recurrence in risk organs. The extent of reactivated disease did not match 
the extent of disease at diagnosis except where risk organs were involved. The number 
of reactivations per patient ranged from 1-6 with the vast majority of survivors having 
only one or two [98].   In a long-term follow up study of 40 cases in Stockholm, 18% 
had reactivated disease 10 years after diagnosis. The disease progressed in 12 cases; six 
cases of unifocal SS disease developed multifocal or MS disease and in six cases of MS 
disease it progressed to risk organs [97].  
 
2.1.6 Permanent consequences 
Since LCH may affect several organs, sequelae or permanent consequences may follow 
or be concurrent with active disease [63, 95, 99]. Children are thought to be at particular 
risk of developing long-term sequelae from LCH because the disease may interfere with 
normal growth and development. The main permanent consequences and their estimated 
frequencies are shown in table 2.4.  The reported sites vary quite considerably with wide 
ranges in the percentages of cases. This may be due to various factors including the 
study size, treatments used and follow-up period.  The most common permanent 
consequences are orthopaedic problems and diabetes insipidus [96, 100].  In a study by 
Willis et al, among 71 cases with a median follow up of 8.1 years, 42% had skeletal 
problems and 25% had diabetes insipidus. In contrast, the proportions of cases with 
these sequelae in a multi-centre study in France (with a median follow up of 3.3 years) 
were 2.5% and 17.5% respectively [56]. 
 
In a study of 123 cases with a median follow-up of three years, Braier et al reported 
sequelae in 28% of cases [95].  In the long-term follow up study (5.5-33.5 years after 
diagnosis) in Stockholm mentioned above, the proportion of cases with sequelae was 
higher (42%) [97].  This may be due to there being a longer period in this study in 
which the disease progressed and sequelae developed.  In children with SS LCH 
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(usually bone or skin) the outcome is frequently very good. The disease may regress 
spontaneously or a complete recovery may be made with conservative treatment. 
However, of 178 cases with SS disease in a multi-institutional study in Europe, 25% 
had permanent consequences [58]. For those with MS disease, the proportion may be 
higher and in two studies by Willis et al and Haupt et al, 64% and 71% of cases 
respectively were left with significant permanent consequences after more than three 
years of follow up [101, 102].  
 
 The effects of multiple LCH lesions of the skull after diagnosis and treatment are 
shown in figure 2.3 [63]. Risk factors for the development of permanent consequences 
are described in section 2.6.2. 
 
 
Table 2.4 Main permanent consequences of LCH (adapted from Haupt et 
al) [99] 
LCH Permanent consequences 
Frequency in 
LCH patients 
Bone Orthopaedic problems – deformities, 
scoliosis, facial asymmetry 
2.5-42% 
Posterior pituitary Diabetes insipidus  15-50% 
Anterior Pituitary, 
hypothalamus 
Growth failure – short stature, 
Hormone deficiencies – delayed puberty, 
obesity 
Up to 20% 
Central nervous 
system 
Learning difficulties, psychological problems, 
ataxia, gait disturbances, tremor 
Up to 10% 
Orbits Ophthalmic problems, proptosis (rarely 
blindness) 
Not reported 
Ears Hearing loss 3-16% 
Dental Tooth loss 1-30% 
Liver  Chronic liver disease e.g. sclerosing 
cholangitis, cirrhosis 
1.3%&,18%#           
Lung Restrictive lung disease, fibrosis, 
pneumothorax 
1-8% 
 
Estimates from &[56], #[103]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 
2.1.7 Survival 
Several long-term follow up studies have been reported and children with MS disease 
involving risk organs have the poorest outcome in terms of survival as well as 
permanent consequences [97, 101, 102, 104].  Although children under two years old at 
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diagnosis are thought to be particularly at risk, Jubran et al reported a significantly 
higher risk of progression of disease or death in infants with MS disease aged less than 
one year old at diagnosis [94].  Similarly, in a multi-centre study in France of 348 cases 
between 1983-1993, the median age at diagnosis of those who died was 8.5 months 
(range 0 months to 11 years) [56]. 
 
Mortality and survival rates are described in section 2.6.  
 
 
Figure 2.3 3D CT scan of skull 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Persistent, multiple, large lytic lesions with „full-thickness‟ loss of bone, 15 years 
after initial diagnosis of LCH and 8 years from the end of treatment. (From Nanduri 
2002)[63] 
 
2.2 UK and Republic of Ireland studies 
UK and Irish clinicians have contributed to a wide range of publications on LCH [62, 
105, 106].  However, there have been few reports from large hospital series. Studies in 
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the UK and Ireland include case reports, clinical features, specific organ disease, and 
reviews of treatment, outcome and quality of life. A list of studies with the largest 
patient groups is shown in table 2.5. 
 
Cases were mainly from hospital series although one study obtained cases from the 
Scottish Bone Tumour Registry [107].  As can be seen in table 2.5, the number of cases 
varied between studies.  Over a 31-year period in Dublin (1959-1989) an average of 1.3 
patients per year were diagnosed while at Great Ormond Street Hospital (GOSH), over a 
26-year period (1957-1982), there was an average of three patients per year [23, 108]. 
The difference may simply reflect the larger population served by GOSH. In later years 
(1980-1987), 58 patients were seen at GOSH – an average 7.2 per annum [90]. 
However, this series appears to overlap with another in a study of children with lung 
involvement in which 61 cases of LCH were examined (1981-1987) [109]. In the 
second (lung) study, 10/61 cases were referred from outside the UK so the increase in 
average numbers may be due in part to non-UK resident referrals rather than more 
prevalent disease or better recognition and diagnosis. The 51 UK residents were mainly 
boys (70%). One study which identified cases from the Scottish Bone Tumour Registry 
reported similar numbers of children (39) and adults (31) with bone LCH [107]. 
 
A follow up study of patients at GOSH with MS LCH was carried out by Nanduri et al 
in 2006 [110]. They identified a subset of patients from 275 cases seen between 1966 
and 1998 of which 147 (53.5%) had MS disease. This is a higher proportion of MS 
cases than that seen in the Dublin study (46%) and elsewhere where the majority of 
cases are of SS disease [56, 58].  This may be accounted for by the fact that GOSH is a 
tertiary paediatric centre and national children‟s hospital, and more numerous complex 
cases may be referred there. There were 36 deaths at GOSH (13%) and eight (21%) in 
Dublin over 34 years and 31 years respectively. 
 
With regard to the frequency of organ involvement, data from several GOSH studies are 
available.  In a study over 26 years, 18/76 (23%) had ophthalmic LCH.  However, 
(unspecified) changes in referral patterns had meant that half the cases presented in the 
last six years [108]. From a total of 275 cases diagnosed between 1966-1998, endocrine 
disorders were found in 35% of 144 patients with MS disease, and 34% had diabetes 
insipidus [111]. In the same series, five cases (1.8% of all patients and 3.3% of those 
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with MS disease) had colon involvement; the median age at diagnosis was 0.6 years 
[87].  Ear involvement was also investigated; 58 cases (21%) had ear disease although a 
more recent study of 40 MS cases found that 70% had had ear involvement and, five 
years on, 38% suffered from hearing loss [112].  Head and neck were involved in 
82/131 (62%) cases treated over a 30-year period at Cambridge and GOSH, and, of 
these, 44 (34%) presented with SS disease. The most common site was skull vault 
followed by skin of the ear canal. A further 14 children developed head and neck lesions 
[86]. 
 
In an earlier series, of 61 patients diagnosed with LCH between 1981-1987, 45 had MS 
disease and 16 had SS disease [109]. Lung involvement was found in 42% of MS cases 
and in none of the SS cases which is similar to another report from Philadephia [113]. 
Lung disease was most common in the youngest patients; the median age was 0.6 years. 
The frequency of various sites of disease may not be typical from UK accounts since 
nearly all the studies have been carried out at GOSH where a large proportion of MS 
cases were seen. 
 
Recurrence and progression of bone disease in children and adults was compared in 
Scotland in 39 and 31 cases aged under and over 16 years respectively [107]. In the 
younger age group, 17% had recurrence of disease including additional sites; in the 
skeletally mature group, 12% had reactivation of bone disease only. The authors 
concluded that the outcome for paediatric patients with SS bone disease was less good 
than previously reported.  Long-term morbidity and health-related quality of life have 
been reported in several studies by Nanduri et al [63, 110, 114].  In a cohort of 40 cases 
with MS disease, almost half had moderate to severe sequelae and ten had 
psychological, learning or physical problems which affected their independence.  They 
concluded that regular follow-ups would help to identify early signs of sequelae and to 
make appropriate interventions.  
 
None of the UK studies was population based.  Three regional children‟s cancer 
registries in the Northeast, Northwest and West Midlands have published incidence 
rates for LCH and one other in the Southwest has reported the number of cases 
registered [2, 21, 25, 33].  These are described in section 2.3.2. 
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Table 2.5 Studies in the UK and Republic of Ireland 
Title Patient 
population 
Number and age 
of cases at 
diagnosis 
Time period Type of 
disease 
M:F 
ratio 
Deaths Reference 
Langerhans Cell Histiocytosis – a 31 year Review 
(1991) 
Hospital series – 
Dublin 
41 <15 yrs 1959-1989 22 UF/MF 
bone, 19 MS 
2.4:1 9 [23] 
Langerhans cell histiocytosis and the pediatric 
population (Abstract 2003) 
Hospital series – 
Dublin 
68 - age not 
stated 
Not stated  46 SS, 22 MS – 6 [115] 
Eosinophilic Granuloma in children and adults – the 
Scottish Experience (Abstract 2006) 
Scottish Bone 
Tumour Registry  
39 < 16 yrs,  
31 > 16 yrs 
Not stated 61 UF, 
9 MF 
–  [107] 
Histiocytosis X: an ophthalmological review Hospital series – 
London 
76 <12 yrs 
(18 ophthalmic 
LCH) 
1957-1982 SS and MS –  [108] 
Langerhans cell histiocytosis: the case for 
conservative treatment (1990) 
Hospital series – 
London 
58 <15 yrs 1980-1987 14 SS, 44 MS 2.2:1 8 [90] 
Lung involvement in Langerhans Cell Histiocytosis: 
Prevalence, Clinical features, outcome 
Hospital series – 
London 
61 (51 UK 
residents) <16 yrs 
1981-1987 16 SS, 45 MS 2.4:1 7 [109] 
Growth and endocrine disorders in multi-system 
Langerhans cell histiocytosis 
Hospital series – 
London 
54/144 (subset) 
<17 yrs 
1966-1998 MS  1.2:1  [111] 
Long-term morbidity and health related quality of 
life after multi-system Langerhans cell histiocytosis 
Hospital series – 
London 
40/147 (subset) 
<16 yrs 
1966-1998 MS 1.1:1  [110] 
Cognitive outcome of Long-term survivors of 
langerhans Cell histiocytosis: A single Institution, 
Cross-sectional Study 
Hospital series – 
London 
28/40 (subset) 
<16 yrs 
1966-1998 MS 1.3:1  [114] 
Langerhans' cell histiocytosis in childhood: 
Management of head and neck manifestations 
2 centres – 
London, 
Cambridge 
131 <17 yrs 1960-1991 SS and MS 1.7:1  [86] 
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2.3 Incidence studies 
2.3.1 National studies 
It has been estimated that approximately one in 200,000 children are diagnosed each 
year although evidence for this has been sparse [1, 20]. However, since this study began 
the incidence of disease has been reported elsewhere [3].  
 
The first national study, published in 1993, which is still quoted in all publications when 
discussing the incidence of LCH in children, was in Denmark [1]. Only an abstract is 
available.  The authors obtained data retrospectively from 1975-1989 asking relevant 
clinical departments in hospitals in Denmark to look for all cases of LCH.  The list of 
clinical specialties approached was comprehensive and included Dentistry and 
Radiology departments. Records were reviewed and biopsies were re-examined for all 
90 children under 15 years of age.  The incidence rate (IR) was 5.4 per million per year 
rising to 16.4 per million per year in those with MS disease under the age of two years.  
The study relied on clinicians reporting cases and although there may have been some 
under-ascertainment, over-ascertainment is unlikely as biopsies were reviewed to 
confirm the original diagnoses.   
 
Since the publication of the Danish abstract several studies have reported national 
incidence rates of LCH and a summary of these and other population-based reports are 
presented in table 2.6.  Although their source was not stated, Lavin and Osband reported 
that there were approximately 1200 new cases a year in the US, an estimated incidence 
of 2-5 children per million per year [116, 117]. In addition, for a study on ophthalmic 
cases, Kramer et al calculated an expected incidence rate for children in Arizona based 
on the number of cases reported between 1980-1989 to the Surveillance Epidemiology 
and End Results (SEER) program of the National Cancer Institute [118].  The age-
specific IRs reported by SEER ranged from 0.6-4.3 per million per year aged 0-4 years. 
(The study by Kramer et al is further discussed in section 2.5.4.) 
 
The most recent national study was performed in France with 254 children aged  <15 
years diagnosed between 2000 and 2004 [3].  The IR was 4.6 per million per year.  As 
can be seen from table 2.6 the national incidence in children from all reports ranges 
from 1.37 (aged <15 years) in Taiwan to 8.3 per million per year (aged <20 years) in 
Belgium [44, 119]. The difference in rates may reflect the different methods of 
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ascertainment, different age groups or underlying differences in the rates in each 
country or region.  
 
In table 2.6 the age of the study population reported is given in column six; IRs (last 
column) are for children aged 0-14 years, unless otherwise indicated.  Among the 
national studies, the IR for Hungary is for those aged 0-18 years, and IRs for Belgium 
are for those aged 0-20 years and adults; a French multi-centre study included cases 
aged 0-17 years and the estimated IR was for 0-15 year olds.  An overall IR was 
calculated for Taiwan from published case numbers and mid-year population figures for 
the five-year study period; the annual IRs were 1.37, 1.59, 3.23, 3.29, 1.68 per million 
per year aged 0-14 years.  Among the regional studies, the children‟s registry in the 
North of England records cases up to 24 years and the IRs presented are for those aged 
0-14 years and 15-24 years; an IR was calculated for Southwest England from a report 
on children aged up to 16 years; the IR reported by Raney and D‟Angio in the US was 
for cases aged 0-20 years. 
 
Sources included surveys of single specialty clinicians (mainly oncologists and 
haematologists) cancer registers, and combinations of these and other specialists such as 
pathologists in the Belgian survey [44]. The 2008 French study was thought to have 
almost complete ascertainment of cases (97%) using two sources, the French National 
Registry of Childhood Hematopoietic Malignancies and the French LCH Study Group 
[3]. In contrast, a Japanese nationwide survey of LCH and Haemophagocytic Syndrome 
used only one source of cases – paediatric haematologists – with a 60% response rate. 
The annual number of cases (20.4) was comparable with those registered by the Japan 
Children‟s Cancer Registry (22.3). However, since only haematologists were contacted, 
the authors conceded that some cases treated by orthopaedic clinicians or dermatologists 
may have been missed [120]. Adjusting to account for the 60% response rate, the 
estimate of case numbers was 34 cases per year (1.5 per million per year aged <15 
years).   
 
In the French study, completeness of ascertainment was calculated using two-source 
capture-recapture methods which were also used in this study and are described in 
Chapter 4.  Few of the studies listed in table 2.6 gave an estimate of completeness of 
ascertainment but where published the estimates ranged from 90-97%. 
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All the studies were carried out retrospectively, with the exception of the Belgian survey 
which used both retrospective and prospective data [44].   Most studies stated the basis 
on which cases had been diagnosed. In the Japanese study, the diagnosis was 
presumptive or not specified for over half the cases; in Taiwan, diagnosis was based on 
symptoms and histology and 60% of cases were confirmed by immunohistochemistry 
[119, 120]. In two studies in France, diagnosis was by biopsy or radiological findings 
for 97% and 98% of cases respectively [3, 56].  Case numbers are likely to be accurate 
in reports from registries since they collect data from several sources, and patient 
information may include pathology reports. In addition, many have procedures in place 
to cross-check and correct anomalies [20, 29].   
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Table 2.6 Summary of population-based reports of incidence of LCH 
National studies 
Authors Publication Data Source Period 
No. of 
cases 
Age 
(years) 
Sex ratio 
M:F 
IR (per million per year) 
(aged 0-14 years) 
Carstensen & Ornvold [1] Abstract 
National – All Danish 
paediatric and specialist 
clinics and departments 
1975-89 90 <15 2.2:1 
 
5.4  
 
Kaatsch, Haaf, Michaelis et 
al [20] 
Article 
National – German Registry of 
Childhood Malignancies 
1980-1992 488 <15 1.4:1 4.0
1
 
Muller, Garami, Hauser et al 
[27] 
Article 
National – Hungarian 
Childhood Cancer Registry 
1981-2000 111 <18 1.36:1 2.24 (aged 0-17 years) 
French Langerhans Cell 
Study Group [56] 
Article 
National – 32/37 French 
Oncology Centres 
1983-93 348 0-17 1.3:1 4.5 (aged 0-15 years) 
 
Imashuku, Ikushimu, Hibi et 
al [120] 
Article 
National survey of Japanese 
Society of Paediatric 
Haematologists  
1986-1990 102 <15 1.6:1 1.5
2
 
Chen, Lin, Chang et al [119] Article 
National – 23 Taiwan Pediatric 
Oncology departments 
1995-1999 55 <15 1.5:1 2.22
3
 
 
1
based on data for 1987-1992   
2
estimate after adjusting for 60% response rate
   3
calculated rate   
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Authors Publication Data Source Period 
No. of 
cases 
Age 
(years) 
Sex ratio 
M:F 
IR (per million per year) 
(aged 0-14 years) 
German Childhood Cancer 
Registry [26] 
Registry 
report (web- 
pages) 
National – Data from German 
Oncology Clinics and trials 
2000-2004 330 <15 1.6:1 6.0 (ASR)
1
 
Guyot-Goubin, Donadieu et 
al [3] 
Article 
French National Registry of 
Childhood Haematopoietic 
Malignancies and French LCH 
Study Group 
2000-2004 258 <15 1.2:1 
4.6 
5.0 (ASR)
1 
Swiss Childhood Cancer 
Registry [29] 
Article 
National and Swiss Paediatric 
Oncology clinics (9) 
2001-2005 24 <15 1.4:1 4.3 (ASR)
1
 
Vangeebergen, Van Eycken, 
Van Gool [44] 
Abstract 
LCH-Belgian Survey of 
pathologists/clinicians plus 
sampling from Belgian Registry 
2001-2006 128 All ages – 
8.3 (aged <20 years) 
2.2 (adults) 
Belgian Cancer Registry [44] 
National – Belgian Cancer 
Registry 
2004-2006 53 All ages 1.2;1 3.0 (all ages) 
 
1
ASR = Age standardized rate 
 
 
  
36 
 
 
Regional studies 
Authors Publication Data Source Period 
No. of 
cases 
Age 
(years) 
Sex ratio 
M:F 
IR (per million per year) 
(aged 0-14 years) 
Alston, Tatevossian, McNally 
et al [2] 
Article 
Regional  Children‟s Registry – 
Northwest England  
1954-1998 101 <15 1.1:1 
2.6 (ASR)
1 
 
Cotterill, Parker, Malcolm et 
al [25] 
Article 
 
Regional Children‟s Registry – 
Northeast England  
 
1968-1995 46 <24 1.15:1 
2.5 (ASR)
1 
0.3 (ASR
1 
aged 15-24 
years)  
Muir, Parkes, Mann et al [33] Article 
Regional Children‟s Registry – 
West Midlands, England  
1980-1984 13 <15 2.3:1 
2.2,  
3 (ASR)
1
 
South West Childhood 
Cancer Research Registry 
[21] 
Registry 
Report (web-
page) 
Regional Registry – Southwest 
England 
2002-2006 16 <16 – 3.4 <16 years2 
Stalemark, Laurencikas, 
Karis et al [28] 
Article 
Regional – Stockholm County, 
Sweden 
1992-2001 29 <15 1.4:1 8.9 
Raney and D‟Angio [113] Article 
Greater Delaware Valley – 
referral area for Philadelphia 
Children‟s Hospital, US 
1970-1984 83 <21 1.4:1 2.0 (age 0-20 years) 
 
1
ASR = Age standardized rate 
   2
calculated rate
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2.3.2 Regional rates 
In the UK, using data from children‟s cancer registries, regional IRs of LCH for those 
under 15 years have been published for Northwest England (1954-1998) and the North 
of England (1968-1995); they were 2.6 and 2.5 per million per year respectively [2, 25]. 
The West Midlands Regional Children‟s Tumour Research Group reported 13 cases of 
Histiocytosis X over a five year period (1980-1984) with a similar IR of 2.2 per million 
per year [33].  In that publication the IR was compared with those reported by the 
Northwest region (2.3) and nationally, (0.6) by the Children‟s Cancer Research Group 
(which houses the NRCT).  The national rate was presumed to be an under-estimate 
because of poor LCH registration in registries contributing to NRCT. A rate of 3.45 per 
million aged <16 years has been calculated for the Southwest Region based on the 
reported numbers of cases between 2002-2006 [21]. However, there may have been 
some cross boundary referrals; 12% of CCLG (cancer and LCH) registrations from 
Bristol, the main centre in the Southwest, were from outside the region.  
 
The West Midlands registry estimated that ascertainment was 95% complete. 
Completeness of ascertainment was 95% for the Northwest and 98% for the North of 
England children‟s cancer registries. 
 
In the Danish study it was reported that regional IRs varied only slightly although the 
actual rates were not published [1]. Similarly, in the Belgian survey there were no major 
differences between regions in Flanders [44].  In the Greater Delaware Valley in the US, 
the referral area for Philadelphia Children‟s Hospital, the IR for those under 21 years 
between 1970-1984 was just over two cases per million per year [113]. This is 
comparable with the US estimated rate of 2-5 cases per million per year [116].  
 
A higher rate of 8.9 per million per year has been reported in Stockholm County in a 
study of 29 cases over 10 years; other regional rates in Sweden are not reported.  All 
children in the county with LCH are referred to a single centre which is advantageous in 
identifying cases. Ascertainment was considered to be very comprehensive and this may 
be reflected in the higher incidence compared to those reported in parts of the UK and 
US [28]. 
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An epidemiological study of histiocytic disorders (LCH, HLH and malignant 
histiocytosis) was reported in Northeast Egypt from a hospital centre which admits 
patients from four governorates [121]. Over a five year period 22/27 cases were 
diagnosed with LCH, all less than 10 years of age. The region has a childhood 
population of 7 million although the age range was not stated. The childhood incidence 
of LCH is estimated at approximately 0.6 per million per year. Most of the 27 cases 
(74%) came from one governorate. This may be because it has the highest population of 
the four governorates reported or may implicate some environmental factor.  
 
2.3.3 Age 
The incidence of childhood LCH decreases with age, the highest rate being in children 
with MS disease under one year of age.  Published rates by age group are reported in 
table 2.7. In a study in France IRs decreased from 15.3 in children less than one year old 
to 2.0 per million per year in the 10-14 years age group [3]. Similarly IRs reported by 
the German Childhood Cancer Registry ranged from 23 per million per year in those 
aged less than one year to 3.0 per million per year in those aged 10-14 years [26].  The 
rates in two UK regional studies showed the same trend but were lower in all age 
groups. 
 
There have been several reports of congenital and neonatal cases. Guyot-Goubin et al 
reported that 5/14 infant cases identified from French registries were diagnosed under 
four weeks old [3].  Using data from the German Childhood Cancer Registry, Minkov et 
al estimated the incidence of neonatal LCH (diagnosed age <28 days) to be 2 per 
million per year [54].  This may be suggestive of a prenatal origin of the disease [53, 
122, 123].   
 
Table 2.7 Reported incidence rates (per million per year) by age group 
Author Place <1 year 1-4 years 5-9 years 10-14 years 
Guyot-Goubin et al 
[3] 
France 15.3 7.2 3.2 2.0 
Cancer Registry 
report [26] 
Germany 23 7 4 3 
Alston et al [2] NW, UK 9 4.6 1.1 0.7 
Cotterill et al [25] NE, UK 8 3.2 1.5 1.4 
39 
 
 
2.3.4 Adults 
There have been no population-based studies of LCH in adults and only three studies 
with over 100 adult cases, one being an international multi-centre study [55, 76, 79]. In 
a large study at a hospital centre in the US, 58% of 314 patients ranging from 2 months 
to 83 years were aged over 20 years; the median age at diagnosis was 24.5 years [55].  
In a second US study of 541 patients, 39% of cases were aged over 21 years and had a 
mean age of 32 years [79].  In the international Histiocyte Society Registry of 274 
adults (aged over 20 years) from 13 countries, the mean age was 35 years at diagnosis. 
The peak incidence was in young adults and it decreased with age – 46% were aged <30 
years, 32% were 30-44 years, 16% were aged 45-59 and 6% were > 60 years [76].  
 
Estimates of incidence range from 1-2 adults per million to “at least 10-15 per million 
persons per year” based on a study of lung disease by Colby et al [124, 125]. More 
recently, between 2001-2006 the LCH-Belgian Survey prospectively registered similar 
numbers of children (aged 0-20 years) and adults – 67 and 61 cases respectively, giving 
IRs of  8.3 and 2.2 per million per year. The rates were similar to that for all ages from 
the Belgian Cancer Registry (3.0 per million per year between 2004-2006) where data 
had been collected retrospectively [44]. A national database of adult LCH cases is being 
established in Germany which may eventually confirm these incidence rates [77].  
 
2.3.5 Sex  
In most studies a slight male predominance has been reported with a male to female 
ratio ranging from 1.1 to 2.2 (see table 2.1.1). The reason for this difference is not 
known. However, the IR in France for boys and girls aged less than 15 years was similar 
at 4.9 and 4.3 per million per year respectively and Alston et al found no difference in 
the incidence rate by sex in Northwest England (p=0.81) [2]. The LCH-Belgian Survey 
registry has a total of  247 children and adult patients registered, of which 56% are male 
(ratio 1.3:1) [44]. 
 
2.3.6 Type of disease 
Several studies have published incidence rates by type of disease. Infants and young 
children have a higher incidence of disseminated disease than older children in whom 
SS disease is predominant [22]. The incidence in children under two years of age was as 
high as 16.4 per million per year in Denmark [1]. In France, Guyot-Goubin et al 
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reported an incidence of 2.6, 1.3 and 0.6 per million per year for children under 15 years 
with SS (unifocal), MS RO- and MS RO+ disease respectively [3].  In Stockholm 
County the rates were higher  6.2 for those with SS disease and 3.3 and 1.2 per million 
per year for cases with MS RO- and MS RO+ disease respectively [28]. The disease 
progressed in several children and at its maximal extent (after a median of six years 
follow up) the incidence was 4.3 for those with MS RO- disease and 1.5 per million per 
year for those with MS RO+ disease.  
 
Incidence rates by type of disease were broken down further by age group in France as 
shown in table 2.8 [3].  The highest rate (8.2) was in children aged less than one year 
with unifocal disease although this age group had the highest rates of all forms of the 
disease. 77% of these children had skin disease which accounts for the high incidence 
rate of unifocal disease in this age group. It is generally accepted that unifocal disease 
occurs mainly in children over five years old, bone being the most common site.  
Although the IR is low (2.4 per million per year), 93% of children in the 5-9 years age 
group had bone disease compared with 10% in <1 year, 80% in 1-4 years and 86% in 
10-14 years age groups. 
  
In the UK, Alston et al similarly found that skin was the most common site of disease in 
those under one year of age (76%) [2]. Bone disease occurred in 69% of patients aged 
1-4 years (as single or MS disease) and was present in 100% of those aged 5-14 years. 
The proportion of those with MS disease was 64% aged <1 year, 71% aged 1-4 years 
and 17% aged 5-14 years. 
 
Table 2.8 Incidence rates (per million per year) in France by age group and 
type of disease [3] 
Age group 
(years) 
Unifocal MS RO- MS RO+ Total 
<1 8.2 2.4 4.7 15.3 
1-4 3.0 3.0 0.9 7.2 
5-9 2.4 0.7 0.1 3.2 
10-14 1.5 0.3 0.1 2.0 
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De Filippi et al have suggested that the risk of developing SS as opposed to MS disease 
may be genetic with “specific cytokine gene variants affecting susceptibility to LCH 
and its clinical heterogeneity” [126].  
 
2.3.7 Trends over time 
There is no evidence that the incidence rate of LCH has changed over the period during 
which incidence studies have been conducted.  The LCH-Belgian Survey reported that 
incidence remained stable over a six-year period [44].  In the Northwest of England 
cases diagnosed between 1954-1998 showed a decline in the rate of LCH in children 
under one year of age from 10.9 per million per year in the early years to 6.1 per million 
per year in the latter years. However, the overall incidence rate for children under 15 
years remained fairly constant over the diagnostic time period with a rate of 2.6 per 
million per year.  This study also reported an increase in the diagnosis of bone and soft 
tissue disease and a decrease in liver and lung lesions over time. Better diagnostic 
techniques may account for the increased identification of cases [2].  
 
2.4 Aetiology  
The cause of LCH remains unknown except for isolated pulmonary disease in adults 
which is strongly associated with smoking; the majority of patients with the disease are 
smokers or ex-smokers [55]. The association is supported by mouse models in which 
exposure to tobacco smoke induced inflammation similar to pulmonary LCH in humans 
and which regressed when the exposure stopped [81]. Isolated lung disease in children 
is rare and its origins are unknown but smoking has been thought to be causal in a few  
reports including a child who had smoked for two years and in a toddler exposed to 
passive smoking [127, 128]. Bernstrand et al followed up 41 LCH cases (34 children 
and 7 adults) more than five years after diagnosis and 7/10 with radiographic 
abnormalities were smokers. 7/10 of these cases had had lung involvement at diagnosis 
although only 2/10 had any respiratory symptoms at follow up.  Numbers were very 
small but they concluded that smoking may be a risk factor for pulmonary LCH in 
patients previously diagnosed with LCH [97].   
 
LCH is not hereditary although familial cases have been reported, most frequently in 
monozygotic twins [129, 130].  Familial cases are further described in section 2.5.2.  
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Genetic factors may be involved, suggested by familial susceptibility in some cases, and 
an increased risk of cancer [91]. Although there have been a few genetic studies there 
have as yet been no genetic analyses of familial cases.  Da Costa et al, in a 
comprehensive multi-national study testing for genomic defects using 72 samples, 
found no evidence of abnormalities although unidentified genes may still be involved 
[131].  
 
LCH has been described as a reactive disorder because of the association between 
pulmonary LCH and smoking. In contrast others have described it as neoplastic. LCH 
cells have been found to be clonal which may be a feature of cancer or a localised 
inflammatory response [132-134]. Clonality has been demonstrated in several studies 
using a Human Androgen Receptor gene Assay (HUMARA) which can distinguish 
clonal or polyclonal X chromosome inactivation patterns in female tissues [132, 133]. In 
female LCH patients heterozygous for the HUMAR gene, in a clonal population of 
cells, inactivation will occur consistently on one chromosome whereas in polyclonal 
cells some will show inactivation on the paternal X chromosome and some on the 
maternal X chromosome. The disease is unlike cancers in other respects; the forms are 
heterogeneous, there is a high probability of survival in most cases and the occurrence 
of spontaneous regression, even in MS cases [11, 133]. However, abnormally shortened 
telomere lengths seen in pre-malignant lesions and some cancers, including leukaemia, 
have been observed in LCH cases with disseminated disease [135].   
 
Although LCH is caused by a proliferation of Langerhans-like cells and other cells of 
the immune system there is no evidence of it being a primary immune disorder. An 
over-production of proteins (cytokines) which regulate the immune system has been 
found in LCH cases [8, 136] as has a decreased capacity of antigen presentation in LCH 
cells [137]. An abnormal immune response may be triggered by some external factor 
such as a virus but investigations of viruses in LCH lesions have been inconsistent [133, 
138]. In a study published in 1994, McClain et al investigated the presence of common 
viruses which affect children under five years old, the age group in which the incidence 
of LCH is the highest. Their case-control study, used bone and lymph biopsy specimens 
from 56 cases; the controls had reactive hyperplasia, Hodgkin‟s disease and 
dermatopathic lymphadenopathy. They tested for nine viruses but found no significant 
difference in viral infection between LCH cases and controls [138]. Subsequently, 
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Glotzbecker et al found an association with Human Herpes Virus (HHV) in cases of 
bone LCH.  However, their results were not repeated in a second study the following 
year using more specialised techniques [139, 140].  It is possible that other common 
viruses (such as RSV) which were not tested for may be involved or that, at the time of 
the biopsy, the agent which triggered the disease was no longer present.  
 
There is also little epidemiological evidence of viral illness leading up to the onset of 
disease. A few associations such as maternal infections and familial thyroid disease 
have been reported but there is no conclusive evidence of causality. A time-space 
cluster was reported in a community in Arizona/Mexico by Kramer et al as evidence of 
a shared environmental exposure [118]. However, numbers were extremely small; there 
were three cases over a five–year period (section 2.5.4). The cause of LCH may be a 
combination of genetic, infectious and environmental factors. Associations with LCH 
and case-control studies performed to assess risk factors for the disease are discussed 
further below.  
 
2.5 Risk factors and associations 
2.5.1 Exploratory studies 
In Carstensen and Ornvold‟s study no association was found with previous disease, 
delivery route, birth complications, low birth weight or blood group or type [1].  Risk 
factors for the development of LCH were further investigated in two large cohort 
studies in the US in the mid-1990s [141, 142]. Patients were ascertained from several 
institutions around the country plus the Children‟s Cancer Group. Data were collected 
by self-completion questionnaires sent to parents which addressed demographic details, 
pregnancy and birth, childhood diseases, maternal diseases, drug usage, residential and 
family medical history and environmental factors. The questionnaires had been 
developed for previous studies of potential risk factors for childhood cancer. 
 
The first of these studies by Hamre et al was a case-control study of 200 individuals 
aged less than 21 years, diagnosed between 1971-1986 at several institutions. 
Information was collected from clinical notes and by a 22-page questionnaire completed 
by parents. 56 cases were lost to follow up or did not return questionnaires. Clinical data 
were available for 144 cases and questionnaire data were available for 177 cases. Cases 
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were compared with two control groups, the first being a group diagnosed with various 
childhood cancers. It was thought that recall by parents of children in the cancer control 
group and the LCH group would be very similar. However, any risk factors common to 
both groups might not be obvious and for this reason, a second control group (a 
community group) was selected. All three groups were matched on age, ethnicity, 
region and income [142].  
 
The clinical features of disease in the LCH cases were similar to other reports: 62% had 
SS disease (bone 80% and skin 14%) and 38% had MS disease, 77% of whom were 
under three years of age at diagnosis. The male to female ratio was similar in all groups 
(1.4:1 in the LCH and cancer groups and 1.1:1 in the community control group). Family 
sizes in all groups were also similar. As indicated by the length of the questionnaire, a 
large number of factors were assessed. LCH was associated with parental exposure to 
solvents, a family history of benign tumours and infant medication use. However, the 
factors most significantly associated with LCH were maternal urinary tract infections, 
and feeding problems and blood transfusions in the child during infancy. In utero 
transfer of maternal lymphocytes to the foetus may be a possible trigger for LCH. With 
regard to the other factors, an existing but undiagnosed childhood illness may have led 
to increased medication, feeding problems or the use of blood transfusions in the 
neonatal period.  The study also found that significantly fewer LCH cases used 
supplemental vitamins when compared with both control groups.  No associations were 
found between childhood environmental exposures and LCH.  The authors carried out 
multivariate analyses to estimate the strength of these associations and the factors which 
were independently associated with LCH were family history of benign tumours 
compared with both control groups, and feeding problems in infancy compared with the 
control group. The possibility of reporting bias was acknowledged; 24% of cases did not 
participate and there may have been differential recall between the parents of cases and 
the community control group. However, they felt that the findings of increased risk with 
solvent exposure, family history of benign tumours, infant blood transfusions and 
maternal urinary infections warranted further study. 
 
Following this paper, the same group, led by Bhatia, conducted a second large case-
control study to look for risk factors for SS and MS LCH [141].  The same 22-page 
parental questionnaire was used with another to obtain clinical details from the primary 
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clinician. 459 children diagnosed aged less than 15 years whose parents were members 
of the Histiocytosis Association of America and Canada were identified.  Patients were 
categorized into two groups of those with SS or MS disease. As children with SS 
disease tend to be diagnosed at an older age than those with MS disease it was thought 
that categorizing them may give some insight into why this occurs. There were 683 
community controls and 3719 controls with cancer. LCH patients tended to have been 
born later, were more likely to live in towns and to have a higher socio-economic status. 
Adjustments were made for these differences in the analysis, in an attempt to avoid 
recall and selection bias respectively.   
 
The age and sex distribution in cases was reported to be similar to other studies; the 
median age at diagnosis was 1.8 years and the sex ratio was 1.1:1. However, the 
proportion of MS cases (53.8%) was much higher than in their previous study (38%) 
which may account for the relatively young median age at diagnosis. Postnatal 
exposures associated with MS LCH included infections (ear, skin, oral thrush) and 
medication use (mainly antibiotics).  Both SS and MS LCH were strongly associated 
with thyroid disease in the child and in other members of the family although this was 
reduced after excluding patients with LCH involving thyroid involvement and diabetes 
insipidus. The lack of vaccinations and chickenpox in childhood were similarly 
significant risk factors for both SS and MS LCH.  There may have been a protective 
effect from vaccination, although immunisation in these cases may have been delayed 
because of illness.  Gastrointestinal problems were associated with an increased risk of 
SS LCH as was exposure to solvents (most commonly acetone) although parental 
exposure was not a risk factor. In this study LCH was not associated with feeding 
difficulties or infant blood transfusions nor was LCH associated with maternal urinary 
tract infections as earlier reported by Hamre et al. Although cigarette smoking has been 
shown to be a risk factor for LCH in adults, a history of smoking in parents pre-
conception and during pregnancy was not associated with LCH in children in this study 
[55, 76].   
 
Although the authors adjusted their analyses to account for the higher socio-economic 
status of cases, this group of patients, though large, was a „convenience‟ sample. All 
parents were members of the Histiocyte Society, 96.5% patients were white and they 
were more likely to live in an urban environment.  Two control groups were used in an 
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attempt to reduce reporting bias. The association with postnatal infections, lack of 
immunisations and association with thyroid disease led the authors to speculate that an 
immune dysregulation may be involved in LCH patients. 
 
 No consistent hypothesis regarding risk factors for LCH emerged from these two large 
studies.  
 
Donadieu et al also studied vaccination in association with LCH [143]. In contrast to the 
study by Bhatia et al, they found 6/621 cases in which they considered that vaccination 
may have exceptionally triggered LCH, i.e. that LCH occurred within a month from 
vaccination and the site of the lesion was in the same area as the injection.  
 
Other studies of pregnancy and birth characteristics have found associations with 
various malignancies. In a large case control study of 800 individuals in the US, Kaye et 
al found an association of ALL with birth weights above 3800g in those diagnosed less 
than four years of age. In addition, history of miscarriage and Caesarean sections 
suggested an increased risk [144].  In a report from the UK Childhood Cancer Study, 
Smith et al also found that heavier birth weight is associated with an increased risk of 
leukaemia; lower birth weight was associated with hepatic tumours [145].  
 
2.5.2 Familial and genetic factors 
No clusters or familial cases were found by Carstensen et al in Denmark and none have 
been reported in other national studies [1]. However, although there is limited data it is 
estimated that about 1% of cases have a relative with LCH suggesting a genetic 
component in the development of the disease [129]. Studies have been mainly of twins 
although as might be expected, if the disease is hereditary, other siblings, parents and 
cousins with LCH have been reported [122, 146]. In an international study of family 
clusters, 7/8 monozygotic twin pairs were concordant for LCH compared with 1/10 
dizygotic twin pairs and five twin pairs in which zygosity could not be established 
[129].  In this study there were also two sibling pairs and two sets of first cousins 
among whom consanguinity was reported.  In studies of twins, however, siblings (and 
to a lesser extent) other family members share a common environment and an inherited 
disease may only be expressed after a specific environmental exposure.  
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 Arico et al further reported LCH in two generations in four Italian families. The parents 
were diagnosed in adulthood and 3/4 of their children were diagnosed in childhood.  
The diagnosis was simultaneous in one family but the time delay between the two 
diagnoses was between 2-7 years in the others [130].  Given that only a subset of LCH 
cases is familial, it has been suggested that family members may share a genetic 
predisposition for the disease although no single gene has been implicated and a 
common viral aetiology cannot be excluded [130, 147].  Human leukocyte antigen 
(HLA) typing has been carried out in a few studies. The HLA complex found on 
chromosome 6 is characteristic for each individual. In a study to examine whether LCH 
was associated with any HLA antigens, Yu and Chu conducted a study of 74 patients 
with LCH from Great Ormond Street Hospital and Hammersmith Hospital and 
compared them with 117 healthy controls [148]. Of those patients tissue typed (46/74) 
they found an increase in HLA-B7 antigen – 41.3% in LCH patients compared with 
16.2% in the control group (p=0.013). The authors acknowledged a probable bias in that 
since patients were recruited from two tertiary centres they were likely to be more 
severe cases. However, the increase in antigen HLA-B7 was not associated with either 
SS or MS disease or with disease outcome groups (inactive disease, active disease and 
death).  In a later study of 29 patients and 37 healthy family members, McClain et al 
examined the frequencies of HLA types and compared them with published frequencies. 
They found an increase in two antigens (DR4 and Cw7) in Caucasian LCH cases 
(21/29) which were particularly frequent in those with SS bone disease.  (There were 
insufficient numbers for analysis of cases of other ethnicity.) Unaffected family 
members also showed an increase in the prevalence of one of these antigens (DR4) 
compared with published frequencies and controls tested during the same period [149].  
They suggested that individuals with these HLA types may have increased susceptibility 
for specific types of LCH.  In addition, a study by De Filippi et al found that patients 
with SS or MS disease had different genetic characteristics (cytokine genes) which they 
suggested may vary susceptibility to LCH [126]. 
 
2.5.3 Ethnicity and socio-economic factors 
Cases of LCH have been reported from many parts of the world and while there has 
been a predominance of white children in published literature this may be a bias in 
reporting.  Raney et al reported that the incidence of LCH in the Greater Delaware 
Valley between 1970-1984 was 9% for black children which was lower than the 
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percentage of blacks in the local population (15%) [113]. In a UK hospital series 
between 1980-87, 8/58 (13%) cases were „Asian, oriental or negroid‟ and in the US, in a 
study of cases between 1974-1979, 21/92 children were Latin-American, black or 
American Indian (22%) [90, 150]. The proportions of Caucasian to non-Caucasian 
children in each of the four groups they studied (based on the progression of disease) 
were similar.   
 
None of the above was a population-based study. The West Midlands Children‟s Cancer 
Registry registered 13 cases of LCH over a five-year period 11 of whom were 
Caucasian and one was Asian (the ethnicity of the other case was not stated). The 
proportion of non-Asian and Asian LCH cases in the registry were 2.2% and 2% 
respectively [33]. In Stockholm County, Stalemark et al reported 29 cases of LCH over 
a ten-year period of whom eight (27%) were of non-Caucasian European origin. 
However, it was not stated whether this proportion of non-Caucasian patients was 
representative of Stockholm County and there is little evidence for an association with 
ethnicity [28]. 
 
Bhatia et al found that their LCH cases belonged to a “higher socioeconomic status, 
were more likely to live in urban areas and had a higher percentage of white subjects 
compared with their control groups”.  However, the authors felt that the difference 
between cases and controls was probably explained by the fact that the parents of the 
children included were all members of the Histiocytosis Society and as such, were not 
representative of the case population [141]. 
 
2.5.4 Seasonality and environmental factors 
Patterns of disease may vary by geographical location, for example, lung disease 
appears to be more common in China and orbital disease more common in Mexico [118, 
151]. Kramer et al described three cases of orbital LCH in children born in a community 
in Arizona/Mexico – an incidence of 26 times the expected rate of 1.5 per million 
(p=0.0001) [118]. The study was of three children born over an 18-month period and 
diagnosed aged between 21-24 months. The cases were all from middle class families 
which represent approximately 20% of the local population among which additional 
cases may not have been reported. In spite of the very small sample size, the authors felt 
that this time-space cluster was evidence of a shared environmental exposure 
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particularly as increased rates of other diseases (including leukaemia and multiple 
myeloma) had been reported.  Braier et al have reported larger proportions of cases with 
lung and liver disease in children in Buenos Aires [103, 152]. Between 1987 and 1999, 
66 MS patients were identified from a hospital series of 182 and 36 had liver 
involvement (20%). In a later study they found pulmonary involvement in 36/220 
patients (16%), 34 of whom had MS disease.  The reasons for these differences are 
unknown but may reflect environmental or genetic differences in the populations.  
 
A few studies have reported possible seasonal variations in diagnosis or onset of LCH 
which may be suggestive of an infective aetiology; certain viruses may be more 
prevalent at particular times of the year. Seasonality can also include some 
environmental factors that have seasonal variations in exposure levels. Variations in 
temperature, rainfall and sunlight may influence human behaviour and consequently the 
spread and load of infection. In a different study in Mexico, by Soto Chavez et al, the 
onset of LCH was mainly during the rainy season and was more commonly found in 
patients residing in (colder) high altitude inland cities [153]. In a second report, 
however, with three more cases, they found the peak month of first presentation of the 
disease was March (just before the rainy season) with the peak month of birth being 
September [154]. The reports are from abstracts and there were few data available for 
these analyses (38 cases with month of onset and 21 with month of birth). However, the 
authors‟ suggestion that environmental factors may be important in the onset of LCH 
may warrant further investigation.  In Taiwan, Chen et al studied cases of LCH over a 
five–year period and found a higher incidence during the summer months in 1997-1998 
when rainfall was at its peak during a very severe El Nino [119].  The increased 
incidence (which did not occur in childhood cancers) was accounted for by a 
significantly higher number of cases with disseminated disease (p=0.012), particularly 
those with multifocal bone disease (p=0.017), compared with other years; these cases 
were also diagnosed at a younger age. In addition, reactivation and progression was 
found to occur more frequently in cases presenting during this El Nino. In a study of 29 
cases in Stockholm County over a 10 year period 76% of cases were diagnosed during 
autumn and winter months [28]. Significantly, all nine cases with MS disease and 3/5 
with SS disease who went on to develop MS disease were all diagnosed during the 
autumn or winter. Although LCH is associated with diagnostic delay (which may affect 
the interpretation of any seasonal variation) the authors reported that the median time 
50 
 
 
from parental observation of symptoms to diagnosis was only one month. They 
concluded that infections or other environmental factors may be associated with the 
development of the disease.  
 
In utero exposure to infections during early pregnancy may cause disease as the foetus 
is more at risk of damage at that time. However, in their study in the Northwest region 
of England, Alston et al found no evidence of seasonality by month of birth, month of 
first symptom or month of diagnosis [2].  
 
The infections specified by Bhatia et al which may increase the risk of LCH were ear 
infections, bullous impetigo and oral thrush [141]. Several viruses have been studied in 
connection with LCH including human herpes virus and cytomegalovirus but as 
discussed in section 2.4 there is no consistent evidence for a viral cause of LCH and 
further studies are needed [138, 139]. 
   
2.5.5 Associations with cancer  
LCH has been associated with childhood cancer, including both leukaemias and solid 
tumours, and is more frequent than could be expected by chance [91, 155, 156]. The 
Histiocyte Society Malignancy Registry which was established in 1991 identified 73 
cases of children less than 18 years old with malignancy. Those most often diagnosed 
were solid tumours (27), acute myeloid leukaemia (AML) (23), acute lymphoblastic 
leukaemia (ALL) (16) and lymphomas (7). ALL tended to precede LCH, and solid 
tumours and AML mainly occurred later, possibly as a result of therapy for LCH. 
Tumours occurring in the radiation field of treatment for LCH suggested that it was 
inducing malignancy in these patients and radiotherapy is no longer used [91]. 
Consequently, in future, fewer cases of AML and solid tumours may be observed. ALL 
was associated with 16 cases of LCH. It preceded LCH in 10 cases; the median interval 
between the diagnosis of ALL and subsequent LCH ranged between 0.3-5 years. The 
authors speculated that LCH may have been induced while the patients were immuno-
suppressed while receiving treatment. In the six cases of ALL diagnosed after LCH the 
interval between the diagnoses ranged from 3.7-7 years [99].  There were seven cases of 
LCH with either neuroblastoma or retinoblastoma which may indicate a common 
genetic predisposition [91, 157].   
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Haupt et al investigated the risk of secondary leukaemia after treatment for LCH with 
etoposide (now excluded) in two cohorts of over 600 cases (an Austrian-German-Dutch-
Swiss cohort and an Italian cohort) [155]. Secondary leukaemias (AML) only occurred 
in the Italian cohort. Characteristics of both groups were similar although the Italian 
group had received higher cumulative doses. In the particular subtype of AML reported, 
aberrations occur on chromosomes 15 and 17 in virtually all cases. An exchange of 
material between these two chromosomes occurs (reciprocal translocation) resulting in 
the formation of two hybrid genes (fusion genes). The authors suggested that, since this 
variant of AML is more common in Italy than in other European countries and is also 
more frequently reported among other Latino populations and Japanese, “the break 
points on either chromosome 15 or 17 that are involved in the translocation are more 
fragile in these populations”.  The higher doses of etoposide that the Italian group 
received may have lead to these chromosome mutations. 
 
2.5.6 Congenital anomalies 
The frequency of congenital anomalies in patients with LCH was reported by Sheils and 
Dover in a case control study in Baltimore in 1989 [158]. 39 cases were identified over 
a 30 year period and were compared with control groups of childhood bone cancer and 
children with suspected child abuse, matched on sex and race. 18% of the LCH group 
had a major congenital abnormality compared with 3% and 8% in the other groups.  
LCH cases with congenital anomalies were more likely to have MS disease involving 
risk organs and earlier onset of disease; only one case of unifocal disease had congenital 
anomalies. Since the study included cases diagnosed 30 years earlier, not all were 
diagnosed histologically and the authors were wary of sampling bias. However, the 
LCH group were thought to be representative of published LCH populations.  They also 
considered the possibility that patients with congenital defects may require treatment 
which increased the risk of LCH although no evidence of iatrogenesis had been 
reported. 
 
In a US study of mortality from Letterer-Siwe disease 1960-1964, Glass et al suggested 
that LCH may begin before birth given the peak in the frequency of deaths in infants 
and the deaths of five pairs of siblings, including one pair of twins [122]. They 
suggested that if congenital anomalies and LCH were concurrent, as in the case of some 
childhood cancers and congenital anomalies, this might be interpreted as evidence of a 
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prenatal oncogenic and teratogenic agent.  (At that time (1968) no congenital anomalies 
in LCH cases had been reported.) 
 
2.5.7 In vitro fertilization (IVF) 
There have been three publications (based on overlapping data) reporting cases of LCH 
in children conceived by in vitro fertilization [159-161].  In the second, Kallen et al 
collected data on over 16,000 children born in Sweden (1982-2001) conceived after 
various types of IVF and matched them with the Swedish Cancer Registry to assess 
morbidity and cancer risk [160]. 29 children with cancer or LCH were identified over a 
1-20 year follow-up period (median 5.5 years).  There was no significant increased risk 
of childhood cancer. However, the expected number of cases of LCH was 0.9 compared 
with the observed number of five (RR 5.6, 95% CI: 1.8-13.0). This excluded an 
additional two cases which were identified from hospital registers which were not 
reported to the Cancer Registry.  This apparent increased risk of LCH in children 
conceived by IVF was not confirmed in their most recent study with a larger cohort of 
26,692 children and only one additional LCH case although there was a moderate 
increased risk of cancer (OR 1.34) [161].   
 
2.5.8 Associations with other conditions  
As well as cancers and congenital defects, LCH has been reported to be concurrent with 
other conditions. Most of the reports of co-morbidity have been of small numbers of 
cases or among hospital series. However in a large multi-centre survey in France of 348 
cases, 11 children had different concurrent conditions including two cancers [56].  
Associations include sclerosing cholangitis, myelodysplasia and other histiocytic 
conditions – HLH,  juvenile xanthogranuloma and Erdheim-Chester disease  [103, 162-
165].  The authors speculated that overlap in these conditions might be due to a 
common histogenetic background. Cases have also been reported with partial DiGeorge 
syndrome and Evans syndrome both of which are disorders of the immune system [166, 
167]. In the case of the latter, it was thought that cytokine imbalance in LCH may have 
played a role in the development of autoimmune disease. 
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2.6 Mortality and survival 
The few national studies of LCH which have reported mortality or survival rates are 
tabulated in table 2.9. Mortality ranges from 1-12% and survival is around 90% after 
five years. The majority of deaths were among those with MS disease, particularly with 
risk organ involvement.   
 
In addition to these studies, Glass et al reported mortality from Letterer-Siwe disease 
(disseminated LCH) in the US between 1960-64 by age, race and sex in children under 
15 years [122]. There were 270 deaths, 157 males and 113 females (ratio 1.4:1); 240 
were white and 30 were non-white.  There was no significant annual variation between 
States. Deaths declined with increasing age; the majority (163 (60%)) being under two 
years of age with only a few deaths aged 3-14 years (57 (20%)).  For those under two 
years of age, deaths from Letterer-Siwe (MS) disease, which is more common in this 
age group, were estimated at between 3-5 per million per year.  However, the study 
relied on coding of the cause of death from the death certificate (ICD 202.1 – “other 
neoplasms of lymphatic tissues”) and the term “reticuloendotheliosis”, and it is possible 
that other histiocytic disorders may have been included.  In particular, the inclusion of 
five pairs of siblings raises the possibility that deaths were from familial HLH (which 
has significant mortality) [14]. 
 
Recently, Donadieu et al investigated death from LCH in France between 1979-2005 
using data from the French LCH Registry and national death certification registry [168]. 
Deaths were obtained based on appropriate ICD codes for the cause of death and, in 
addition, the text of the cause of death was checked. For the later years of the LCH 
registry (2000-2005) data is particularly good for those aged under 15 years old since it 
was collected prospectively. There were 791 deaths of all ages. For those under 15 years 
the death rate (per million per year) ranged from 1 in 1980-1990 to 0.5 between 1990-
1999 and 0.1 since 1999. This decrease reflected the more aggressive therapy and 
curability of the disease over the decades. In the whole population, the death rate 
declined from 0.8 to 0.35 per million per year with the most frequent causes of death in 
adults being respiratory disease, liver failure and neurological complications. 
 
Various clinical studies with over 50 patients have reported similar survival rates to 
those in national studies [84]. Willis described survival of 71 patients in California over 
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25 years with a median follow up of 8.1 years.  All except one patient were diagnosed 
before the age of three years [101]. Survival at 15 years was 83%, 100% and 76% for 
SS skin disease, bone disease (unifocal and multifocal) and MS disease respectively.   
 
In the UK, Nanduri reported that 36/275 (13%) cases of LCH (all MS) at Great Ormond 
Street Hospital diagnosed between 1966-1998 died [63]. Leavey et al reported 21% 
mortality among 41 cases in Dublin over three decades (1959-1989) although survival 
increased from 57% to 95% with only one death in the last decade [23]. Similarly, in the 
Northwest of England study of 101 cases, survival increased from 57% in 1954-1968 to 
74% in 1985-1998. Improved survival in this region after 1969 was related to different 
chemotherapy regimen and the employment of a paediatric oncologist [2].   
 
In 1991 the Histiocyte Society introduced the first international clinical trial for the 
treatment of MS LCH and has since introduced further trials which categorise patients 
depending on the severity of disease.  The results have been compared with previous 
European multi-centre clinical trials and mortality remains similar at around 20%, the 
probability of survival being around 80%.  It is thought that for patients who do not 
respond to treatment within the first six weeks the probability of mortality is 75% 
within two years from treatment.  Clinical trials have also reinforced the efficacy of 
conservative treatment for those patients thought to be less at risk thus reducing possible 
toxic effects [74, 169]. 
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Table 2.9 Deaths from LCH and survival rates reported by national studies  
Author Year No of 
cases 
No of 
deaths 
Disease type Interval between 
diagnosis and 
death (median) 
(months) 
Median age at 
diagnosis of 
deaths (months) 
Survival (years 
after diagnosis) 
Carstensen [1] 1975-1989 90 9 (10%) 9 MS (8 RO+) Within 6 months   
French Group 
[56] 
1983-1993 348 28 (8%) 26 MS RO+ 11.9 (range 0-64) 8.5 90% at 4 years 
Kaatsch et al [20] 1980-1992 488     90% at 3 years, 
88% at 5 years 
Muller et al [27] 1981-2000 111 14 (12%) 14 MS   88.3 at 5 years, 
87.3% at 10 and 20 
years 
Guyot-Goubin et 
al [3] 
2000-2004 212 2 (1%) 2 MS RO+ Within 12 months  99% at 1 and 2 
years 
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2.6.1 Mortality risk factors  
As described above, the site of disease, i.e. whether risk organs (liver, spleen, lungs, 
bone marrow) are involved, is the most important factor in determining mortality 
especially if there is poor response to initial treatment [74, 92]. Although MS disease is 
more common in younger children, age is not an independent predictor of a poorer 
prognosis [169]. With regard to the reporting of mortality and survival, the era in which 
treatment occurred may also be important because the introduction of more aggressive 
treatment (combination therapy as opposed to monotherapy) and greater understanding 
of the progression of the disease has resulted in increased survival [84].   
 
In a review of cases in Dublin between 1959-1989 all deaths were under two years of 
age and had liver involvement [23].  Similarly liver and spleen involvement was a risk 
factor in survival of cases in the Northwest of England.  Five year survival was only 
25% for these cases compared with 78% for those without liver involvement (p<0.0001) 
[2].  In the study of 348 cases in France 26/28 patients who died had organ dysfunction 
[56].   
 
In addition, although there is a reported predominance of male cases of LCH, boys may 
be at a higher risk of mortality than girls. In the French study (above), in which the sex 
ratio was 1.3:1, 82% of deaths were male [56]. 
 
2.6.2 Risk factors for permanent consequences 
Permanent consequences of LCH were described in section 2.1.6. Risk factors depend 
on the initial site, extent and recurrence of disease and organ dysfunction.  In a study in 
Stockholm of cases over 39 years, children with MS disease had a poor outcome; only 
33% (7/21) had no permanent consequences compared with 58% (14/24) of  those with 
SS skin or uni- or multifocal bone disease [97]. Similarly, a study by the Histiocyte 
Society Late Effects Group reported that significantly more cases with MS disease had 
permanent consequences compared with those with SS disease (71% vs 24%, 
p<0.0001).  This study, with data from twelve oncology centres, had a 
disproportionately large number of MS cases (108 compared with 74 SS cases).  Cases 
of SS disease may have been less likely to have developed sequelae and more likely to 
have been lost to follow up, leading to an over-estimation of permanent consequences 
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among survivors. Risk factors for various permanent consequences reported in this 
study are shown in table 2.10 [102].  
 
Grois et al found that those with MS or SS disease of the craniofacial area have a higher 
risk of developing diabetes inspidus [73].  Similarly, Jubran et al reported that in 
patients with MS disease the risk of diabetes insipidus was six times higher than in 
those with unifocal bone disease.  Diabetes insipidus was also associated with skull 
lesions in this study [94].  
 
Table 2.10 Risk factors for permanent consequences of LCH (from Haupt 
et al) [102] 
Permanent consequences Risk factor 
Diabetes insipidus LCH in skull or ear or central nervous system 
Neurological LCH in ears, facial bones, orbit or diabetes 
insipidus 
Growth retardation LCH in facial bones or diabetes insipidus 
Orthopaedic  Young age at treatment 
 
 
Reactivation of disease also increases the likelihood of permanent consequences which 
correlates with the site of disease activity [58, 94, 96].  In a more recent publication 
from the International LCH Registry of over 335 cases with MS disease (excluding 
intracranial disease), LCH reactivation was estimated to increase the risk of permanent 
consequences two fold compared with those without disease recurrence.  Reactivation 
did not, however, increase the risk of mortality; most reactivations were lesions of the 
skeleton and risk organs were rarely affected [98]. 
 
In the Histiocyte Society study by Haupt et al, the effect of age at treatment was 
assessed; children with skeletal LCH aged under three years at diagnosis had a higher 
risk of developing permanent consequences than older children when followed up aged 
14 years or above [102].
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Chapter 3. Methods of ascertainment 
 
Given the rarity of LCH, studies on at least a national level are required to estimate its 
incidence and to obtain sufficient numbers of cases to fulfill the aims of the study. Since 
a single source is unlikely to ascertain all cases of LCH, multiple sources were 
considered to be necessary. Children with LCH may be seen by paediatricians and 
clinicians of various specialties and therefore this study aimed to approach as many 
specialists as possible.  Four sources of cases were chosen and these are described 
below. To identify cases and gather information to achieve the study aims (described in 
Chapter 1) and identify any potential risk factors for the disease, a questionnaire was 
devised, to be completed by reporting clinicians. The questionnaires used are detailed 
below as well as the methods of ascertainment and data collection.  A summary 
flowchart of methods used is shown in Appendix C. 
 
Prior to commencing the surveys, an application for Multi-centre Research Ethics 
Committee (MREC) approval was submitted by the author in April 2003 and approval 
was obtained from The London MREC in May 2003. Appropriate ethical approval was 
also obtained for the Republic of Ireland.  
 
Part-funding was obtained from the Histiocytosis Research Trust (HRT), a registered 
charity founded by a parent group. The main aim of the HRT is to fund research and 
scientific study into the causes of histiocytosis and the development of improved 
methods for diagnosis and treatment. They also provide information and support to 
families affected by histiocytic disorders [170].  A successful application was made for 
an additional year‟s funding during the course of the study. 
 
The study commenced in June 2003. Cases were ascertained via the British Paediatric 
Surveillance Unit (BPSU), a complementary postal survey of other clinicians (carried 
out from Newcastle), the Children‟s Cancer and Leukaemia Group (CCLG), and death 
notifications from the Office for National Statistics (UK) and the Central Statistics 
Office (RoI).  To increase awareness of the study before it started, it was publicised in 
the BPSU Newsletter.  In addition, leaflets, adapted from the study protocol (and 
produced by another member of the study team), were sent to members of the Royal 
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College of Paediatrics and Child Health and the Royal College of Radiologists. 
Surveillance ended in June 2005 and follow up of cases was at one and two years after 
diagnosis. 
 
As mentioned in section 1.8, it was hoped that the study would eventually contribute to 
a wider investigation also involving Canada and the Netherlands.  To this end, copies of 
the study protocol were sent to collaborators in both countries. The Canadian Paediatric 
Surveillance Program (CPSP) began a survey of LCH in 2009 [46]. 
 
3.1 British Paediatric Surveillance Unit (BPSU)  
The BPSU is part of the Research Division of the Royal College of Paediatrics and 
Child Health (RCPCH) [39, 171].  It was founded in 1986 in collaboration with the 
Health Protection Agency and the Institute of Child Health (London).  It is currently 
funded by the Department of Health and is run in partnership with Health Protection 
Scotland (HPS) and the Faculty of Paediatrics of the Royal College of Physicians of 
Ireland.  Its remit is to facilitate epidemiological research into rare diseases and 
conditions – usually those expected to have less than 300 cases per year. Studies of 
incidence alone are not undertaken.  It also aims to increase awareness of and 
disseminate information about uncommon disorders. Since its inception over 60 studies 
have been carried out, including a study on a related histiocytic disorder, 
haemophagocytic lymphohistiocytosis (HLH) in 1991. 
 
There is a two-phase application process for studies.  An outline is submitted for 
consideration in the first instance. If approved in principle, more details are requested 
including the questionnaires and letters which will be used to collect data.  The author 
began participation in the study at this stage. The proportion of cases that might be 
reported through the BPSU is considered.  If this is not high, then sound mechanisms 
are needed to ascertain cases through other sources. Additional sources of ascertainment 
are in any case desirable to improve ascertainment [45]. Each application is vetted by 
the Executive Committee to ensure that studies comply with eligibility criteria and that 
funding and organisational support will be available.  Studies must have relevant 
ethical, Caldicott Guardian and data protection approval before they can begin and 
(since 2005) must have National Information Governance Board (NIGB) approval 
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[172]. This approval is now required to obtain patient data without patient consent and 
is discussed further in section 3.13. However, in this study NIGB approval was not 
sought.  It is a condition of BPSU studies, that they do not seek patient consent as case 
ascertainment is more likely to be incomplete and subject to bias, and delay monthly 
case reporting. 
 
Non-eligible BPSU studies also include clinical trials, case control studies, registry 
development, and those requiring long-term follow up or retrospective reporting.  The 
system is essentially anonymous since no patient identifiable data passes through the 
BPSU.  There is an annual charge for surveillance and studies are publicised in their 
quarterly and annual reports.   
 
Surveillance for this study was undertaken for one year from mid-2003 in the first 
instance. An application was made by the author to continue for another year (2004 to 
mid-2005) to confirm the number of cases reported in the first year and to give 
sufficient numbers to look for any patterns in presentation and delays in diagnosis.   
 
3.1.1 Modus operandum 
The BPSU operates an active surveillance method.  There is a monthly reporting system 
using a mailing list of over 2300 consultant paediatricians in the UK and Republic of 
Ireland.  The list comprises mainly general paediatricians but also a number of 
specialists including dermatologists, histopathologists, metabolic disease specialists, 
endocrinologists, haematologists, oncologists and pathologists. 
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Figure 3.1 Case report card - “Orange card” 
 
Reproduced with permission from BPSU 
 
 
Every month paediatricians receive a two-part case report card („orange card‟) with a 
list of conditions being studied (figure 3.1).  They are asked to report any newly 
diagnosed or suspected cases seen in the past month for whatever reason they have been 
referred and regardless of whether they are the main clinician responsible for the 
patient.  If they have seen a child with a condition listed, they tick the appropriate box 
on one half of the card and return it to the BPSU. The clinician keeps details of the 
patient(s) reported on the remaining half.  There is an additional box on the card 
indicating „no cases to report‟ and clinicians are asked to return cards whether or not 
they have seen cases of interest. The return rate is reported to be over 93% [39]. The 
names of the reporting clinicians are then forwarded to the investigating team. The 
reporting system is summarised in figure 3.2. 
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Figure 3.2 BPSU reporting system 
 
Reproduced with permission from BPSU 
 
 
All paediatricians who reported cases to the study were sent letters asking them to 
provide further information (including family history, referral and diagnosis details) by 
completing the study questionnaire and returning it to Newcastle in a prepaid envelope.   
 
Once the questionnaire had been returned by the clinician an audit form was completed 
for BPSU.  This indicated whether a case had been confirmed, was a possible case, a 
duplicate, had been reported in error or whether follow up had not been possible.  A 
copy of the BPSU response form is shown in Appendix D.  Periodically throughout the 
surveillance period the BPSU sent a list of cases notified and the outcome was recorded 
on their database for cross-checking.   
 
Annual reports of study progress were produced for 2003-2004 and for 2005-2006 and 
in addition, quarterly reports and bulletins were produced for the BPSU at regular 
intervals. 
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3.2 Newcastle-based survey 
A Newcastle-based postal survey was also conducted to include clinicians who were not 
members of the RCPCH but who may diagnose or see children with LCH.  A mailing 
list was compiled from various sources.  Convenors of RCPCH specialty subgroups 
were approached to ask for a list of their members and for permission to include them in 
the mailing exercise. In addition, medical directories and hospital web pages were used 
to obtain a list of specialists (both paediatric and non-paediatric) which included 
oncologists, endocrinologists, haematologists, gastroenterologists, dermatologists, 
pathologists, orthopaedic surgeons, rheumatologists, radiologists and respiratory 
paediatricians.  It was thought that histopathologists, in particular, would be key in 
notifying cases and would complement those reported by paediatricians. A list of 
sources is given in Appendix E.  Since the BPSU mailing list comprises some specialist 
paediatricians it was made available for cross-checking with the postal survey list to 
avoid duplication.  
 
Clinicians were mailed four times over a two-year period (November 2003 and 2004, 
and June 2004 and 2005) inviting them to notify cases seen in the previous six months.  
A list of over 2200 consultants was compiled initially which was adapted after the first 
mailing to 1634.  Names and departments were removed for the following reasons: 
those who informed us that they or their institutes did not see children with LCH, those 
who had moved, retired or died, letters which were returned unopened, multiple 
members of the same department or institution who recommended a single clinician.  
Thereafter the list was adjusted slightly for similar reasons at each mailing. The 
numbers of letters sent at each Newcastle mailing can be found in table 5.1.  
 
On the first mailing an explanatory leaflet with a definition of the disease and reporting 
instructions was included with the survey letter and reply slip (see Appendix F).  The 
reply slip included a box to report both children and adult cases to aid clarification.  On 
receipt of a paediatric case report, the clinician was sent a copy of the study 
questionnaire to obtain further information. In the case of a reply from a pathologist, if 
stated, the treating clinician was sent a questionnaire or the pathologist was contacted 
for the clinician‟s details.  Prepaid envelopes were included with the letters to encourage 
replies. 
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3.3 Children‟s Cancer and Leukaemia Group (CCLG) formerly the United 
Kingdom Children‟s Cancer Study Group (UKCCSG) 
Cases were cross-checked regularly with a third source of ascertainment – those 
registered by the United Kingdom Children‟s Cancer Study Group (UKCCSG) which 
merged with the UK Childhood Leukaemia Working Party in 2006 to form the 
Children‟s Cancer and Leukaemia Group (CCLG) [173].   
 
At the time of data collection, the main function of the CCLG was to organise and run 
high quality clinical trials aimed at improving the outcome and quality of life of 
survivors. This function has changed in recent years and the CCLG no longer runs 
clinical trials; these are being carried out at Birmingham University Clinical Trials Unit.  
The CCLG maintains a Tissue Bank and is custodian of nearly 20 years of research 
data. It is also concerned with patient and family support and improving services, and in 
education, communication and fundraising.  It publishes guides on children‟s cancer and 
a regular magazine for families. 
 
There are over 500 multi-disciplinary members of the CCLG working in 22 paediatric 
oncology centres in hospitals throughout the UK. There are clinical trials for each type 
of cancer (and LCH) and development of each trial is devolved to 30 individual working 
groups.  The CCLG Histiocytoses Working Group works with the Histiocyte Society in 
implementing international clinical trials for the treatment of LCH.   
 
All patients with LCH who receive treatment at one of the children‟s oncology centres 
in the UK and Ireland should be registered with the CCLG.  However, it is estimated 
that CCLG have details of 90-95% of all UK and Irish childhood cancers and LCH 
cases and therefore may not have registered all children with LCH.  A formal 
application was made to the CCLG in January 2004 for data and a confidentiality 
agreement was completed and signed by members of the study team. Subsequently a list 
of cases registered by CCLG since the start of the study was provided. 
 
Clinicians with eligible cases identified only via the CCLG were sent the same 
questionnaires to obtain further details as those identified via the BPSU or Newcastle 
surveys.   Cross-checks were made regularly as there was expected to be a lag time 
between diagnosis and reporting to CCLG. Cases registered slightly later or earlier than 
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the study period were checked with clinicians to verify the date of diagnosis recorded by 
CCLG and establish whether they were eligible for the study or not. 
 
3.4 UK Office for National Statistics (ONS) and Central Statistics Office 
(CSO), Republic of Ireland 
To complete the ascertainment of cases, deaths from LCH, which may not have been 
reported through any of the other methods employed, were sought from the UK and 
Irish national registry offices. 
 
3.4.1 UK deaths 
The National Health Service Central Register (NHS-CR) is part of the General Register 
Office which was operated by the Office for National Statistics (ONS) at the time of the 
study [38].  It is now the responsibility of the NHS Information Centre [174]. The NHS-
CR contains birth and death details of all those registered with the National Health 
Service to maintain primary care medical records within the general practitioner 
network.  As well as births and deaths it records name changes and the movement of 
patients between health authorities, emigration and related events.  In addition to its use 
in administration, NHS-CR data are also used in medical research, particularly as an 
epidemiological resource. For example, in a Newcastle study assessing whether there 
was an increased risk of solid tumors among children whose fathers workers at the 
Sellafield nuclear installation in Cumbria, the births of all those born in Cumbria 
between 1950 and 1991 were identified by NHS-CR [175].   An individual‟s record can 
further be marked for identification („flagged‟) for major events including death, cancer 
and emigration.  
 
A formal application was made to the ONS ethics committee for UK deaths data in 
August 2006.  The causes of deaths are coded on the NHS-CR database using the WHO 
International Classification of Diseases (ICD) coding systems described in section 1.3. 
Several versions of the coding system have been used over the years and ONS are 
currently using versions 9 (1979-1994) and 10 (1995 to the present time) [16, 176].  A 
list of individuals with LCH who died aged less than 18 years between 1996-2005 was 
obtained by searching the NHS-CR for relevant ICD codes (ICD-9 and ICD-10) for 
LCH.  Codes for LCH as both the cause of death and the underlying cause of death on 
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the death certificate were searched. Table 3.1 shows the ICD codes used by ONS to 
look for these deaths. There were four codes in total - two version 9 codes and two 
version 10 codes - which cover the various forms of the disease. A description of the 
four codes is also shown in the table.  
 
Table 3.1 International Classification of Diseases (ICD) codes used to 
search death certificates [16, 176] 
Coding 
system 
Code Description 
ICD-9 202.5  Letterer-Siwe Disease  
Acute differentiated progressive histiocytosis 
Acute (progressive) histiocytosis X 
Acute infantile reticuloendotheliosis 
Acute reticulosis of infancy 
 277.8 Histiocytosis (acute) (chronic) 
Histiocytosis X (chronic) 
Eosinophilic granuloma 
Hand-Schüller-Christian disease  
Also “other” in “Other and unspecified disorders of 
metabolism” 
ICD-10 D76.0 Langerhans' cell histiocytosis, not elsewhere classified –
Eosinophilic granuloma  
Hand-Schüller-Christian disease 
Histiocytosis X (chronic) 
 C96.0 Letterer-Siwe Disease 
Non-lipid reticuloendotheliosis and reticuculosis 
 
 
3.4.2 Republic of Ireland deaths 
Deaths in the Republic of Ireland were checked by approaching the Central Statistics 
Office (CSO) in 2007 for the number of those who had died with LCH on the death 
certificate over the same 10 year period.  The CSO accounts for the vast majority of 
official statistics in Ireland  [37]. It was established in 1949 as a separate Office from 
the Irish Government in order to ensure its independence on statistical matters.  It is 
widely used by all sectors of society from Government departments and universities to 
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the media and general public providing statistics which are internationally comparable 
particularly with EU countries. 
 
An identifiable list of individuals who had died of LCH was not available. The Vital 
Statistics Section of the CSO provided only the number of deaths by age and sex for 
1996-2005 by searching for ICD-9 codes for LCH. The codes used on the death 
certificates were notified but the actual causes of death were not.  As described above, 
the ICD-9 code used for LCH Letterer-Siwe disease is 202.5 but the other code (277.8) 
may be used for conditions other than LCH.  Therefore further clarification was 
requested for a very small number of (potential) LCH cases identified from the first 
search. Consent was obtained from the General Register Office (who hold death 
certificates) to enable the text on the death certificates to be checked for the exact cause 
of death.  It was thus possible for CSO to confirm whether any of the childhood deaths 
during the study period were from LCH or another cause, without sending patient 
identifiable data.  The data provided for 1996-2004 were final figures based on the year 
of occurrence; deaths for 2005 were preliminary figures based on the year of 
registration. 
 
3.5 Potential cross-checks of data 
The NRCT was approached to cross-check our cases with theirs.  However, since the 
NRCT had not received any notifications of LCH for many years, other than from the 
CCLG,  it was considered that this would only provide an extra check on the cases 
ascertained by the CCLG and would not add any new cases  [177]. 
 
After the start of the study an orthopaedic surgeon (member of the British Society for 
Children's Orthopaedic Surgery) responded to the Newcastle survey and reported that a 
survey was being set up by the European Paediatric Orthopaedic Society, co-ordinated 
by a UK member and a surgeon in Vienna.  Interest was expressed initially in sharing 
data.  However, in spite of several attempts by the author and other members of the 
study team to discuss collaboration, no reply was received and thus no progress made.  
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3.6 Case definitions 
Notifications were requested for any new or suspected cases whatever the reason for 
referral and whether or not they were the main clinician responsible for the patient. 
Cases were defined as children aged less than 18 years and resident in the UK or 
Republic of Ireland at the time of diagnosis and newly diagnosed with either (a) or (b). 
 
(a) biopsy-proven LCH; lesional cells (LCH cells) must contain Birbeck granules or 
be CD1a positive or S100 positive with characteristic H&E morphology. 
(b) Lytic bone lesion or pituitary/hypothalamic abnormality with the characteristics 
of LCH but not biopsied because either 
i. clinical features suggest spontaneous resolution  
or 
ii. the risk of the biopsy procedure in view of the location of the lesion (e.g. 
cervical vertebra, pituitary mass) is too great. 
 
Although unconfirmed cases might be reported the questionnaire captured information 
on the method of diagnosis thus enabling the eligibility of cases to be established. 
 
3.7 Questionnaires 
Clinicians were sent a five-page questionnaire to collect details of the cases reported. 
Shorter follow up questionnaires to obtain information about the outcome of treatment 
were sent one year and two years after diagnosis.  
 
3.7.1 Initial questionnaire  
The study questionnaire was designed with input from all members of the study group 
in discussion with the BPSU and was approved by the BPSU Executive Committee.  
The questionnaire has seven sections which collected data on: patient demographics; 
family history, pregnancy, delivery and neonatal history; diagnosis; referral history; 
system(s) involved and diagnostic procedures; status.  These are described below.  A 
copy of the questionnaire and letter to clinicians can be found in Appendixes G and H. 
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Patient demographics (Section A) 
With regard to data collection, the BPSU operates on the basis that patient consent is not 
sought as this would prejudice the completeness of ascertainment and introduce delay. 
Consequently, because patient consent is not obtained, there is a requirement that only 
minimal identifying data are collected to preserve patient anonymity as far as possible.  
The inclusion of hospital number, NHS number, sex and date of birth were agreed with 
the BPSU, with the addition of the first part of the postcode, to allow identification of 
duplicate reports. The inclusion of part of the postcode would also allow regional 
differences in the incidence of cases, if any, to be assessed.  
 
Family history (Section B) 
Certain conditions discussed in the review of the literature in Chapter 2, such as 
maternal history of thyroid disease and family history of LCH, were suggested as risk 
factors for LCH in two large epidemiological studies (section 2.5.1) [141, 142]. 
Questions on these were therefore included, as were questions on country of birth and 
ethnicity to assess whether there were any ethnic differences in the incidence of LCH.  
Ethnicity was based on nine categories used in the 1991 Census [178].  Also of interest 
was the possibility of consanguinity (reported in an LCH study described in section 
2.5.2) which is more common in some ethnic groups than others.  The offspring of 
consanguineous couples may be at greater risk of certain rare conditions or childhood 
illnesses. Higher perinatal mortality and congenital malformation rates have been 
recorded in the UK, particularly in UK-born Pakistani children [179].   
 
Pregnancy, delivery and neonatal history (Section C) 
Questions included maternal health during pregnancy since (urinary tract) infection was 
found to be associated with LCH in a study by Hamre et al [142]. In two large case 
control studies of LCH questionnaires addressed a large number of factors including 
pregnancy and birth [141, 142]. Birth weight and gestational age were recorded in this 
study as these have also been investigated in association with childhood cancer. These 
associations were described in section 2.5.1.  
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Diagnosis (Section D) 
This section recorded the diagnosis date and the tissue and histological methods used in 
diagnosing LCH, i.e. staining and the presence of Birbeck granules (as described in 
section 1.4).  
 
Referral history (Section E) 
The referral history of each case from the onset of symptoms to diagnosis was 
documented including the first presentation, route to diagnosis (via GP, hospital or 
tertiary centre) and the number of clinicians and specialties involved.  Since some forms 
of the disease may be mistaken for other conditions, they may be associated with 
significant diagnostic delay. Early diagnosis may lead to treatment of the disease at an 
earlier stage, thus improving outcome and survival.  
 
System(s) involved and diagnostic procedures (Section F) 
Additional information about diagnosis was recorded – the organs involved at diagnosis 
or at any time – plus the diagnostic procedures used and any positive or negative 
findings. Radiological diagnoses were also recorded in this section.   
 
Status (Section G) 
As discussed in Chapter 2 there have been reports of cancer both preceding and 
following the diagnosis of LCH and malignant disease (or history of maligancy) was 
therefore noted.  Such cases are registered by the Histiocyte Society Late Effects sub-
group. The date of the last follow up and vital status were included in this section, and 
whether or not the patient was registered with the CCLG.   
 
Space was also provided at the end of the questionnaire to collect any other relevant 
information since LCH has also been associated with congenital anomalies and to be 
concurrent with other conditions such as sclerosing cholangitis and HLH [103, 158, 
162]. 
 
The questionnaire was piloted by Dr Windebank and colleagues at Newcastle and after 
some cosmetic modifications to the layout the final version was agreed. 
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3.7.2 Other potential questions 
In the course of developing the questionnaire, the inclusion of other questions was 
raised. These included a section on environmental exposures – smoking in the 
household, foreign travel, childhood infections and immunisations, siblings and birth 
order. Environmental exposures had been investigated in two large case-control studies 
in the US and there is evidence that first born children are at an increased risk of 
leukaemia and lymphoma (suggesting an infective aetiology) [141, 142, 180].  
However, although of interest, questions on these were rejected by the BPSU for 
reasons of them being considered better suited to a case-control study.  
 
3.8 Collection of questionnaires 
Questionnaire returns were monitored regularly and every effort was made to collect 
them.  Reminders were sent as appropriate to non-responding clinicians at regular 
intervals by post, email and by phone.  In addition, an oncologist (member of the study 
team) assisted in questionnaire completion for cases at Great Ormond Street Hospital, 
and other team members were asked to exercise their influence in persuading clinicians 
to return the questionnaires.   
 
3.9 Case identification 
Cases were identified based on questionnaire demographic data, i.e, a combination of 
sex, date of birth, hospital number, first part of postcode plus date of diagnosis. Those 
aged over 18 years, diagnosed outside the study period or with a diagnosis of a 
condition other than LCH were excluded.   
 
3.10 Questionnaire data 
3.10.1 Database 
A 4D relational database was set up on a Macintosh computer network to facilitate the 
mailing process and to hold the data. The database and mailing procedures were 
designed by the Computer Officer in the Institute of Health & Society (Child Health), 
Mr Richard Hardy, in consultation with the author. An automated process was used for 
the six-monthly survey of clinicians to produce covering letters and response slips.  
Clerical assistance was obtained to help with mailing and to record the replies on 
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database. Dates of initial mailing, receipt of questionnaires and mailing of reminders 
were recorded.   
 
The database consists of a series of related tables linked by common unique identifiers. 
As the initial questionnaires arrived data were entered into the Questionnaire table. For 
each unique patient identified, a single record was created in the Patient table with their 
demographic data, vital status and diagnosis. Each patient was linked to single or 
multiple entries in the Questionnaire or Follow up Questionnaire tables by their unique 
identifier. Similarly, reporting clinicians (in the Consultants table) were linked to single 
records in the Notification Request table (which recorded their responses to mailing) or 
to single or multiple records in the Questionnaire tables, depending on whether they 
reported more than one patient.  A figure showing the structure of the database is given 
in Appendix I.   
 
3.10.2 Data 
For analysis purposes datasets were constructed with one record for each LCH case by 
joining data from the Patient to the Questionnaire or Follow up questionnaire tables.  In 
some cases there were multiple questionnaires for an individual, and data from each of 
these questionnaires were combined into one record by hand. The combining of textual 
data, for example, symptoms, referral patterns and comments was especially time-
consuming.  
 
Responses from the treating consultant oncologist were regarded as definitive. 
Inconsistencies which could not be resolved (e.g. dates, type of treatment) were referred 
to the clinician or their data manager, where possible, or to Dr Windebank. The date of 
diagnosis was taken to be the date of biopsy, X-ray or autopsy. Where only the month 
was given for a date, e.g. the date of first symptom, the first day
 
of the month was used.   
 
3.10.3 Data checking 
A two-page form was designed by the author to enable all questionnaire data entered on 
the database to be printed and cross-checked with original paper copies.  Additional 
programs were written in 4D‟s programming language, for example, to cross-check 
notifications with the BPSU or CCLG, and to check the validity of the data. Since each 
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questionnaire was flagged with an appropriate status code, a list of those not returned 
could be easily produced.  
 
3.11 One-year follow up questionnaire 
A two-page questionnaire was sent to the reporting clinician one year after diagnosis 
(see Appendix J).  The sections of the questionnaire were as follows: 
 
A Pre-printed demographic patient information (from the database) to enable the 
clinician to identify the patient. 
 
B Current vital status and whether the patient was with or without active disease 
and, if disease was active, whether on treatment. 
 
C The type of treatment received, i.e. whether the patient was „wait and see‟, had 
had curettage, a biopsy or surgery, or was on LCH protocol or other treatment. 
 
D Sequelae/permanent consequences.  This section listed ten permanent 
consequences most often reported in LCH cases as discussed in Chapter 2 
(section 2.1.6).   
 
In addition, space was allowed for any other relevant information to be noted by the 
clinician. 
 
Data were entered in a „Follow up Questionnaire‟ table on the database and checked as 
for the initial questionnaire data.  There were fewer cases with multiple Follow up 
questionnaires as follow up tended to be by only one clinician. 
 
At the end of the one year follow up period in 2006, a representative at each CCLG 
treatment centre who had reported cases was sent a summary list of patients to check 
and to return missing information, if appropriate.   
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3.12 Two year follow up questionnaire 
In order to obtain better information on treatment, survival and outcome, MREC 
approval was obtained by the author in July 2007 for an amendment to the study 
protocol to send further follow up questionnaires to reporting clinicians.  The 
questionnaire contained the same questions as in the first follow up questionnaire but 
the design was modified to a single page format.  It was hoped that this slightly 
simplified, shorter format would appear less time-consuming than the previous 
questionnaires and elicit a speedy response from clinicians [181]. A copy of the two 
year questionnaire is given in Appendix K.  All those who returned a one year follow up 
questionnaire were sent a second follow up questionnaire. 
 
3.13 Ethics 
The main point of ethical concern is that patient consent was not sought to collect 
patient identifiable data for the study.  The BPSU only accepts studies on the basis that 
patient consent will not be sought on the grounds that ascertainment is likely to be 
incomplete and subject to bias, and that delay would be introduced.   
 
When ethical approval was sought for this study in 2003, BPSU studies were not 
required to obtain approval from the National Information Governance Board for Health 
and Social Care (NIGB) before proceeding. NIGB is a statutory body which can allow 
patient identifiable information to be collected without the consent of patients under 
section 251 of the NHS Act 2006 under specific circumstances [172].  This function 
was formerly carried out by the Patient Information Advisory Group (PIAG).  Members 
of the Board are either members of the public appointed by the Appointments 
Commission or represent stakeholders in health and social care. 
 
Permission to collect identifiable data without seeking patient consent may be granted 
by the NIGB Ethics and Confidentiality Committee under the following conditions:  
 
1. the data are only to be used to support medical purposes that are in the interests 
of patients or the wider public 
2. gaining patient consent is not a practicable alternative and  
3. anonymised information are insufficient 
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In this study although neither patient consent nor NIGB approval were sought the first 
two criteria were met.  1) The data were collected to provide information to inform all 
those concerned with children with LCH from specialists to parents.  2) Only a 
relatively small number of cases were likely to be identified but gaining consent from 
patients was not practicable or compatible with BPSU surveillance methods for the 
reasons described above.  With regard to the third condition, some identifying data were 
required to identify duplicate cases; a degree of anonymity was preserved as patient 
names and addresses are unknown. 
 
Patient confidentiality was respected according to the conditions of each of the bodies 
concerned in this study – BPSU, CCLG and ONS – and, additionally, according to the 
terms of employment at Newcastle University and those specified by Newcastle 
Hospitals NHS Trust in Honorary Research Contracts.  
 
At the time ethical approval was obtained, the London MREC indicated that the 
continuation of BPSU studies without patient consent and without PIAG (NIGB) 
consent was not sustainable and that sooner or later the issue would have to be raised 
and resolved.  In the intervening years it has become mandatory for new BPSU studies 
to obtain both ethical and NIGB approval. These are now part of the Integrated 
Research Application System (IRAS) which is a single system for obtaining relevant 
research governance approvals for health research in the UK [182].
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Chapter 4. Data analysis methods  
 
This chapter describes the statistical and epidemiological methods of analysis used in 
the study. All statistical analyses were performed using the statistical software 
packages, Stata version 10 and SAS 913, an epidemiological software package, Epidat 
version 3.1 and Excel [183-185]; the geographical information system ArcGIS 9.2 was 
used for mapping [186]. 
 
4.1 Estimates of completeness of ascertainment 
4.1.1 Capture-recapture analysis (C-RA) 
Capture-recapture analysis (C-RA) was used to estimate the number of cases missed by 
all reporting sources [187]. C-RA was first used in ecological studies to estimate 
populations of animals by capturing (tagging) and releasing animals and then repeating 
the procedure (recapturing) them. The number of animals identified by both samples 
and the number identified by one sample are used to estimate the number not 
ascertained by either. The method has since been used by human disease registries to 
estimate completeness of ascertainment and has been applied to epidemiological studies 
to adjust estimates of incidence or prevalence of a disease by allowing for under-
ascertainment of cases [188-191]. It has also been extended to include more than two 
sources [187]. 
 
The underlying assumptions of these methods are: 
1) The study population is closed, i.e. there is no change to the study population 
during the period of data collection. 
2) All cases identified by one source can be matched to another source using the 
same identifiers. 
3) The chance of being identified by one source is the same as the chance of being 
identified by a second source. 
4) Capture by one source, is not dependent on capture by another source, i.e. 
survey lists are independent. 
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The main criticism of C-RA has been that the assumptions above can rarely be complied 
with, in particular, 3 and 4. One source may have a greater possibility of identifying 
cases than another. In addition, the presence of a case from one list may be contingent 
on being present on another list.  For example, LCH cases recorded by NRCT may all 
have come from CCLG registrations. 
 
Where only two sources are used, the degree of overlap in identification may result in 
under- or overestimation of the number of cases. Estimates should therefore be viewed 
with caution. In addition, although C-RA methods may be potentially useful, for 
example, in estimating disease rates without the use of costly surveys, the requirement 
for the services of an experienced statistician to apply multi-source modelling methods 
may be costly [190, 191].  The simplest method of C-R estimation using two sources 
can be calculated by hand. However, as indicated above, calculations are more 
complicated with increasing number of sources and additional methods which take 
account of any dependencies which might exist between sources.   
 
Epidemiological studies and registers, in spite of exhaustive efforts, are likely to miss 
cases and C-RA gives a method of quantifying undercounting [187, 190]. Bearing in 
mind the cautions above, an estimate of the completeness of ascertainment was obtained 
using the two-source model and compared with the results of three-source model 
analysis which also indicates the dependency between sources.  
 
4.1.2 Sources and models 
With reference to the assumptions made when using CR-A (in section 4.1.1), the first 
two criteria were met – the cases were all newly identified from the same population 
over the same time period; case eligibility was clearly defined and the same criteria 
were used to identify individuals.  The mailing lists for the Newcastle and BPSU 
surveys were cross-checked and no clinician appeared on both lists. The chance of being 
identified by either source was thought to be equivalent since one group of clinicians 
tended to be involved in the diagnosis of cases (Newcastle survey) and the other in the 
treatment of them (BPSU survey).  
 
The surveys were thus assumed to be independent sources and were used in the two-
source model below (section 4.1.3). The CCLG may not have been an entirely 
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independent source as cases may have been notified by clinicians on either the BPSU or 
Newcastle mailing lists. The independency of the CCLG, and interactions between all 
the sources were estimated using three-source model analysis (section 4.1.4).  The 
methods were described by Hook and Regal in 1995 with errata published in 1998 and  
have been used frequently in epidemiological studies [187, 192]. 
 
Both estimates were cross-checked using the Epidat epidemiological analysis package.  
This is a free distribution program developed by public institutions under the Pan-
American Health Organisation (PAHO) which serves as the regional office for the 
Americas of the World Health Organisastion [185, 193]. 
 
4.1.3 Two-source model 
This model was used to estimate the completeness of ascertainment by the BPSU and 
Newcastle surveys and the overall number of cases using the number of cases 
ascertained by each source and the number ascertained by both (figure 4.1).  
 
Figure 4.1 Cases used in two-source model 
 
 
 
 
 
 
 
 
The calculations, which were done by hand, are shown in table 4.1. The terms a, b, c 
denote the numbers observed in each cell and x is the number in the unobserved cell, 
denoting the number missed.  An adjustment of the estimate (the maximum likelihood 
estimator - MLE) to account for sample bias results in a “nearly unbiased estimator” - 
NUE.  
NCL 
Source Z 
BPSU 
Source Y 
Both 
a 
b 
c 
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Table 4.1 Two-source model (from Hook and Regal) [187] 
 
Source Y (BPSU) 
  Yes No  
Source Z 
(NCL) 
Yes a b Total  a+b=Z0 
No c x  
Total  a+c=Y0 
 
x= unidentified cases 
N= a+b+c+x      the total number of cases in the population 
 
______________________________________________________________________ 
Estimated values    
Maximum 
likelihood 
Estimator (MLE) 
 
Nearly unbiased 
estimator (NUE) 
Unobserved cell  x  bc/a  bc/(a+1) 
Completeness of source Y  Yc  a/(a+b)  =a/ Z0  (a+1)/(a+b) =(a+1)/ Z0 
Completeness of source Z  Zc  a/(a+c)  =a/ Y0  (a+1)/(a+c) =(a+1)/ Y0 
Total population  
 
 a+b+c + (bc/a) 
or 
(a+b)(a+c)/a 
or  
Y0/ Yc     or Z0/ Zc    
 
 a+b+c + (bc/(a+1)) 
or 
[(b+1)(c+1)/(a+1)]-1 
 
  
N ˆ 
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Confidence intervals for the adjusted estimate of the total number of cases were 
calculated by hand as described by Rahi and Dezateux [188]. The variance was 
calculated by  
 
Var( ) = (a+b+1)(a+c+1)(b)(c) 
   (a+1)
2
 (a+2) 
 
and 95% confidence intervals were  ± 1.96 (√Var( )). 
 
The level of ascertainment was the proportion of total cases expected that were actually 
identified, expressed as a percentage. 
 
The results of the two-source model are subject to error if the assumptions listed in 
section 4.1.1 are not met. A large overlap (positive dependency) in cases will result in 
an underestimation of the population while very little overlap (negative dependency) 
will result in an overestimation of cases. In spite of the lists of clinicians on the 
Newcastle and BPSU survey lists being independent a degree of overlap in cases may 
be expected. For example, a case identified by a pathologist may have been reported via 
the Newcastle survey and the same case may have been reported to the BPSU by the 
treating clinician. However, if these clinicians collude and only one of them reports a 
case the overlap may be reduced resulting in an overestimation of cases. 
 
4.1.4 Three-source model 
Multiple-model C-RA allows greater accuracy of estimates of completeness of 
ascertainment and reduces the problems of source dependence or independence. Since 
the CCLG contributed cases, but may not have been an entirely independent source of 
ascertainment (as some reporting clinicians may have also reported cases via one of the 
BPSU or Newcastle surveys) the estimate of the number of missing cases was 
performed using three-source (log-linear) modelling [187]. The degree of inter-
dependence between the sources was also estimated using this method.  Figures 4.2 and 
4.3, adapted from Hook and Regal, show the data layout and methods for deriving 
estimates. The terms a, b, c etc are used to denote both the names of cells and numbers 
observed in each. 
 
  
Nˆ
Nˆ Nˆ
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Figure 4.2 Cases used in three-source model  
 
 
 
 
 
 
 
 
 
 
With three sources there are eight possible models. A case can be identified by all three 
sources, by two out of three, one out of three or none of them. By knowing the 
frequencies for seven out of the eight possible combinations the number of cases 
captured by none of the sources can be estimated.  The eight different models allow for 
interaction between the three sources and are compared in the analysis. The simplest is 
the independent model. Three of the models allow an interaction between two of the 
sources and further more complicated models allow for two pair interactions. 
 
The estimate of the missing number of cases by each ( ) can be summarised as follows 
 
 =  (values exclusive to interaction)  x (values exclusive to non-interaction) 
values shared  
 
 
An error was spotted in the original paper by Hook and Regal in the estimates of the 
number of missing cases in the three-source model.  This was confirmed by a colleague 
who found an erratum publication (corrections are shown in bold in figure 4.3) and a 
more detailed description by Orton et al of how to accomplish the analysis using the 
statistical package SAS [192, 194].   
 
  
xˆ
xˆ
Source 1 
BPSU 
Source 2 
NCL 
Source 3 
CCLG 
d 
f 
c g 
a 
e b  
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Figure 4.3 Three-source model (from Hook and Regal including published 
errata) [187, 192] 
  
 
 
Source 1 (BPSU) 
  Yes  No 
     
  Source 2 (NCL)  Source 2 (NCL) 
       
  Yes No  Yes No 
Source 3 
(CCLG)  
Yes a b  e f 
No c d  g x 
 
Nobs = a+b+c+d+e+f+g 
N1 = a+b+c+d (BPSU) 
N2= a+c+e+g (NCL) 
N3= a+b+e+f  (CCLG) 
 
_____________________________________________________________________ 
Maximum likelihood estimates of x using alternative models 
Model    df* Model  Estimator† 
 
1 
 
3 
  
Independent 
  
xˆ = Nˆ - Nobs   †† 
2 2 Equivalent  
to two 
independent 
sources 
1-2 interactions  xˆ = (c+d+g)(f)/(a+b+e) 
3 2 1-3 interactions  xˆ = (b+d+f)(g)/(a+c+e) 
4 2 2-3 interactions  xˆ = (e+f+g)(d)/(a+b+c) 
5 1 Two 
independent 
subsets  
1-2, 1-3 interactions  xˆ = gf/e 
6 1 1-2, 2-3 interactions  xˆ = df/b 
7 1 1-3, 2-3 interactions  xˆ = gd/c 
8 0  1-2, 1-3, 2-3 
interactions 
 xˆ = (adfg)/(bce) 
 
*df = degrees of freedom; the unobserved cell = ; 
†Where not given explicitly the total population Nˆ  = xˆ  +Nobs 
†† Nˆ is the solution of ( Nˆ - N1)( Nˆ - N2)( Nˆ - N3) = Nˆ
2
( Nˆ -Nobs) 
  
xˆ
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Rough calculations were made for models 2-8 by hand using the formulae above.  
Estimates of missing cases and total population, along with corresponding goodness of 
fit values and confidence intervals for all models were obtained using SAS.   
 
The SAS code published by Orton et al adapted for three sources of data is shown in 
table 4.2.  
 
Table 4.2 SAS code (adapted from Orton et al) [194] 
 
Source 
1 
(BPSU) 
Source 
2 
(NCL) 
Source 
3 
(CCLG) 
 
1 1 1 a 
1 1 0 c 
1 0 1 b 
1 0 0 d 
0 1 1 e 
0 1 0 g 
0 0 1 f 
 
The values of a, b, c etc are the number of cases found by each source or combination of 
sources.  The SAS procedure genmod was then run repeatedly with each model as a 
parameter, e.g. 1-3 (BPSU-CCLG independent of NCL) or 1-2, 2-3 (two independent 
subsets BPSU-NCL and NCL-CCLG) etc [184]. 
 
The best model can be selected by comparing the goodness of fit and the degrees of 
freedom of each model; ideally the goodness of fit value should be as small as possible 
with a high degree of freedom. A measure of the goodness of fit of a particular model is 
the value of the likelihood ratio statistic G
2.   In addition, the values of “information 
criteria”, Bayesian Information Criterion (BIC) and Akaike Information Criterion 
(AIC), which can be calculated using the G
2 
statistic are used to select the optimal 
model. Those with negative values are preferred.  The model chosen by investigators is 
usually the least complex with the most adequate fit [187]. 
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The AIC and BIC values were calculated using Excel using the formulae described in 
Hook and Regal‟s paper. 
AIC = G
2  
- 2(df) 
 
BIC = G
2
 - [log(N/2 )]  [df] 
  
Where G
2 
is the value of the goodness of fit statistic, N the value of the observed 
population and df the degrees of freedom for each model.  
 
The degree of dependency between the sources was also assessed (table 4.3). There are 
three different possible two-source estimates that can be obtained by disregarding one of 
the other sources. An underestimation by a model will suggest positive dependency (a 
large overlap in cases) while an overestimate will suggest negative dependency (a small 
overlap in cases). 
 
Table 4.3 Estimate of dependency between sources (from Hook and 
Regal) [187] 
Two-source restricted estimates of same population  
(restricted by disregarding a third source) 
Sources  Nˆ MLE  Nˆ NUE 
     
1 versus 2  (N1)( N2 )/(a+c)  (N1)( N2 )/(a+c+1) 
1 versus 3  (N1)( N3 )/(a+b)  (N1)( N3 )/(a+b+1) 
2 versus 3  (N2)( N3 )/(a+e)  (N2)( N3 )/(a+e+1) 
 
MLE maximum likelihood estimator; NUE nearly unbiased estimator 
 =  +Nobs 
 
 
The results of the three-way analysis were cross-checked using Epidat [185].  
 
4.2 Population and incidence rates  
Incidence and prevalence are commonly used indicators for measuring diseases among 
populations.  Prevalence is a measure of existing cases of a condition in a population at 
a given time, while incidence is the number of new occurrences of a condition in a 
population over a given period.  Incidence was the measure used in this study and can 
be defined as follows: 
Nˆ xˆ
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Incidence Rate  = number of newly diagnosed cases over a specific time period 
   population at risk during the same time period 
 
ONS annual mid-year population estimates for the study period were used (pro rata as 
necessary) for the UK population [195]. Averages of the 2002 and 2006 Census data 
were used in calculating the population for the RoI [196].  Age-standardized (to 
European Standard Population) and age-specific incidence rates were calculated with 
corresponding 95% confidence intervals. The rate is expressed per million persons per 
year.  For UK regional rates, ONS Government Office Region (GOR) mid-year 
population data were used pro rata. 
 
4.2.1 Age-standardized incidence rates 
Age standardized incidence rates (ASR) of LCH were calculated for comparison with 
other European studies.  Standardisation removes effects due to differences in 
population structure allowing populations with different age distributions to be 
compared directly with each other [197]. The ASR is the number of events that would 
occur in a given country if the standard population lived there and the age-specific 
incidence rates of that country were applied.  The European Standard Population (ESP) 
which has defined age-groups was used for standardisation.  The age specific rates of 
LCH multiplied by the ESP in the corresponding age groups gave the number of cases 
of LCH which would be expected in the ESP, if it experienced the UK and RoI age-
specific rates.   
 
The following table was used in the calculation and shows the ESP [198]. 
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Table 4.4 The European Standard PopulationTable  [198] 
Age group  European Standard 
Population  
0  1,600  
1-4  6,400  
5-9  7,000  
10-14  7,000  
15-19  7,000  
20-24  7,000  
25-29  7,000  
30-34  7,000  
35-39  7,000  
40-44  7,000  
45-49  7,000  
50-54  7,000  
55-59  6,000  
60-64  5,000  
65-69  4,000  
70-74  3,000  
75-79  2,000  
80-84  1,000  
85+  1,000  
Total  100,000  
Source: 1991 World Health Annual of Statistics - based on Waterhouse et al (eds). 
Cancer Incidence in Five Continents, Lyon, IARC, 1976 (Vol. 3, p 456).  
 
Age standardized rates for all 0-14 year olds and for boys and girls were calculated 
using the direct method as shown in Table 4.5 [197].  The numbers in each age group of 
the standard population are multiplied by the incidence observed over the two year 
period. This number is then divided by the total number in the standard population to 
give the expected cases in the standard population.  
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Table 4.5 Calculating the ASR for 0-14 year olds [197] 
Age 
range 
(years) 
No. of 
children in 
population 
No. of 
LCH 
cases 
Observed 
incidence 
Nx    
No. of 
persons in 
standard 
population 
Expected 
cases in 
standard 
population 
Variance 
x Px Nx   Rx / Px  Wx Ex=RxWx Vx=ExWx/(YPx)* 
0       
1-4       
5-9       
10-14       
Total       
 
* Y = number of years on which rates were based. In this study Y=1 as the population Px is the 
total population over the study period   
 
 
The ASR is the sum of the expected cases divided by the sum of number of cases in the 
standard population, expressed as cases per million per year: 
ASR = ∑Ex/∑Wx 
 
The method of calculating the standard error is also shown in Table 4.5. The variance 
was calculated for each age group and the standard error (SE) calculated by summing 
the variances, taking the square root and dividing by the total number of persons in the 
standard population. 
SE = (√∑Vx)/∑Wx 
 
The 95% confidence intervals were calculated as ASR + or – 1.96 x SE of the rate in the 
population. 
 
4.2.2 Regional incidence rates 
The population studied covers 13 geographic regions.  Incidence rates and 
corresponding confidence intervals were calculated using Stata for each region and the 
different rates compared. Comparable regional population data for 0-14 year olds were 
unavailable for the three years over which the surveillance was carried out. Therefore 
mid-2004 population data for the UK Government Office Regions (GORs) were used to 
calculate the ASRs for cases aged 0-14 years [199, 200]. For age-specific incidence 
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rates, different quintiles of population data (for those aged 0-15 years) were available 
for each of the study years and were used pro rata [195].  2002 and 2006 Census 
population data for the RoI were used in calculating both incidence rates [196].  
 
An analysis of heterogeneity was carried out using the Stata command metan to 
determine whether there were genuine differences underlying the regional incidence 
rates (heterogeneity) or whether the variation in the proportions in each region was 
compatible with chance alone (homogeneity).  This command provides methods for 
meta-analysis, a process in which data from a comparable set of studies is synthesised to 
increase statistical power and to investigate discrepancies and inconsistencies between 
their results.  Studies included in a meta-analysis must fulfill predetermined criteria. All 
must have used essentially the same or closely comparable methods and procedures; the 
populations studied must be comparable; and the data must include all eligible studies.  
The command is also suitable for analysis of estimates with confidence intervals or 
standard errors [201].  
 
The test assumes that there is no significant difference (homogeneity) between the rates. 
Metan uses middle (incidence rate), lower and upper confidence interval values as 
parameters and generates a graph (forest plot) showing the ranges of these values for 
each region.  Consistency of rates is assessed by using an appropriate weighted sum of 
the differences between each rate and the overall estimate.  The weight that each region 
contributes is shown by the size of the plotting symbol on the graph. The test generates 
an I-squared value and a p value; I-squared is the variation in rate attributable to 
heterogeneity expressed as a percentage; a low p value would indicate that there is a 
statistically significant difference in the proportions in each region.   
 
4.2.3 Mapping of regional rates and cases 
Geographic Information Systems (GIS) are now frequently used by health authorities, 
emergency services, public health specialists and researchers to identify potential causes 
of ill health and to assist in health care planning. The focus for health-related uses of 
GIS is usually on either epidemiology of specific diseases or management of health care 
services. GIS applications in health studies range from simple mapping and visual 
display to investigating data relationships, exploring risk factors and modelling the 
spread of infectious diseases [202-204]. For example, Hjalmars et al used GIS in cluster 
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detection of childhood leukaemias in Sweden and Dummer et al mapped stillbirth rates 
in Cumbria comparing wards and postcode districts over four decades  [175, 203].  
However, mapping problems have been described by Dummer, one being the 
modifiable areal unit problem (MAUP). Depending on the geographical unit selected 
large rural areas (with low populations) may have high disease rates which may have 
only one or two cases and no biological significance [202].  Caution was also advised in 
mapping p values (to identify areas with extremely high or low observed number of 
events). Since significance is related to sample size, highly populated urban areas are 
more likely to have significant p values which are not the result of underlying variation 
in risk. In practical terms, GIS generates a substantial amount of data although with 
increasing advances in microtechnology this is becoming less of a problem [204]. 
GIS choropleth maps, which use shading proportionally to display statistical variables, 
were used to visualise the differences in regional rates. Incidence rates were calculated 
for each region, grouped into categories and displayed using gradient shades. The 
approximate location of cases was also dispalyed.   
 
UK mapping 
National and regional digitised boundary (polygon) data for the UK were downloaded 
from the Edina UKBORDERS service using ArcMap version 9.2. (Edina is a national 
centre for geographic data for higher education) [205]. The geographic areas were 
Scotland, Wales and Northern Ireland plus nine English Government Office Regions 
(GORs). GORs have been the primary classification for the representation of regional 
statistics since 1996 (figure 4.4) [199]. Six-figure grid references (i.e. Easting and 
Northing co-ordinates) for cases were obtained from the first part of the postcode data 
using Edina [205].  
The full postcode represents an average of 17 properties ranging from a single code for 
a large business address to approximately 100 households. However, the full postcode 
was not available in this study because of the patient anonymity issues discussed in the 
previous chapter. Either the postcode district or postcode sector, collected from 
questionnaires, was used.  Both postal districts and sectors vary in geographic size 
depending on the number of households therein. There are approximately 3000 UK 
postcode districts, e.g. PO1 and approximately 11,500 postcode sectors, e.g. PO1 3 
[206].  The exact locations of cases are therefore approximate.  The partial postcode 
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data were however, sufficient to assign each case to a region to calculate regional 
incidence rates.  Northern Ireland postcodes were mapped using the same grid as that 
used for the RoI, i.e. the Irish National Grid, as opposed to the Great Britain Ordnance 
Survey Grid.   
 
Republic of Ireland mapping 
The Edina service, being a provider of UK data, did not supply a digital boundary map 
for the RoI. This was obtained from another source, the Digital Chart of the World 
(DCW), a product of the Environmental Systems Research Institute, Inc. (ESRI). 
Boundaries and other geographic information of different countries can be downloaded 
in Arc/INFO export format from their web-site [207]. However, these data (View files) 
differ in format from Edina data but are compatible with an earlier version of GIS 
software.  Data were converted to a suitable format for ArcMap by importing it using 
ArcCatalog ArcView 8 conversion tools. The file produced was suitable for adding as a 
„layer‟ to the UK map. 
 
The geographic coordinate systems for UK and DCW maps are different, i.e. British 
National Grid system (Ordnance Survey GB) versus GCS_Clarke_1866. To avoid 
alignment or accuracy problems with the data, ArcMap adjusted (transformed) the 
coordinates automatically to the Ordnance Survey coordinates. The resulting map with 
English regional boundaries is shown in figure 4.4. 
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Figure 4.4 Map of the geographical boundaries used to compare regional 
incidence rates 
 
 
 
 
 
Postcodes were introduced in the RoI after the end of the study period. Since the RoI 
was treated as one region all cases reported by clinicians in Ireland were mapped to 
Dublin and the incidence rate calculated accordingly.  Irish and Northern Ireland 
coordinates use the Irish National Grid system and were mapped using Irish Transverse 
Mercator Grid [208]. 
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4.3 Epidemiological analyses 
4.3.1 Comparisons 
The data for all descriptive analyses were provided by questionnaires which varied in 
their completeness. In a few cases data were provided by data managers in a spreadsheet 
format.  Dates, such as date of diagnosis or follow up, varied in their accuracy; in some 
cases only the month and year were provided and in these cases the day was taken to be 
the 1
st
 of the month.   
 
The Mann-Whitney test (Stata command ranksum) was used to compare differences 
between two groups, for example, in the time from symptoms to diagnosis between 
sexes.  The test does not assume a normal distribution. It uses ranking to compare 
whether observations in one group tend to be larger than in the other (i.e. it compares 
medians) and calculates the probability of there being no difference between them.  
 
The Kruskall-Wallis test similarly uses ranking to compare more than two groups, for 
example, differences between types of disease. The test does not assume a normal 
distribution and is suitable for small samples. The Stata command was kwallis. 
 
The Fisher-exact test was used to compare sub-groups of cases, for example, of those 
with and without active disease, and is suitable for small samples. The Stata command 
was tabi. 
 
The subgroups used were as for survival analyses described below in section 4.4 (table 
4.10). 
 
4.3.2 Seasonality 
Seasonal variation in birth, symptom onset and diagnosis of LCH may be indicative of 
an infectious aetiology or the involvement of a seasonal variation in an environmental 
factor such as sunlight, diet or use of pesticides. An association with month of 
presentation was reported by Soto-Chavez et al (in section 2.5.4) and there have been 
contradictory reports of seasonality in association with leukaemia [154, 209, 210]. 
Potential seasonality was thus assessed using Edwards‟ test [211]. This test has been 
used in other epidemiological studies to test for seasonality of events where population 
data are not available [210, 212].  The model tests whether the distribution of events 
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follows a harmonic curve (having one peak and one trough) in a single year.  The data 
consist of the frequencies of events (in this study births, diagnoses, first symptoms) 
grouped into time intervals (months). The data are presented in the form of the 
circumference of a circle divided into 12 sectors (months).  The angle of the maximum 
rate indicates the peak month. The relative strength of the peak is given by the 
amplitude – the percentage by which the rate at the peak month is greater than the mean 
rate for all months combined.  However, the test does not take account of the size of the 
population at risk or the variable length of calendar months.  A modification of 
Edwards‟ test (by Walter and Elwood) was therefore used in the analysis to allow for 
unequal time intervals and the assumption of a constant underlying population.  The 
Stata command seast was used to compare the observed and expected number of cases 
per month, and the p-values for the significance of amplitude and for the goodness of fit 
were calculated [213].  
 
4.3.3 Ethnicity 
The ethnic categories used in the questionnaire for ethnicity were based on the ethnic 
group question in the 1991 Census in England, Wales and Scotland (see table 4.4) 
[178]. The 1991 census did not include a „mixed‟ ethnic group category although LCH 
cases of mixed race may be reported in the „Any other ethnic group‟ category. 
Confidence intervals were obtained for the numbers in each category. The proportion of 
ethnic minorities was compared with those reported by the Office for National Statistics  
using a binomial probability test [214].  This test is suitable for small samples and 
calculates the probability (p) of the observed number of cases of an ethnic category in 
the study population given the proportion of ethnicity in the whole UK population. The 
Stata command bitesti was used.  It allows summary information to be provided rather 
than providing the actual data. 
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Table 4.6 Ethnic group categories (from 1991 Census) [178] 
  
White 
 Black – Caribbean 
 Black – African 
 Black – other, please specify 
 Indian 
 Pakistani 
 Bangladeshi 
 Chinese 
 Any Other ethnic group – please 
specify 
 
 
4.3.4 Birth weight and gestational age  
Although birth weight has been recorded routinely as part of the birth registration 
process, gestational age has not. Data have been published, however, via Hospital 
Episode Statistics [215]. A new system for allocating NHS numbers at birth (NN4B) 
was introduced in 2002 which has facilitated a small amount of birth information, 
including gestational age, to be collected [216]. In 2005 these data were linked by NHS 
number to birth registration data held by the Office for National Statistics enabling 
gestation-specific mortality rates to be published.  The birth weight and gestational ages 
of LCH cases were grouped and compared with 2005 data for England and Wales 
(E&W).  The World Health Organisation definitions for gestational age are shown in 
table 4.7 [217].  The proportion of live births by birth weight is shown in table 4.8.  
Comparisons were made using a binomial probability test (bitesti in Stata) as described 
in the previous section. This calculated the probability (p) of the observed number of 
births in a category in the study population given the proportion of births in that 
category in the whole population.  
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Table 4.7 Gestational age definitions (from Moser et al) [217] 
Age 
(weeks) 
WHO 
Description 
% live births 
in E&W 
(2005) 
<37 Pre-term 7.6 
37-41 Term 88 
>42 Post-term 4 
Unknown  0.4 
 
 
Table 4.8 Percentage of live births by birth weight (calculated from Moser 
et al)  
Weight 
(grams) 
% live births in 
E&W (2005) 
<1000 0.5 
1000-1499 0.7 
1500-2499 6.3 
>=2500 92 
unknown 0.3 
 
 
4.4 Follow up 
Cases were followed up one and two years after the date of diagnosis. Short 
questionnaires (see Appendixes J and K) were sent to reporting clinicians to collect 
information about vital status, treatment and permanent consequences. The categories 
for each of these are shown in table 4.9.  Where more than one questionnaire was 
received for a case, data were combined.  The date of follow up was taken to be the last 
date the patient was seen at clinic, or if not stated, the date on which the questionnaire 
was completed by the clinician.  Data from text fields were examined to improve clarity 
of questionnaire replies, for example, on treatment.  Anomalies were checked with the 
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clinician where possible and definitive responses were taken to be those from the 
treating consultant oncologist. 
 
 
Table 4.9 Status, treatment and permanent consequences categories 
Status  Treatment  Permanent 
consequences 
Alive, no active 
disease 
 Wait and see  Diabetes insipidus 
Alive, active disease  Curettage/surgery/ 
biopsy 
 Growth failure 
Alive, active disease, 
on treatment 
 LCH protocol  Anterior pituitary 
dysfunction 
Dead  Other  Hearing loss 
    Ophthalmologic 
problems 
    Tooth loss 
    Orthopaedic difficulties 
    Neurological 
consequences 
    Chronic liver disease 
    Chronic lung disease 
 
 
Patients may have had several types of treatment for their disease but for analysis were 
grouped according to the main type of treatment received. For example, if treatment was 
„LCH protocol‟ and „Other‟, the case was included in the „LCH protocol‟ group.  Those 
cases which were reported to have received no treatment, i.e. were „Wait and see‟, were 
checked and were included in the „Surgery‟ group if a diagnostic biopsy had been 
performed.  For cases which were likely to have received treatment on LCH protocol 
(according to the criteria in table 2.3) but where this was not stated on the follow up 
questionnaire, the original questionnaire data and LCH III clinical trials data were 
checked.  
 
97 
 
 
The status of cases, treatment received and permanent consequences which developed 
are described.  The Mann-Whitney test and Fisher‟s Exact test were used to assess 
differences between groups, comparing those with/without disease and those 
with/without permanent consequences (as described in section 4.3.1).   
 
4.4.1 Disease-free and sequelae-free survival  
Survival analysis can be used to study the time to death or other events such as hospital 
discharge or recurrence of disease. In this study it was used to assess the probability of 
being without active disease or permanent consequences at two intervals after diagnosis. 
The analysis allows for the unequal amounts of follow up time contributed by patients 
(which depends on whether they were diagnosed at the beginning or end of the study 
period).  It also assumes that patients have the same prospects of developing active 
disease or permanent consequences. The event, i.e. the development of active disease or 
permanent consequences, may not have taken place in all cases by the end of the follow 
up period and for these cases the observation time has been censored.  The Kaplan-
Meier survival method was used to take account of censoring and results are presented 
as survival „curves‟.  The method uses conditional probability, i.e. the probability of 
being disease-free at the end of a time interval given the probability of being disease-
free at the beginning. As events (reactivation or permanent consequences) occur, 
changes in probability are indicated by steps on the survival curve [218, 219].  
 
The analysis was carried out using the Stata commands stset, sts graph and sts list. 
These commands describe the number of observations and events, calculate the number 
of person years at risk, produce survival curves (graphs) and list the events and Kaplan-
Meier survival function. Cases which were lost to follow up or for which follow up data 
were less than six months from diagnosis were excluded.   The censor (cut-off) time was 
the date of the individual‟s last follow up period.  
 
Disease-free survival and survival without permanent consequences (sequelae-free 
survival) between different subgroups was assessed.  The sub-group categories - sex, 
age group, type of disease, type of treatment and the time period between symptoms and 
diagnosis – were as shown in table 4.10.  The logrank test was used to test for equality 
between subgroups [220]. This test calculates the observed and expected number of 
events for each group (assuming no differences between them) and a Chi-squared test 
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tests for any significant differences between groups by calculating a p-value.  In Stata, 
the command sts test was used. 
 
Table 4.10 Subgroups and categories used in analyses 
Subgroup Categories 
Sex Male, Female 
Age group (years) 0-4, 5-9, 10-15 
Type of disease SS, SS multifocal (SS-MF), MS 
Treatment Wait & see, Biopsy/surgery/curettage, LCH protocol, Other 
Symptoms to 
diagnosis period 
<12 weeks, >12 to <26 weeks, >26 weeks 
 
 
Diabetes insipidus (DI) in patients may be regarded as current active disease or as a 
permanent consequence [98].  For the purposes of sequelae-free survival analysis, if DI 
was present at diagnosis, the date of the „event‟ (permanent consequence) occurring was 
taken to be the date of diagnosis. However, if a patient with DI at diagnosis 
subsequently developed other permanent consequences, the event date was the date of 
follow up.  Therefore patients with DI as their only sequela did not contribute to the 
analysis. The types of permanent consequences are described. 
 
4.5  Mortality  
Deaths data were obtained from ONS for the UK and CSO for RoI. Age-standardized 
Mortality (ASR) rates were calculated using European Standard Populations and the 
same methods as described in section 4.2.1 for the incidence rate [198]. 
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Chapter 5. Results (1): Ascertainment and incidence of LCH 
cases 
 
This chapter describes the results of ascertainment of cases and the incidence of LCH in 
the UK and RoI by age, sex and region.  The results of the surveys and patterns of case 
reporting are also described. 
 
5.1 Survey respondents 
BPSU reported that, on average, 92% of paediatric members of the RCPCH returned 
case report cards to them for our study.   
 
The number of letters sent in each Newcastle mailing is shown in table 5.1. For the 
reasons described in section 3.2, the list was adjusted after the first mailing and slightly 
thereafter at each mailing for similar reasons. Replies remained fairly constant over the 
study period, although the response rate increased as a percentage of letters sent. 
 
Table 5.1 Numbers of letters sent in each Newcastle mail shot 
Date sent Number of letters sent Number of replies received 
November 2003 2229 930 
June 2004 1634 936 
November 2004 1606 964 
June 2005 1587 911 
 
An average of 53% of clinicians responded to each mailing from the Newcastle survey.  
 
The specialty of responding clinicians compared with those on the mailing list is shown 
in table 5.2.  The largest group of clinicians was pathologists (65%) with 
dermatologists, oncologists and orthopaedic surgeons comprising 21% of the mailing 
list.  As can be seen from table 5.2 the specialties of the respondents were proportional 
to the specialties on the mailing list. 
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Table 5.2 Specialty of clinicians on database and response to mailing 
  Specialty  % on mailing list  % of respondents 
  Dermatology 8.3 9.7 
  Endocrinology 4.3 2.9 
  Haematology 0.1 0.2 
  Nephrology 0.7 0.2 
  Neurosurgery 0.2 0.1 
  Oncology 7.4 6.9 
  Orthopaedics 6.1 6.3 
  Paediatrics 0.1 0.2 
  Paediatric Surgery/Neurosurgery 3.1 2.6 
  Pathology 65.1 65.8 
  Radiology 0.2 0.2 
  Rheumatology 2.4 3 
  Missing 2 2 
  Total 100 100 
 
5.2 Case reporting 
In response to cases notified by all three sources (BPSU, NCL, CCLG), 358 
questionnaires were mailed to clinicians to obtain further information. Of these, there 
were 217 replies confirming cases. However, questionnaires were not completed for 
some cases where clinicians were aware that colleagues had already returned a 
questionnaire.  In other cases, clinicians did not have access to full patient history and 
data was received in a different format, e.g. a pathology report or printed output from a 
database.  
 
The results of questionnaire mailing are shown in table 5.3. Almost a quarter of 
questionnaires returned were found to be ineligible and 14% were not returned. After 
removing adult cases (aged over 18 years), cases diagnosed outside the study period, 
changed diagnoses, cases reported in error and duplicate reports, 94 cases were 
identified.    
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Table 5.3 Response to questionnaire mailing 
Category of reply Number Percentage 
Valid case reports  217 61.0 
Changed diagnoses 24 6.7 
Notified in error 12 3.3 
Diagnosed outside the study 
period 
37 10.3 
Adult cases 14 3.9 
Not returned 53 14.7 
Total 358 100 
 
 
In the interval between reporting a suspected case and returning a questionnaire, 
diagnoses were changed in 24 cases. These included patients with the following 
conditions: haemophagocytic lymphohistiocytosis (HLH), inflammatory responses, 
intraosseous dermoid, acute myeloid leukaemia, chronic osteomyelitis, Rosai-Dorfman 
disease, bone cyst, aneurism, and juvenile idiopathic osteoporosis.   
 
Cases diagnosed outside the study period were excluded. Several cases registered with 
the CCLG were subsequently found to be ineligible because the biopsy on which the 
diagnosis was made was performed outside the study period.   
 
In addition to 14 questionnaires being returned for adult cases, there were a further 83 
reports of adult cases on the Newcastle survey reply slips.   
 
53 questionnaires were not returned. However, 14 of these corresponded to confirmed 
cases for which data were received from another clinician at the same institution and, 
similarly, four questionnaires corresponded to ineligible cases. 
 
The 94 cases were confirmed by one or more sources and the frequency is shown in 
Table 5.4.  For 69% there were between 2 and 6 confirmations. Of those with only one 
notification the majority of cases (18/30) were reported by oncologists with the 
remainder reported equally by paediatricians or orthopaedic surgeons.  
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Table 5.4 Frequency of notifications 
Frequency % 
1 32 
2-3 53 
4-6 15 
 
 
Specialties of clinicians reporting cases are shown in table 5.5.  60% of case 
confirmations were from paediatricians and oncologists and 27% were from orthopaedic 
surgeons and pathologists. The remaining 13% were confirmed by radiologists, 
surgeons and neurosurgeons with single confirmations by an A&E consultant, an 
endocrinologist and a gastroenterologist. 
 
Table 5.5 Specialties of clinicians confirming cases 
Specialty % of 
cases 
Oncology 32.7 
Paediatrics 27.6 
Pathology 14.7 
Orthopaedic surgery 13 
Radiology  2.7 
Paediatric surgery 2.3 
Dermatology 2.3 
Neurosurgery 1.8 
Paediatric neurosurgery 1.4 
Other 1.5 
Total 100 
 
5.3 Case ascertainment 
The reporting rates for each source were CCLG 75/94 (80%), BPSU 69/94 (73%) and 
Newcastle University 58/94 (62%) as shown in figure 5.1.  No additional cases were 
identified from deaths data.  
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Figure 5.1 Number of cases ascertained by each source 
 
 
5.4 Estimates of completeness of ascertainment by capture-recapture 
analysis (C-RA) 
The completeness of ascertainment was estimated by using Hook and Regal‟s capture-
recapture methods as described in the previous chapter. 
 
5.4.1 Two-source model 
Since the CCLG contributed cases but may not have been an entirely independent 
source the two-source model was used to estimate the completeness of ascertainment by 
the BPSU and Newcastle surveys only. The number of cases ascertained by each source 
and the number ascertained by both are shown in figure 5.2.   
 
Figure 5.2 Cases used in two-source model 
 
 
 
 
 
 
  
NCL survey 
(62%) 
CCLG register 
(80%) 
6 10 
6 
3 
36 
24 9 
BPSU survey 
(73%) 
NCL 
Source Z 
BPSU 
Source Y Both 
39 
19 30 
104 
 
 
Figure 5.3 Two-source model (from Hook and Regal) 
 
      BPSU  
 
  Yes No  
         NCL  Yes 39 (a) 19 (b) Total NCL =58 
 
No 30 (c) x  
           Total BPSU =69 
 
The estimated number of cases is the total of those found by both sources plus those not 
found by either, i.e. 88+x. 
 
It was estimated that a further 14 cases could be expected giving a total number of 102 
(CI: 88.6-115.8) cases rather than the 88 cases reported by the BPSU and Newcastle 
sources.  Case ascertainment for each was estimated to be 69% and 58% respectively; 
86% of cases were estimated to be ascertained overall by the two sources. However, this 
estimate excludes a further six cases which were identified via the CCLG, all of which 
had been treated by clinicians who had responded to the BPSU or Newcastle surveys. 
 
The estimate was confirmed using Epidat – 102 (CI: 91-113) cases with 86% 
ascertainment. Case ascertainment (exhaustivity) for each was 68% and 57%. See table 
1 in Appendix L. 
 
5.4.2 Three-source model 
The Hook and Regal methods were used to estimate the number of missing cases using 
all sources and to assess the degree of inter-dependence between sources (figure 5.4). 
The number of cases is shown in table 5.6. 
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Figure 5.4 Three-source model (from Hook and Regal) 
   
Source C (BPSU) 1 
       
  Yes  No 
     
  Source B (NCL) 2  Source B (NCL) 2 
       
  Yes No  Yes No 
Source A  
(CCLG) 3 
Yes 36 (a) 24 (b)  9 (e) 6 (f) 
No 3 (c) 6 (d)  10 (g) x 
 
Nobs = 94 
N1  = 69  A BPSU 
N2 = 58  B NCL 
N3 = 75 C CCLG 
 
 
With three sources there are eight possible models which estimate the missing and total 
number of cases.  Estimates were calculated by hand for models 2-8 using the Hook and 
Regal method (table 5.6).  As can be seen the estimated number of cases ranged 
between 95 and 114. 
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Table 5.6 Rough estimate of number of missing cases  
 df*  Model Estimate of  Estimate of   
1 3  Independent = - Nobs †  
2 2 Equivalent  
to two 
independent 
sources 
1-2 interactions 1.6 95.6 
3 2 1-3 interactions 7.5 101.5 
4 2 2-3 interactions 2.4 96.4 
5 1 Two 
independent 
subsets  
1-2, 1-3 interactions 6.6 100.6 
6 1 1-2, 2-3 interactions 1.5 95.5 
7 1 1-3, 2-3 interactions 20 114 
8 0  1-2, 1-3, 2-3 interactions 20 114 
_____________________________________________________________________ 
Sources: 1 = BPSU, 2 = NCL, 3 = CCLG 
 = unobserved cell;   Nobs = 94;   the total population  = + Nobs 
† is the solution of ( - N1)( - N2)( - N3) =
2
( - Nobs);   
*df = degrees of freedom  
 
 
The statistical program SAS was then used to solve the quadratic equation for model 1 
and calculate models 2-8 as described in Chapter 4. The results of SAS analysis are 
shown in the following table. They were cross-checked using Epidat, the results of 
which can be found in Appendix L (table 2).    
 
The estimated number of missing cases ( ) ranged from 1-20 with the estimated total 
number of cases ( ) ranging from 95-114.  Information in tables 5.7 and 5.8 was used 
to assess which was the best model (described in section 4.1.4).   
  
xˆ Nˆ
xˆ Nˆ
xˆ Nˆ xˆ
Nˆ Nˆ Nˆ Nˆ Nˆ Nˆ
xˆ
Nˆ
107 
 
 
Table 5.7 Three-source models using SAS 
 Model  CI  G² df AIC BIC 
1 Independent 2.43 1.26-4.69 96.43 17.77 3 11.77 9.61 
2 BPSU-NCL interactions 1.65 0.64-4.26 95.65 15.31 2 11.31 9.85 
3 BPSU-CCLG interactions 7.50 3.52-15.97 101.50 2.33 2 -1.67 -3.23 
4 NCL-CCLG interactions 2.38 0.94-6.00 96.38 17.65 2 13.65 12.31 
5 BPSU-NCL, BPSU-CCLG 
interactions 
6.67 1.99-22.23 100.67 2.26 1 0.26 -0.51 
6 BPSU-NCL, NCL-CCLG 
interactions 
1.5 0.45-4.98 95.5 14.83 1 12.83 12.08 
7 BPSU-CCLG, NCL-CCLG 
interactions 
20 2.97-
134.73 
114 0 1 -2 -2.90 
8 BPSU-NCL, BPSU-CCLG, 
NCL-CCLG interactions 
20 4.38-91.29 114 0 0 0 0 
 
= unobserved cell;   the total population  = + Nobs 
G
2 
= goodness of fit;   *df = degrees of freedom;  
AIC = Aikaike Information criterion;    BIC = Bayesian Information Criterion 
 
With reference to the eight models in table 5.7, the first model was excluded as the three 
sources were assumed not to be independent. The last which has no remaining degrees 
of freedom was also excluded. In the fourth and sixth models there is evidence that 
BPSU and CCLG may not be independent as the number of cases appears to be an 
underestimate. This is also indicated in the two-source restricted estimates (in table 5.8).  
 
Table 5.8 gives a comparison of estimates of the total number of cases using 
combinations of two sources, i.e. by disregarding the third source (the restricted two-
source models in Hook and Regal).  Calculations for these were made by hand as 
described in Chapter 4.  The second interaction (BPSU and CCLG), gives a much 
smaller value for the number of missing cases (and therefore a higher estimate of 
completeness) than the other combinations suggesting there is positive dependence 
between these two sources.  The two-source restricted estimates were also confirmed by 
Epidat which in addition produced an estimate of completeness of each model 
(exhaustivity) (see table 2 in Appendix L). 
 
xˆ Nˆ
xˆ Nˆ xˆ
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Table 5.8 Two-source restricted estimates of same population (from Hook 
and Regal) 
 Estimates restricted by disregarding the third source 
  
MLE  NUE 
     
BPSU versus NCL  102.6  100.1 
BPSU versus CCLG  86.25  84.8 
NCL versus CCLG  96.6  94.6 
 
MLE maximum likelihood estimator; NUE nearly unbiased estimator 
 
 
The models in table 5.7 with the best fit are the third, fifth and seventh which have the 
lowest G
2
 value and negative BIC values.  However, model 3 (BPSU and CCLG 
independent of NCL) has narrower confidence intervals, a higher degree of freedom and 
is a less complex model. Additionally, the interdependence between BPSU and CCLG 
has been indicated by the results above and coincides with knowledge of the survey 
lists.  The number of missing cases was therefore estimated to be 7 (CI: 3.52-15.97) and 
the estimated total number of cases was 101.   
 
Analysis using Epidat confirmed the results above although slight differences in the G² 
values resulted in small differences in the AIC and BIC values (see table 1 in Appendix 
L). The best model estimated 7 missing cases with 101 in total (CI: 94-109).  
Ascertainment by all three sources was estimated at 93.1% with this model; the 
estimated individual contributions of each source were CCLG – 74%, NCL – 57% and 
BPSU 68%. 
 
To summarise, the number of cases ascertained and the estimates of completeness by all 
methods are shown in table 5.9. 
  
Nˆ Nˆ
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Table 5.9 Summary of estimates of completeness of the survey by all 
methods 
Method Cases 
observed 
Cases 
missing 
Total 
expected 
cases 
Confidence 
Intervals 
% 
Complete 
Two-source method – Hook 
and Regal 
88 14 102 89-126.2 86 
Two-source method – Epidat 88 14 102 91-113 86 
Three-source method – Hook 
and Regal 
94 7 101  93 
Three-source method – 
Epidat 
94 7 101 94-109 93.1 
 
 
 
5.5 Cases ascertained 
Data were received on all 94 cases, although questionnaires varied in their 
completeness. There were 57 boys and 37 girls with a M:F ratio of 1.5:1 and an age 
range of 0.09-15.1 years. The surveys asked for "children of any age" to be reported.  At 
the upper age range there was a single 15 year old with unifocal (UF) bone disease 
reported to all three groups and no 16 or 17 year olds.  A detailed description of cases is 
given in Chapter 6. 
 
5.6 Population and incidence rates  
5.6.1 Age-standardized incidence rate 
From this study population the age-standardized incidence (ASR) of LCH in 0-14 year 
olds was 4.12 per million per year (CI: 4.11-4.13).  The ASR for boys and girls was 4.8 
and 3.4 per million per year respectively.  
 
For comparison with other studies incidence rates by sex and age group for those aged 
0-14 years are shown in table 5.10.  The incidence was 9.9 per million per year (CI: 5.5-
16.3) in children less than one year old. 
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Table 5.10 Incidence rates by age group and sex, per million per year 
 IR 
 Age (years) 
 <1 1-4 5-9 10-14 0-14 
Boys 10.3 5.7 5.0 2.6 4.7 
Girls 9.5 3.9 3.9 1.0 3.2 
Both  9.9 4.8 4.5 1.8 4.0 
Sex Ratio (M:F) 1.1 1.5 1.3 2.7 1.5 
 
Overall the M:F sex ratio was 1.5:1 which increased to 2.7:1 in the 10-14 years age 
group. 
 
5.6.2 Age-specific incidence rate 
Only one child over 15 years was identified during the study period. The age-specific 
incidence rate for all cases was therefore only a little lower than the ASR for 0-14 year 
olds at 3.74 per million per year (CI: 3.02-4.6).  If the number of cases (101) estimated 
by C-RA had been ascertained, the rate would have been 4.02 per million per year (CI: 
3.27-4.89). 
 
5.6.3 Regional incidence rates 
The population studied covers 13 geographical health care regions.  Regional age-
standardized (age 0-14 years) and age-specific incidence rates (0-15 years) were 
calculated and the results are shown in table 5.11. With the addition of only one case (in 
Wales) the rates estimated by each method are similar. Regional ASRs varied from 
2.99-5.68 per million per year and age-specific IRs ranged from 2.6-6.11. 
 
Age-specific rates were used to assess heterogeneity between regions using Stata as 
described in section 4.2.2.  The results are shown in figure 5.5.
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Table 5.11 Regional age-standardized incidence rates (for cases age 0-14 years) and age-specific rates (for cases  
age 0-15 years), per million per year 
 
 Age-standardized IR (ASR)  Age-specific IR 
Region Cases IR CI  Cases IR CI 
Scotland 8 5.34 5.29-5.39  8 4.27 1.84-8.42 
Northeast 3 3.79 3.73-3.85  3 3.12 0.64-9.12 
Yorkshire & Humber 7 3.71 3.67-3.75  7 3.53 1.42-7.27 
Northwest 12 5.08 5.04-5.12  12 4.44 2.29-7.75 
West Midlands 8 4.23 4.19-4.27  8 3.72 1.61-7.34 
East Midlands 5 3.72 3.68-3.77  5 3.02 0.98-7.05 
East 10 4.84 4.80-4.88  10 4.63 2.22-8.53 
London 10 3.72 3.68-3.75  10 3.46 1.66-6.37 
Southeast 11 5.68 5.64-5.71  11 3.47 1.73-6.21 
Southwest 6 3.35 3.31-3.38  6 3.22 1.18-7.01 
Wales 6 5.45 5.39-5.51  7 6.11 2.46-12.6 
Northern Ireland 2 2.99 2.93-3.05  2 2.6 0.32-9.4 
Republic of Ireland 5 3.20 3.18-3.22  5 2.76 0.89-6.44 
All 93 4.11 4.12-4.13  94 3.74 3.12-4.26 
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Figure 5.5 Results of test for heterogeneity for age-specific IRs using Metan 
Overall  (I-squared = 0.0%, p = 0.999)
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The overall estimate and confidence interval are marked by a diamond. The size of the 
plotting symbol for each region is proportional to the weight each region contributed in 
the analysis. The I-squared value (the variation rate in effect size (ES on figure 5.5) due 
to heterogeneity) was 0.0%; confidence intervals for each region overlapped and the p-
value was large (0.99) indicating no statistically significant difference between the rates 
in each health region.   
 
A Geographic Information Systems (GIS) choropleth map was used to visualise the 
differences in national and regional age-specific IRs (figure 5.6).  The rate is presented 
as graduated colour with the darker colours representing the higher rates.  
 
The geographical variation in age-specific IRs appears to be random. For example, there 
is no north to south gradient although the rate was slightly higher in Scotland (4.27) 
than in the Southeast (3.47), London (3.46) and the Southwest (3.22). The lowest IRs 
were in Northern Ireland and the Republic of Ireland (2.6 and 2.76 respectively) while 
the highest rate was in Wales – 6.11 per million per year.   
 
The location of cases based on (partial) postcode of residence at the time of diagnosis is 
shown in figure 5.7. As can be seen the cases in Wales, which had the highest IR, were 
widespread. 
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Figure 5.6 Regional age-specific incidence rates (for cases age 0-15 years), 
per million per year 
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> 6.0 
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Figure 5.7 Location of cases 
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5.7 Reporting patterns 
5.7.1 Reporting according to disease extent 
The pattern of reporting according to disease extent (SS, MS, risk organ involvement) is 
shown in table 5.12.  The table shows those cases uniquely identified and those not 
identified by each source.   
 
The 10 cases identified uniquely by the Newcastle University survey were all unifocal 
(UF) bone disease, eight of which were diagnosed and treated at a single national 
orthopaedic centre.  
 
The two cases of MS disease with risk organ involvement (RO+) uniquely reported to 
the BPSU were diagnosed post mortem. Of the 25 cases not identified by the BPSU 20 
had UF bone disease, but two cases of MS disease without risk organ involvement  
(RO-) were not reported.  Similarly, 16/19 of cases not reported to CCLG were UF bone 
disease.  CCLG were notified of all cases with multifocal (MF) bone involvement and 
of MS disease, apart from the two cases diagnosed at autopsy.   
 
 
5.7.2 Comparison with previous CCLG reporting 
At the end of the study 89 cases had been notified by the CCLG. However, only 75 of 
these were included. Of those excluded the date of the biopsy on which the diagnosis 
was based was outside the study period for nine cases. The others had a change of 
diagnosis or the diagnosis had not been confirmed, and one was not resident in the UK. 
The average number of cases per year registered over the two-year study period was 
37.5 and was similar to the average of those reported to the CCLG in the previous 11-
year period (36.7 cases per year, range 29-52) as shown in Chapter 1 (figure 1.3). 
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Table 5.12 Pattern of case reporting 
Source 
Total 
Cases 
SS  MS  
  Bony Other RO+ RO- 
  UF MF    
Total 94 53 10 6 7 18 
Uniquely identified by 
BPSU 6 3 – 1 2 – 
Newcastle University 10 10 – – – – 
CCLG 6 4 1 – – 1 
Not identified by 
BPSU 25 20 2 1 – 2 
Newcastle University 36 19 3 3 5 6 
CCLG 19 16 – 1 2 – 
RO = risk organ involvement 
 
 
 
5.7.3 Incidence by type of disease 
For comparison with other studies, incidence rates were calculated by age group and 
type of disease for those aged 0-14 years, i.e., 93/94 cases identified, as shown in table 
5.13.  
 
Table 5.13 Incidence rates by age group and type of disease (per million 
per year, aged 0-14 years)  
Age 
group 
(years) 
SS MS Total 
 Bony Other All RO+ RO- All  
 UF MF       
<1 2.0 – 1.3 3.3 4.6 2.0 6.6 9.9 
1-4 2.5 0.9 – 3.4 – 1.4 1.4 4.8 
5-9 2.8 0.5 0.4 3.7 – 0.8 0.8 4.5 
10-14 1.5 0.1 0.1 1.7 – 0.1 0.1 1.8 
0-14 2.2 0.4 0.3 2.9 0.3 0.8 1.1 4.0 
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The highest rate of MS disease was in those under one year of age and rates declined 
with increasing age. With regard to SS disease the rate in infants was half that of MS 
disease. Rates of SS disease were thereafter similar in other age groups with a lower rate 
in 10-14 year olds. The highest rate of those with MF bone disease was in the 1-4 years 
age group. 
Incidence rates by sex and type of disease are shown in table 5.14. In both sexes MS 
disease rates decreased with age, the highest rate being in males under one year of age 
(7.7 per million per year).   The rate of SS disease was highest in females aged less than 
one year (three females compared with two males); the highest rate in males was in the 
1-4 years age group.   
 
Table 5.14 Incidence by sex and type of disease (per million per year, aged 
0-14 years) 
Age group 
(years) 
Male Female Total 
 SS MS Total SS MS Total  
<1 2.6 7.7 10.3 4.1 5.4 9.5 9.9 
1-4 4.0 1.7 5.7 2.8 1.0 3.8 4.8 
5-9 3.8 1.3 5.1 3.7 0.3 4.0 4.5 
10-14 2.3 0.2 2.6 1.0 – 1.0 1.8 
0-14 3.3 1.42 4.7 2.5 0.7 3.2 4.0 
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Chapter 6. Results (2): Descriptive epidemiology and analyses 
of outcome  
 
As reported in the previous chapter, 94 cases of LCH were ascertained. There were 57 
boys and 37 girls with a M:F ratio of 1.5:1.  A detailed description of these cases 
follows including spectrum of disease, time taken to diagnosis, birth and other 
associated factors, and ethnicity.  The status of cases after the first and second follow up 
periods and permanent consequences are also described. In addition, disease-free 
survival and survival without permanent consequences are assessed and mortality 
estimated.   
 
A list of the 94 cases and those included in both follow ups are shown in Appendix M. 
As patient names were unknown the list is anonymous. However, sex, dates of birth and 
dates of diagnosis of cases are given with type of disease and their inclusion or 
exclusion in the follow ups. 
 
6.1 Diagnosis 
Diagnostic biopsies were reported in 78 cases. The basis of diagnosis is shown in table 
6.1. Eleven bony lesions and two cases with isolated diabetes insipidus (DI) were 
diagnosed by typical radiological appearance. For one case of bone disease the basis of 
the diagnosis was not stated.  Two young children with MS LCH were only diagnosed 
at autopsy. 
 
Table 6.1 Basis of diagnosis of cases 
Basis of diagnosis Cases 
Biopsy 78 
Radiology 13 
Post mortem 2 
Not known 1 
Total 94 
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6.2 Symptoms and presentation 
Not all questionnaires recorded the first symptoms (87/94) or the date on which they 
appeared (85/94). However, the frequency of symptoms reported is shown in table 6.2. 
One case was found incidentally following a skull X-ray and nine cases presented after 
a fall or minor trauma. Seven of these had SS bone disease and the other two had MS 
RO- disease – of skin and bone, and skin, bone and nervous system. „Other‟ symptoms 
included fever or infections, hepatosplenomegaly, lymph node enlargement, colitis, 
poor weight gain and diarrhoea/vomiting. Infections or fever occurred mainly in those 
with MS disease (5/8) cases. 26 cases had more than one symptom. 
 
Table 6.2 Frequency of presenting symptoms 
Presenting symptoms Number of cases 
Pain or restricted movement 39 
Swelling or lump 29 
Rash or lesion 14 
Polyuria/polydipsia 6 
Ear discharge 5 
Proptosis or swelling above the eye 5 
Other 11 
 
 
The patient‟s initial consultation is recorded for 64 cases as shown in table 6.3. For 78% 
of these the first consultation was with a GP and 16% went to Accident and Emergency 
(A&E).  Two children were already under the care of a consultant for cancer treatment 
and neurological problems respectively. One child with disseminated congenital LCH 
remained in Paediatric Intensive Care from birth.  
 
Table 6.3 Initial consultation of cases 
Initial consultation Number of cases 
GP 50 
A&E 10 
Consultant 3 
Optician 1 
Total 64 
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However, in addition to those cases that were referred via A&E (10), a further 17 cases 
were first referred to their local hospital services including non-paediatric services. 
 
6.3 Time to diagnosis from first symptoms 
The time from first symptom to diagnosis was reported for 85/94 cases and is detailed in 
table 6.4. The cases for which there was no information all had SS bone disease. The 
median time was 11.5 weeks. There is wide variation with the longest median time to 
diagnosis in patients with non-bony SS disease and the shortest median time in patients 
with MS RO+ disease.  The longest time to diagnosis, 170 weeks, was in a patient with 
a single bony lesion. There was no significant difference in the time from symptoms to 
diagnosis between SS, SS multifocal (SS-MF) and MS groups (p=0.12), by sex (p=0.15) 
or by age group (p=0.28). 
 
Table 6.4 Number of weeks from first symptom to diagnosis by type of 
disease 
Type of disease Median  
(weeks) 
Range 
(weeks) 
SS 10 0.5–170 
Bone   10 0.5–170 
    UF 10 0.5–170 
    MF 13 0.5–65 
Other  28 6.7–37 
MS 17 2.5–149 
    RO+  9 3.1–27 
    RO–  20 2.5–149 
 
 
Table 6.5 shows the number of cases diagnosed by the interval from first symptoms to 
diagnosis.  Overall, 45% of cases were diagnosed in less than twelve weeks from the 
first symptoms.  Those diagnosed in under four weeks comprised seven SS bone cases, 
two of which were MF, and two MS cases (one RO+ and one RO-). Those who took 
longest to be diagnosed, over a year, had persistent skin rash, recurrent ear infections 
and multiple visits to their GP with back or leg pain. 
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Table 6.5 Frequency of cases by time from first symptom to diagnosis 
Interval from symptoms 
to diagnosis (weeks) 
Number of cases 
<4 9 
4-11 34 
12-25 20 
26-51 14 
>=52 8 
Not known 9 
Total 94  
 
6.4 Spectrum of disease  
Table 6.6 shows cases by type of disease, sex and age at diagnosis. Overall 69/94 (73%) 
of cases had SS disease and 25 (27%) had MS disease; 18 were RO- and seven were 
RO+.  There were two cases of isolated skin disease and the „Other‟ cases were two 
each of lymph and diabetes insipidus. 
 
Table 6.6 Cases of LCH by type of disease, sex and age at diagnosis 
LCH system Number 
Sex 
 
M       F 
Median age 
at diagnosis 
(years) 
Age range 
(years) 
SS 69 40 29 6.7 0.12–15.1 
Bone  63 36 27 6.7 0.38–15.1 
    UF  53 31 22 7.3 0.38–15.1 
   MF  10 5 5 4.8 1.58–13.63 
Skin 2 1 1 0.54 0.12–0.96 
Other 4 3 1 9.0 8.8–10.0 
MS 25 17 8 1.2 0.09–14.8 
    RO+  7 5 2 0.7 0.09–0.9 
    RO–  18 12 6 3.2 0.32–14.8 
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6.4.1 Age at diagnosis and sex 
The age range of cases was 0.09-15.1 years.  Table 6.6 shows the median age at 
diagnosis by type of disease.  At the upper age range there was a single 15 year old male 
with UF bone disease and no 16 or 17 year olds.  The median age at diagnosis was 5.5 
years which differed slightly between boys (6.1 years) and girls (5.0 years).   
 
The number of cases by age and sex, and by age and system involved are shown in 
figures 6.1 and 6.2.  There was a significant difference in age at diagnosis among SS, 
SS-MF and MS cases – medians 6.7, 4.8 and 1.2 years respectively (p=0.001).  The 
youngest children (less than one year of age) at diagnosis were those with skin and MS 
RO+ disease, the medians being 0.54 and 1.2 years respectively. There was an age 
difference between those with UF and MF bone disease, the medians being 7.3 and 4.8 
years respectively. The oldest children had SS UF bone disease or disease of pituitary or 
lymph.  
 
16% cases were diagnosed aged less than one year; 30% were 1-4 years, 37% were 5-9 
years and 17% were aged 10-15 years at diagnosis.  
 
Overall the M:F ratio was 1.5:1. There was no significant difference in age at diagnosis 
between the sexes (p=0.2). The M:F ratio in the MS group was 2.1:1 with the RO+ 
cases being diagnosed at the younger median age of 0.7 years compared to 3.2 years in 
the RO– patients.   
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Figure 6.1 Number of cases by sex and age at diagnosis 
 
 
Figure 6.2 Number of cases by age and system involved 
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6.4.2 Single system disease 
Of the 69 cases with SS disease, 53 were cases of UF and 10 were of MF bone disease. 
The remainder comprised two cases each with skin, pituitary (diabetes insipidus (DI)), 
and lymph node involvement.  The sites of SS bone disease and their frequency are 
shown in figure 6.3.  28% of UF cases were of skull, the next most common sites being 
pelvis (15%), vertebra (13%) and femur (9%).  Of the MF bone cases 7/10 had femur 
involvement and 5/10 had vertebral involvement. Only one of the MF bone cases had 
skull involvement. The UF bone cases were diagnosed at a median age of 7.3 years 
compared with 4.8 years for MF bone cases and 0.54 years for those with skin disease.  
 
 
Figure 6.3 Pie chart showing the frequency and distribution of unifocal 
and multifocal bone disease 
 
 
  
Sternum 1 Clavicle 3
Facial bones 1
Femur 12
Fibula 1
Humerus 6
Mandible 4
Orbit 2
Pelvis 9
Radius 2
Rib 4
Scapula 3
Skull vault 16
Ulna 2
Vertebra 12
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6.4.3 Multi-system disease 
Of the 25 MS cases, 18 were RO-, the most common sites being bone, skin, DI, nervous 
system and ear.  The sites of RO- disease and their individual frequency are shown in 
figure 6.4. Combinations of the sites involved were examined to see if there were any 
particular clusters of disease. The frequency of these combinations is shown in figure 
6.5.   
 
Figure 6.4 Pie chart showing the frequency and distribution of systems 
involved in MS RO- cases  
 
Figure 6.5 Pie chart showing the frequency of combinations of sites 
involved in MS RO- cases  
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Nervous system 5
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 Bone, nervous system  
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 Bone, ear, nervous system 
 Bone, skin, lymph 
 Skin, ant/post pituitary 
 Bone, skin, nervous system 
 Bone, skin, DI, nervous system, 
hypothalamus 
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As can be seen in figure 6.5, most RO- cases had a unique combination of disease sites 
although there were multiple bone cases with skin or ear disease or diabetes insipidus.  
 
Among the seven RO+ cases, the combinations of organs involved in each case were 
unique. The most common sites were skin, liver, lung and spleen. Whereas all RO+ 
cases had skin disease, only one had bony involvement.   
 
The frequency of risk organ involvement (liver, lungs, bone marrow or spleen) in the 
seven RO+ cases is shown in table 6.7 
 
Table 6.7 Frequency of risk organ involvement in MS RO+ cases 
No. of systems No. of RO+ cases 
1 1 
2 3 
3 1 
4 2 
 
The case with only one risk organ involved had lung, bone and skin disease. However, 
lung disease was only diagnosed post mortem. 
 
Figure 6.6 Pie chart showing the frequency and distribution of systems 
involved in MS RO+ cases 
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6.5 Seasonality 
Dates of birth and diagnosis were recorded for all cases; the month of first symptom 
was reported for 85 cases. The results of the seasonality tests by month of birth, month 
of first symptoms and month of diagnosis are shown in table 6.8 with the observed and 
expected numbers per month.  
 
Whilst there was no evidence of seasonality of birth (p=0.94) or of first symptom 
(p=0.86), there was a significant association with month of diagnosis (p=0.04). A higher 
number of cases than expected (under an assumption of no seasonal effect) were 
diagnosed between March and June.  The observed number of cases was actually 
slightly lower than the expected number in April, although this was the month with the 
maximum value of the fitted curve. The amplitude was 37%, i.e. the expected value for 
April was 37% above the mean value for the whole year.  The goodness of fit for this 
test was 0.8 (i.e. a good fit). The month of diagnosis of cases by type of disease is 
shown in figure 6.7 which also shows the fitted curve with peak in April.  
 
Table 6.8 Observed and expected number of cases in seasonality tests 
Test by Month of birth 
Month of first 
symptom 
Month of diagnosis 
Month Observed Expected Observed Expected Observed Expected 
January 7 8.18 6 7.65 11 7.59 
February 9 8.25 7 7.47 5 9.09 
March 11 8.21 7 7.21 12 10.16 
April 4 8.07 10 6.89 9 10.71 
May 13 7.87 5 6.63 12 10.47 
June 4 7.65 6 6.49 10 9.51 
July 8 7.49 6 6.51 7 8.12 
August 7 7.42 6 6.68 5 6.61 
September 4 7.46 10 6.97 7 5.44 
October 15 7.59 6 7.27 7 4.93 
November 9 7.8 8 7.54 3 5.2 
December 3 8.01 8 7.67 6 6.15 
Total 94  85  94  
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Figure 6.7 Month of diagnosis of cases by type of disease 
 
 
6.6 Ethnicity 
The number of cases by ethnicity and sex is shown in table 6.9.  Overall 75 children 
were white caucasian (80%, CI: 70-87%), 13 (14%, CI: 7.6-22%) were of mixed or 
other ethnicity and in 6/94 cases ethnicity was not reported (6%, CI: 2.4-13%). The 
proportion of those with mixed or other ethnicity in the general population is 7.9% 
[214]. Where ethnicity was reported (in 88 cases), the proportion of mixed or other 
ethnicity was significantly different from the proportion of ethnic minorities in the 
whole population (p=0.027). However, the probability of mixed or other ethnicity cases 
in all 94 cases was not statistically significant different from the probability of ethnicity 
in the whole population (p=0.051). 
 
 
  
0
2
4
6
8
10
12
14
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
N
u
m
b
e
r 
o
f 
c
a
s
e
s
Month of diagnosis
MS
SS
SMF
Expected number
  130 
Table 6.9 Number of cases by ethnicity and sex 
Ethnicity 
Number 
of Males 
Number of 
Females 
Total 
number 
of cases 
White 46 29 75 
Black – Caribbean    
Black – African 1 0 1 
Black – other    
Indian/Pakistani 2 0 2 
Bangladeshi 1 0 1 
Chinese    
Other or mixed race 4 5 9 
Not known 3 3 6 
Total 57 37 94 
 
6.7 Birth-associated factors 
There were three sets of twins with one of each pair affected. One was born prematurely 
and after many neonatal complications was diagnosed with UF skull vault disease aged 
one year.  The two other cases (2%: CI: 0.2-7%) were reported to have been conceived 
by IVF. One developed UF vertebral bone disease at age 11 years and the other had 
Congenital Self-healing Histiocytosis (Hashimoto-Pritzker disease).   
 
There were three other congenital cases – a boy with proptosis, a female with MS 
disease (skin and bone), and a boy with RO+ disease and multiple gastric atresias who 
died aged one month.  No children of consanguineous parents were reported. 
 
6.7.1 Birth weight  
The birth weights of 60/94 cases were reported and were comparable with live births in 
the general population as shown in table 6.10. The range was 0.99-4.5kg and the median 
was 3.3kg.  There was no difference in birth weights between those with SS or MS 
disease (p=0.35). 
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 Table 6.10 Percentage of live births by birth weight 
Weight (grams) % births in 
study group (60) 
% births in UK 
population 
<1000 1.6 0.5 
1000–1499 0 0.7 
1500–2499 6.6 6.3 
>=2500 91.6 92 
 
The proportion of children with a birth weight of <1000 grams was slightly higher in 
our study group but this was not significantly different from that in the UK population 
(p=0.26). 
 
6.7.2 Gestational age 
Gestational ages were recorded for 82/94 cases and were comparable with those in the 
general population as shown in table 6.11. The range was 27.5-43 weeks and the median 
was 40 weeks.  There was no difference in gestational age between those with MS or SS 
disease (p=0.58). Although the proportion of pre-term births was higher in the study 
group this was not significantly different from the proportion in the UK population 
(p=0.13). 
 
Table 6.11 Gestational age 
Age 
(weeks) 
Description % in study 
group (82)  
% of live births in 
UK population 
(2005) 
<37 Pre-term 12.2 7.6 
37–41 Term 83 88 
>42 Post-term 4.9 4 
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6.8 Associations with other factors 
6.8.1 Cancers  
Two children had medulloblastoma. In one case the tumour preceded the diagnosis of 
SS, UF bone disease. The second was diagnosed six months after SS, UF bone disease 
which had not required treatment.   
 
6.8.2 Co-morbidities 
One child had partial Trisomy 3. Other conditions included seizure disorder and 
developmental delay in one child and pneumothorax and necrotizing enterocolitis in the 
preterm twin.  Juvenile xanthogranuloma was also diagnosed in a child with MS 
disease. 
 
6.8.3 Maternal and family history 
Among maternal history during pregnancy, one of each of the following conditions 
were reported: Darier‟s disease (a rare, autosomal dominant skin disorder – the affected 
child had MS RO+ disease diagnosed at autopsy), hypothyroidism, epilepsy, melanoma, 
thalassaemia, asthma/psoriasis, diabetes/epilepsy and cholestasis. With regard to 
infections, one mother was receiving penicillin for an itchy rash and another had a 
Streptococcus B infection around delivery. 
 
6.9 Deaths 
There were three deaths among the 94 cases ascertained, all male and with MS RO+ 
disease. One of these was a baby with congenital disseminated LCH who died aged one 
month.  The second child died at age 10 months. Both of these children were diagnosed 
post mortem. The third child was diagnosed with skin disease but died at nine months of 
age and was found to have MS LCH post mortem. Although LCH was the recorded 
cause of death on the death certificate there may have been other contributing factors in 
this case.   
 
6.10 First year follow up    
Surviving cases (91) were followed up one year after the date of diagnosis.  For five SS 
bone cases, follow up forms were not returned and the date of the last follow up at 
clinic was less than six months from diagnosis; these were excluded from analysis.  Of 
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the 86 cases assessed, the median number of months from diagnosis was 1.3 years 
(range 0.5-3.3 years). There were 51 males and 35 females (ratio 1.5:1) which 
comprised 18 MS RO-, 4 MS RO+, 48 SS bone, 10 MF bone and 6 other SS cases.  
 
6.10.1 Status at one year 
The status of these 86 patients was as shown in table 6.12. 75 were alive with no active 
disease and 11 children had active disease – four SS UF bone and seven MS cases. 
There were no deaths.  The SS diabetes insipidus (DI) cases were reported by clinicians 
as not having active disease and grouped accordingly.  
 
Table 6.12 First year follow up status by type of disease 
Status 
SS 
(all) 
UF 
Bone 
MF 
Bone 
SS 
Other 
MS 
RO– 
MS 
RO+ 
Total 
(91) 
Alive, no 
active disease 
61 44 10 6 12 3 75 
Alive, active 
disease 
2 2 0 0 4 0 6 
Alive, active 
disease, on 
treatment 
2 2 0 0 2 1 5 
Dead 0 0 0 0 0 0 0 
Lost to FUP 
or excluded 
5 5 0 0 0 0 5 
 
 
There was no significant difference in the age at diagnosis or in the time from 
symptoms to diagnosis between those with and without active disease (p=0.26 and 
p=0.38 respectively), nor was there a difference by sex (p=0.5). However, there was a 
difference by type of disease (SS, SS-MF and MS) (p=0.01) and treatment (p=0.05). 
There were a larger number of MS cases and those treated on LCH protocol than 
expected. 
 
Kaplan-Meier survival analysis was used to assess active disease-free survival at one 
year. There were a total of 129 person years of follow up. Overall there was a 65% 
probability of active disease-free survival after 3.3 years (CI: 38%-83%) as shown in 
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figure 6.8. However the confidence intervals were very wide and the probability of 
being disease-free at two years which includes 10/11 cases was 76% (CI: 59%-87%). 
 
Figure 6.8 Overall probability of having no disease at first follow up 
 
 
 
The logrank test was used to assess disease-free survival between different subgroups 
based on sex, age group, type of disease, type of treatment and the time period between 
symptoms and diagnosis (figures 6.9 to 6.13). Data for each subgroup were available for 
all 86 cases except for the time period between symptoms and diagnosis where the date 
of first symptoms was missing for six (SS bone) cases.  P-values are shown and the 
numbers in each subgroup are given in brackets on each graph.   
 
There was no difference in the probability of being disease-free between any of these 
subgroups except by type of disease. There was a significant difference in disease-free 
survival between MS and SS disease cases (figure 6.11).  The probability of having 
active disease was 55% in MS cases which was 13% less than for SS cases (p=0.03).    
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Figure 6.9 Probability of having no disease by sex at first follow up 
  
 
 
Figure 6.10 Probability of having no disease by age group at first follow 
up 
 
The number of cases in each subgroup is shown in brackets   
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Figure 6.11 Probability of having no disease by type of disease at first 
follow up 
 
 
 
Figure 6.12 Probability of having no disease by time from symptoms to 
diagnosis at first follow up 
  
 
The number of cases in each subgroup is shown in brackets.   
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Figure 6.13 Probability of having no disease by type of treatment at first 
follow up 
 
The number of cases in each subgroup is shown in brackets. 
 
6.10.2 Treatment 
Treatment during the first year by sex and system involved is shown in table 6.13.  12% 
of cases did not receive treatment; 40% had a biopsy, curettage or surgery and 43% 
were on LCH protocol or received other chemotherapy. Four children on protocol had 
additional chemotherapy.   
 
Table 6.13 Treatment at first follow up by sex and system involved 
 Male Female    
Total 
(91) 
Status 
SS MS 
RO– 
MS 
RO+ 
SS MS 
RO– 
MS 
RO+ 
Wait and see 7 0 0 4 0 0 11 
Curettage/surgery 21 2 0 13 0 0 36 
LCH protocol 9 9 2 8 6 2 36 
Other 0 1 0 2 0 0 3 
Lost to FUP or 
excluded 
3 0 0 2 0 0 5 
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Of those eligible, 12 cases were not treated on LCH protocol as shown in table 6.14. 
These included one case with MF bone disease, eight with risk of CNS (skull) lesions 
and three MS low risk patients.  Of the nine patients with bone disease, six had had a 
biopsy, curettage or surgery and one had received „Other‟ treatment. The remaining two 
were „Wait and see‟ and in one case the disease regressed spontaneously. Two of the 
MS cases (bone and DI) were „Wait and see‟ and the third received „Other‟ treatment. 
 
Table 6.14 Eligible cases not treated on LCH protocol 
Treatment SS bone SS-MF bone MS RO- 
Wait and see 2  2 
Surgery 5 1  
Other 1  1 
Total 8 1 3 
 
 
6.10.3 Reactivation 
The follow up questionnaire asked for patient status at their last follow up as described 
in table 4.9.  Any data about reactivation or progression of disease (definitions in 
section 2.1.5) was provided voluntarily by clinicians as additional information. The 
questionnaire did not specifically ask about any periods of complete resolution (CR) of 
disease, nor did any clinician specify any.   
 
Eight children, 1 MS RO+, 5 MS RO- and 2 SS (one skin and one bone) were reported 
to have had reactivated disease since diagnosis although at the time of follow up two of 
these cases had no active disease.  The sites of reactivation were not stated in half the 
cases but two children were reported to have disease in new sites. One MS RO- case 
developed disease of spleen (in addition to skull and ear) and a SS case of scapula bone 
disease progressed to vertebra.  
 
6.10.4 Permanent consequences 
23% of cases (20) were reported to have permanent consequences – eleven males and 
nine females. There were nine MS cases and 11 SS cases including two MF bone cases 
as shown in table 6.15.  There was no significant difference between those with and 
without sequelae by age at diagnosis or time from symptoms to diagnosis (p=0.07 and 
p=0.64 respectively). Similarly, there were no differences by sex (p=0.1) or type of 
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disease (p=0.5) but there was a difference by type of treatment (p=0.01). There were 
nine cases on LCH protocol compared with an expected number of 5.9. 
 
Table 6.15 First follow up: cases with permanent consequences by sex 
and type of disease  
Sex Type of disease 
 SS Bone SS-MF 
Bone 
SS DI MS RO- MS RO+ 
Male 3 1 2 5  
Female 4 1  3 1 
 
 
The main permanent consequences were DI and orthopaedic problems with small 
numbers with various hormone deficiencies, lung, neurological and ophthalmic 
problems. The frequency of permanent consequences by disease type is shown in table 
6.16.  Two MS cases developed DI after the original diagnosis and another MS case 
with DI developed Thyroid Stimulating Hormone (TSH) deficiency.  Eight of the nine 
cases with orthopaedic problems had vertebral collapse.  
 
 
Table 6.16 First follow up: permanent consequences by type of disease  
 Type of disease 
Permanent consequences SS MS 
Orthopaedic 9  
Diabetes insipidus (DI) 2 7 
Growth hormone deficiency (GHD)  3 
Thyroid-stimulating hormone (TSH) 
deficiency 
 2 
Follicle-stimulating hormone (FSH) 
deficiency 
 1 
Adrenocorticotropic hormone 
(ACTH) deficiency 
 1 
Ophthalmic 1  
Neurological  1 
Lung  1 
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Six of the 20 cases had DI at diagnosis (and no other permanent consequences) and 
therefore did not contribute to the person years at risk (118 years) in the Kaplan-Meier 
survival analysis. Of the remaining 14 cases with permanent consequences, there were 
six males and eight females. Overall, sequelae-free survival was estimated to be 42% 
after 3.3 years (CI: 13%-68%) – figure 6.14. However, at two years after diagnosis 
which included 11/14 cases it was 73% (CI: 55-85%). 
 
Disease-free survival for different subgroups, based on sex, age group, type of disease, 
type of treatment and the time period between symptoms and diagnosis, was assessed 
and the results are shown in figures 6.15 to 6.19. Data for each subgroup were available 
for all 86 cases except for the time period between symptoms and diagnosis where the 
date of first symptoms was missing for six (SS bone) cases.  P-values are shown and the 
numbers in each subgroup are given in brackets on each graph. Although there were 
variations there were no significant differences in any of these subgroups in the 
probability of surviving without permanent consequences except with type of treatment 
(p=0.03).  As shown in figure 6.19 the probability of having no permanent 
consequences was 24% in those treated on LCH protocol and 31% in those who 
received no treatment.   
 
 
Figure 6.14 Overall probability of having no sequelae at first follow up 
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Figure 6.15 Probability of having no sequelae by sex at first follow up 
 
 
 
 
Figure 6.16 Probability of having no sequelae by age group at first follow 
up 
 
 
 
The number of cases in each subgroup is shown in brackets. 
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Figure 6.17 Probability of having no sequelae by type of disease at first 
follow up 
 
 
 
 
Figure 6.18 Probability of having no sequelae by time from symptoms to 
diagnosis (weeks) at first follow up 
 
 
 
The number of cases in each subgroup is shown in brackets. 
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Figure 6.19 Probability of having no sequelae by type of treatment at first 
follow up 
 
 
The number of cases in each subgroup is shown in brackets. 
 
 6.11 Second follow up 
All 91 surviving cases were followed up two years after the date of diagnosis.  
Questionnaire replies were received between 2007 and 2009 and the results were as 
follows: 
 ten cases were lost to follow up. 
 one child previously diagnosed with bone disease on the basis of radiological 
findings had a probable change of diagnosis (“likely diagnosis juvenile axial 
osteoporosis – probably not LCH”).   
 two children with SS bone disease who were discharged less than one year 
from diagnosis were excluded from further analysis.  
 
All those lost to follow up were cases of SS bone disease with the exception of one 
child with MF bone disease who had moved elsewhere and a MS RO- case for whom 
no questionnaire was received.   
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Of the 78 cases assessed, the median number of years from diagnosis was 3.5 years 
(range 1.0-6.2 years). There were 45 males and 33 females (ratio 1.4:1) which 
comprised 47 SS, 10 MF bone and 21 MS cases.   
 
6.11.1 Status 
Of the 71 cases without active disease, five had been discharged.  Only seven cases had 
active disease. The SS DI cases were reported and classified as having no active disease. 
The status of cases is shown in table 6.17.  
 
Table 6.17 Cases in second follow up by status and type of disease 
Status MS SS SS-MF Total 
No active disease 16 45 10 71 
Active disease 1 1 0 2 
Active disease on treatment 4 1 0 5 
Total 21 47 10 78 
 
There was no difference in those with or without disease by sex (p=0.12), age at 
diagnosis (p=0.24) or the time from symptoms to diagnosis (p=0.36) although there 
were differences by treatment type (p=0.006) and disease type (p=0.03). There were a 
higher than expected number of MS cases and those treated on LCH protocol or other 
chemotherapy. In fact, all cases with active disease had received or were receiving 
treatment on LCH protocol. A description of these cases is shown in table 6.18.   
 
Table 6.18 Cases with active disease at second follow up 
Case 
ID 
Sex 
Type of 
disease 
Site at diagnosis 
Age at 
diagnosis 
(years) 
Previous 
LCH 
protocol 
Recent/ 
current 
treatment 
86 M SS bone Orbit 2 Yes Other 
4 M SS bone Mandible 10 Yes Surgery 
43 F MS RO- Temporal bone, skin <1 Yes Other 
78 M MS RO- Bone (MF), skin <1 Yes Other 
67 M MS RO- Skull, femur, skin 1 Yes Other 
69 M MS RO- Ears, nervous system 2 Yes Other 
130 M MS RO- Skull, skin, nervous 
system 
14 No LCH 
protocol 
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Kaplan-Meier survival analysis was used to assess active disease-free survival two years 
after diagnosis. There were a total of 272 person years of follow up.  Overall there was a 
62% probability of active disease-free survival after 6.2 years (CI: 28%-83%) as shown 
in figure 6.20.  The probability at 5 years (with 6/7 active disease cases) was 74% (CI: 
46-89%). 
 
 
Figure 6.20 Overall probability having no disease at second follow up 
 
 
 
Since only seven cases had active disease, subgroup analysis was performed only by sex 
and type of disease.  Neither test had significant results (p values were 0.15 and 0.19 
respectively).  
 
 
6.11.2 Reactivation 
Six children (all MS) were reported to have had reactivated disease in the second follow 
up period although only four had current active disease. Five had reactivation of bony 
lesions and one had skin lesions. As can be seen from table 6.19, four cases had 
reactivation of disease in new sites – skin, bone or diabetes insipidus. The first three 
cases had reported reactivation of bone disease in the previous follow up. 
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Table 6.19 Sites of original disease and reactivation at second follow up 
Case 
ID 
Original site of disease Site of reactivation Age at 
diagnosis 
(years) 
Status 
43 Temporal bone, skin Bone (temporal, 
petrous) 
<1 AD 
44 Skin, ears, liver, lung, gut, 
genital mucosa 
Bone, DI <1 NAD 
78 Bone (MF), skin Bone, DI <1 AD 
65 Skin, thymus Skull, pelvis <1 NAD 
69 Ears, nervous system Skin (perianal) 2 AD 
130 Bone, skin, nervous system Bone 14 AD 
 
 
6.11.3 Permanent consequences  
16 cases were reported to have permanent consequences – 11 males and five females. 
There were 10 MS cases and 6 SS cases. The main sequela was DI (11 cases) with small 
numbers with various hormone deficiencies, lung, neurological and ophthalmic 
problems. A list of permanent consequences by disease type is shown in table 6.20.  
Compared with the previous follow up there were three new cases of DI – in a case with 
SS disease of the jaw, a MS case with multifocal bone and skin disease, and a MS RO+ 
case.   
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Table 6.20 Frequency of permanent consequences by system type at 
second follow up 
Permanent consequence 
Type of disease 
SS MS 
Diabetes insipidus (DI) 2 9 
Growth failure 1 1 
Growth hormone deficiency (GHD) 1 4 
Thyroid-stimulating hormone (TSH) 
deficiency 
 3 
Follicle-stimulating hormone (FSH) 
deficiency 
1 1 
Adrenocorticotropic hormone (ACTH) 
deficiency 
1 1 
Ophthalmic 1 1 
Dental  1 
Orthopaedic 2  
Neurological  3 
Lung  1 
 
 
Only 11/20 cases with permanent consequences in the previous follow up were reported 
in the second follow up.  The differences were as follows: 
 2 cases were lost to follow up (including one RO- case with DI) 
 1 case with orthopaedic problems changed diagnosis 
 6 cases previously with orthopaedic sequelae were not stated to have permanent 
consequences 
 5 additional cases had permanent consequences 
 
Of the 16 cases with permanent consequences, six had DI at diagnosis and no other 
sequelae and therefore did not contribute to the person years at risk (249.5 years) in the 
Kaplan-Meier survival analysis.  Overall, sequelae-free survival was estimated to be 
21% (CI: 1.2-59%) at 6.2 years follow up as shown in figure 6.21.  However, at 5 years 
with 8/10 cases with permanent consequences, it was 64% (CI: 37-82%). 
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Figure 6.21 Overall probability of having no sequelae at second follow up 
 
 
 
Although the numbers were small, sequelae-free survival between different subgroups – 
sex, age group, type of disease, type of treatment and the time period between 
symptoms and diagnosis – was assessed.  Data for each subgroup were available for 72 
children, except for the time period between symptoms and diagnosis where the date of 
first symptoms was missing for two (SS bone) cases.  The results were not significant 
for sex or age group (p values 0.66 and 0.29 respectively) but were significant for type 
of disease (p=0.04), treatment type (p=0.02) and the period from symptoms to diagnosis 
(p=0.01). Sequelae–free survival curves for the significant results are shown in figures 
6.22 to 6.24.  
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Figure 6.22 Probability of having no sequelae by type of disease at second 
follow up 
 
 
The number of cases in each subgroup is shown in brackets. 
 
MS cases had a lower probability (42%) of being sequelae-free compared to the SS 
cases (87%) at five years from diagnosis (figure 6.22). All ten patients with permanent 
consequences had been treated on LCH protocol (figure 6.23), the probability being 
40% after 5 years.   
 
Cases that had been diagnosed in less than 12 weeks had a higher probability (92%) of 
being without permanent consequences after five years compared with those diagnosed 
later – 49% and 29% in those diagnosed between l2-25 weeks and more than 26 weeks 
respectively (figure 6.24).   
 
Table 6.21 shows all ten cases with permanent consequences that were included in the 
analysis, by type of disease, sex, the time period between symptoms and diagnosis and 
treatment. There were four cases with diabetes insipidus. These included one SS bone, 
one MS RO+ and two MS RO- cases. Six cases with diabetes insipidus at diagnosis and 
without other sequelae are not shown. 
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Figure 6.23 Probability of having no sequelae by type of treatment at 
second follow up 
 
 
 
Figure 6.24 Probability of having no sequelae by time from symptoms to 
diagnosis (weeks) at second follow up 
 
 
The number of cases in each subgroup is shown in brackets. 
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Table 6.21 Cases with permanent consequences >2 years from diagnosis 
included in analysis 
Case 
ID 
Type of 
disease 
Sex Time from symptoms 
to diagnosis (weeks) 
Treatment type 
7 SS-MF M 7 LCH protocol 
5 SS B M 10 LCH protocol 
45 MS RO- M 13 LCH protocol 
50 MS RO- F 13 LCH protocol 
23 SS B F 17 LCH protocol 
44 MS RO+ F 21 LCH protocol 
4 SS B M 22 LCH protocol 
65 MS RO- F 29 LCH protocol 
69 MS RO- M 31 LCH protocol 
78 MS RO- M 27 LCH protocol 
 
 
6.11.4 Co-morbidity/other conditions 
In addition to the cancers and co-morbidities listed in sections 6.8.1 and 6.8.2, the 
following conditions were reported; one case diagnosed at 13 years of age with MF 
bone disease was reported to have Crohn‟s disease and was also pregnant; a male 
diagnosed with lymph disease was being seen by a dermatologist for a congenital hairy 
compound naevus. 
 
6.12 Mortality  
There were three deaths among the study group (described in section 6.9) giving a 
mortality rate of 3.2%. 
 
The UK and Irish national statistics offices registered 18 deaths over a 10-year period 
(1996-2005) and this survey identified two further deaths.  Combining these data, figure 
6.25 shows that 13 boys and 7 girls died. 19 deaths occurred in the UK and one in RoI 
over the 10-year period.  Figure 6.26 shows the number of deaths by age. All were 
under five years of age. 
 
The age-standardized mortality rate (ASR) was 1.91 per 10 million per year in children 
aged 0-14 years (CI: 1.905-1.916).  For those aged 0-4 years the ASR was 5.25 per 10 
million (CI: 5.22-5.27). 
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Figure 6.25 Number of deaths 1996-2005, by age at death 
 
 
Figure 6.26 Number of deaths with LCH on the death certificate, 1996-2005  
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6.13 Summary of cases at end of study  
Figure 6.27 is a graphic representation of the outcome of all 94 cases at the end of the 
study using information received from both follow ups. The figure shows the number of 
cases by type of disease and progression to other forms, if any, during the interim 
between diagnosis and the last follow up.  For example, looking at the 59 SS cases  
 
 one case had a changed diagnosis 
 one case developed multifocal disease  
 one case developed MS disease 
 in 56 cases the original diagnosis was unchanged 
 
 
 
Figure 6.27 Development of disease from diagnosis to last follow up 
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Disease-free survival was assessed for all surviving cases using the date of the last 
known consultation (90/91 cases) from both follow ups and the survival curve is shown 
in figure 6.28.  There were eight cases with active disease; six males and 1 female, as 
listed in table 6.18, with the addition of another male diagnosed aged 4 years with MS 
RO- disease who was lost to follow up after 1.7 years. There were 283.6 years person 
years at risk with a median follow up of 3.1 years (range 0.2-6.2 years). There was 61% 
probability of being disease free after 6.2 years (CI: 28-82%).  The confidence intervals 
were very wide and the probability was 73% (CI: 45-85%) after five years. 
 
 
Figure 6.28 Probability of having no disease using data from both follow 
ups 
 
 
 
The main permanent consequence at the last follow up was DI and was found in 13% of 
cases. Five cases developed DI after the original diagnosis – three with MS RO- disease, 
one with MS RO+ disease and one with SS bone disease of the jaw.  
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Overall, at their last follow up 
 96% of cases were alive  
 91% had no active disease  
 8% had been discharged 
 18% had permanent consequences 
 
With the loss of one case (probable changed diagnosis) the age-specific IR was adjusted 
to 3.7 per million per year aged 0-15 years (CI: 3.0-4.5) and the ASR was 4.08 (CI: 
4.07-4.09) per million per year aged 0-14 years. 
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Chapter 7.  Discussion and evaluation 
 
 
7.1 Summary 
The incidence of LCH in children in the UK and Ireland is comparable with other 
national studies and with regional UK studies. The mortality rate is comparable with the 
only other rate reported, in France.  The study used a well-established prospective 
method of surveillance with additional sources of ascertainment, the importance of 
which were demonstrated. The estimate of completeness was 93% which is comparable 
with other national studies and registries.  By including a wide range of clinicians in the 
survey, 25% more cases were identified than via the CCLG alone (previously the main 
source of information on LCH cases).  
 
The study fulfilled its aims by describing the presenting features of LCH, referral 
patterns, and the time taken to diagnose. The spectrum of disease was broadly similar to 
that reported in previous studies in that approximately two-thirds of cases were of SS 
bone disease, mainly in older children, and a third of cases were of MS disease, mainly 
in younger children. 50% of MS cases and 10% of SS cases had active disease or had 
reported reactivation of disease at one of the follow ups. Those most at risk of active 
disease were MS cases or those treated on LCH protocol.  18% had permanent 
consequences at the end of the study, the main sequela being DI. These results are 
discussed further below. 
 
The study also aimed to give some indication of possible risk factors for the disease. 
Data collection was limited and since this investigation was conducted over a relatively 
short period, there were insufficient numbers to draw any firm conclusions on 
associations with LCH.  Given these limitations, an association was found with month 
of diagnosis – a higher number of cases than expected were diagnosed in spring months. 
However, no association was found with the month of first symptoms which may better 
suggest a childhood infectious agent.  There was also evidence of a possible association 
with ethnic origin; the proportion of non-Caucasian children was higher than that in the 
general population although this may not reflect the age structure of some non-white 
groups. The results have, however, suggested areas for future study and these are 
discussed in the concluding chapter.   
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7.2 Case ascertainment 
7.2.1 Response to mailing 
On average, 92% of the BPSU report cards were returned by clinicians during the study 
period compared with an overall response rate of 93% in recent years. This high level of 
reporting may be a reflection of regular communication with reporting paediatricians, 
encouraging response. Overall, 53% of clinicians responded to the Newcastle Survey. 
However, the mailing list had been adjusted after the first mailing (reducing numbers) 
and the average response for the other three mailings was 58%.  In retrospect, the 
Newcastle survey may have been improved by more frequent mailing, for example, 
three-monthly rather than six-monthly mailing as this may have enabled clinicians to 
remember the study and identify cases more easily.  However, this was not possible 
because of limited funding and workload considerations.   
 
Other strategies to maximise response rates to postal questionnaires have been 
employed as described by Edwards et al in two systematic reviews [181, 221]. Effective 
methods included the use of short questionnaires and coloured ink, monetary incentives, 
and questionnaires sent by recorded delivery or first class post.  Other strategies which 
were found to increase response rates were contact prior to the questionnaire being sent, 
personalised questionnaires, university-originating questionnaires, stamped return 
envelopes, follow up contact and sending a second copy of the questionnaire – all of 
which the Newcastle survey employed. Respondents were less likely to return 
questionnaires requiring sensitive data and indeed, in this study, one or two clinicians 
queried the lack of patient consent.  In addition, the length of the initial questionnaire 
may have been off-putting.  However, although monetary incentives would not have 
been possible, a shorter more colourful format and the use of first class postage may 
have elicited a better response. 
 
Time lags in reporting were not considered an impediment to ascertainment since the 
BPSU continued surveillance for an additional month beyond the end of the study 
period and the CCLG similarly notified cases for several months after the survey ended.   
 
Although every effort was made to follow up reports of cases 53 questionnaires (14%) 
were not returned. 18 of these corresponded to cases (both eligible and ineligible) 
notified by a clinician at the same hospital at approximately the same time.  Clinicians 
were reminded to return questionnaires but could not remember the name of the patient 
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diagnosed and frequently asked for identifying information.  In a recent evaluation of 
the BPSU system, 68% of paediatricians reported no difficulties in identifying cases but 
other reasons given for not confirming cases included problems with finding notes and 
time consumption with no obvious immediate benefit [222].  The anonymity of the 
BPSU system, while effective in avoiding bias and delay associated with obtaining 
patient consent, does have limitations.  
 
7.2.2 Reporting rates and patterns 
As might be expected, the highest rate of reporting was by the CCLG (80%) with the 
BPSU and Newcastle surveys identifying 73% and 62% of cases respectively. Cases 
treated without chemotherapy may not be registered with CCLG and cases of 
uncomplicated bone disease in older children may be treated without paediatric input.  
The study was therefore designed to use three complementary sources of ascertainment. 
The specialties of respondents to the Newcastle survey were proportional to the 
specialties of those on the mailing list with the majority being pathologists.  Overall, the 
clinicians who confirmed cases were mainly oncologists and paediatricians (60%) with 
15% identified by pathologists and 13% by orthopaedic surgeons. In general, this 
reflected the proportion of cases reported by, and the limitations and advantages of each 
source.  
 
The percentage of cases ascertained by the CCLG was lower than their estimate of 
registering 90-95% cancers and LCH cases in the UK [173]. However, the majority of 
cases missed by CCLG (and BPSU) were of unifocal bone disease requiring little or no 
treatment suggesting that cases were appropriately collected.  During the study period 
LCH III trials began with chemotherapy protocols for MS, MF or special site UF 
disease which most likely contributed to the appropriate registration of cases by CCLG. 
The BPSU survey uniquely identified two infants who had died with MS RO+ disease, 
cases which would not have been reported routinely to CCLG, and neither of which 
were among those registered by ONS.  Thirty-six cases were not identified by the 
Newcastle survey which extended outside general paediatrics. However, by including 
pathologists and orthopaedic surgeons in particular, the survey was successful in 
uniquely identifying 10 UF bone cases although this may indicate under-reporting in 
this area. The study may have further benefited from cross-checking with the British 
Society for Children‟s Orthopaedic Surgery (section 3.5), the Scottish Bone Tumour 
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Registry and other orthopaedic groups although bone cases which regress spontaneously 
may not be recorded by any group.   
 
Only one 15 year old was identified and no older teenagers. Although the survey asked 
for children “of any age” to be reported, it is possible that some in their late teens may 
have been diagnosed and treated at adult centres. This group of older children may have 
been covered to some extent, by the inclusion of non-paediatricians on the Newcastle 
mailing list although targeting of specific non-paediatric societies such as the British 
Association of Dermatologists and dental associations would have widened the net. 
However, in the North of England no cases of LCH were reported in 15-19 year olds 
between 1968-1995 [25]. Referral patterns across the UK are very variable and at many 
CCLG treatment centres relatively few older children are registered [21]. The Paediatric 
Oncology Unit in Bristol reported that 10% of its registrations (cancers and LCH) were 
more than 15 years old which was much higher than at most other CCLG centres except 
Leeds, Manchester and London.  The introduction of Teenage/Young Adult (TYA) 
centres, recommended by NICE in 2005, may have improved both referral pathways 
and registration of older children since then [223].   
 
Although LCH has well-defined diagnostic criteria (section 1.3) cases diagnosed 
without a biopsy may be less certain. In this study 13% had been diagnosed by typical 
radiological appearance and for one case the basis of diagnosis was not stated.  
However, there had been some initial over-reporting. The survey asked for reports of all 
suspected as well as confirmed cases and during the surveillance period almost 100 
cases were identified.   However, over the following months, several of these diagnoses 
changed.  Indeed, it was only at the end of the second follow up period that one case 
was thought „likely to be juvenile osteoporosis, probably not LCH‟.   
 
Incidentally, as many adults as children were reported during the survey  via the 
Newcastle survey and questionnaire returns (section 5.2)  a finding similar to the LCH-
Belgian Survey Registry [44].  This leads one to suspect that a well-designed study to 
identify adults with LCH may confirm an incidence rate much higher than previously 
thought [125].  Interestingly, the Northeast region reported an incidence rate of 0.6 per 
million per year in 20-24 year olds which may be associated with smoking patterns in 
this age group [25]. The aetiology of pulmonary LCH is associated with smoking in 
adults and is most frequent in 20-40 year olds (sections 2.1.2 and 2.4) [55, 224].  
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7.2.3 Capture-recapture estimates of completeness  
38% of cases were identified by each of the sources. As expected, there was a high 
degree of overlap in cases identified by the BPSU and CCLG (25%) and a smaller 
overlap in cases identified by each of these with the Newcastle survey (12%). However, 
there may still have been some under-ascertainment. In a recent BPSU report, the main 
reasons given for not reporting cases, apart from not seeing a case, were that 
paediatricians (12%) thought or expected that a colleague had reported it or had 
forgotten the details when the „orange card‟ arrived [222].  
 
C-RA has been advocated as a useful method of quantifying undercounting in 
surveillance studies although others have questioned its applicability given the inherent 
uncertainties involved [45, 225-227].  In any case, results should be viewed with 
caution, since bias may occur if any of the requirements of C-RA are invalid (section 
4.1.1) [187].  As discussed by Hook and Regal, in epidemiological studies, it is difficult 
to guarantee that all assumptions have been met. In this study, as well as paediatricians 
notifying both the BPSU and CCLG, discussion or collusion between colleagues may 
have taken place affecting ascertainment by all the sources.  In addition, the BPSU 
survey (paediatricians) and Newcastle survey (non-paediatricians) might have been 
considered not „to be fishing in the same pool‟. However, it was assumed that cases 
would have the same chance of being identified by pathologists as by the clinicians who 
treated them.  The main problem with C-RA is that there is an assumption that the 
“unobserved individuals will behave as the observed individuals” and patients who are 
not recorded on any list may be unusual [227, 228]. In this study, there is tendency to 
„capture‟ more severe cases. 
 
With these caveats in mind, ascertainment by the Newcastle and BPSU surveys was 
estimated by C-RA at 86% (14 missing cases) although an additional six cases were 
identified by the CCLG.  The use of multiple sources and models limits the risk of bias 
[225, 227].  In this study, by using the three-source model to incorporate the CCLG 
cases and account for the positive dependence (large overlap) between the BPSU and 
CCLG, the estimate was adjusted.  The total number of expected cases was almost the 
same (101 versus 102 cases) thus confirming the plausibility of the model chosen.  The 
completeness of ascertainment increased to 93% using all three sources.   
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Few incidence studies have reported the completeness of ascertainment and only one 
used C-RA. However, our estimate is comparable with ascertainment in a recent French 
study (97%) and European and UK regional cancer registries that have reported LCH 
incidence rates (90-95%) [2, 3, 20, 29].  However, although cancer registries use several 
sources of ascertainment, given the heterogeneity of LCH, it is likely that ascertainment 
of LCH cases by them is less complete than for cancers.  It has been advocated that any 
epidemiological study or registry collecting data to report incidence rates of disease 
should record the source of each case [187, 225]. As well as allowing monitoring of 
each source, an estimate of the completeness of ascertainment would allow more 
accurate estimates of incidence rates.  Given the estimated of completeness of 
ascertainment of our survey, a further seven cases would have increased the age-specific 
IR marginally to 4.02 per million per year age 0-15 years (CI: 3.27-4.89).  
 
7.3 Strengths and weaknesses of the survey methods 
The study is the first national study to use a prospective method of identifying LCH 
cases. It relied on clinicians notifying new cases as opposed to identifying cases 
previously diagnosed.  Advantages of this method are that new or suspected cases are 
likely to be more easily recalled, records may be more readily available and accurate, 
and cases are unlikely to be missed due to changes in disease classification. In these 
respects a prospective survey is likely to improve ascertainment. In addition, a 
prospective study may capture specific variables whereas historical records, designed 
for other purposes, may not have recorded them. However, new cases of a rare disease 
take a very long time to accumulate.  Retrospective studies may be less expensive to 
conduct and quicker but may be subject to under-counting unless several sources of 
ascertainment are used.  Conversely, over-counting may be a disadvantage in 
prospective studies, unless, as in this study, sufficient time passes to allow eligibility to 
be confirmed.  The survey was also conducted over a relatively short period. A longer 
survey combined with retrospective data collection may have identified cases taking a 
long time to diagnose. 
 
Other artefacts in case ascertainment may bias results; selection bias may be introduced 
if a clinician decided not to respond to the survey, could not remember a patient or was 
unable to find patient notes. Given that a number of questionnaires were not returned for 
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at least one of these reasons, under-ascertainment, also suggested by C-RA, is likely to 
have occurred. 
 
The number of cases identified in this study exceeded those identified by the CCLG in 
previous years (averages of 47 and 37 per year respectively). The combination of the 
three sources used covered the spectrum of disease: more severe cases requiring 
treatment were identified by CCLG, whereas those seen by paediatricians ranged from 
cases found incidentally to congenital fatalities. The Newcastle survey was particularly 
effective in identifying cases referred to orthopaedics although it may have been 
improved by cross-checking cases with the British Society for Children‟s Orthopaedic 
Surgery and the Scottish Bone Tumour Registry. The Newcastle mailing list included 
adult specialists but did not target specific non-paediatric societies. By including 
members of such societies, older children referred to adult services may have been 
identified.  Response rates may also have been improved by increasing the frequency of 
mailing and employing other tactics to encourage replies. Although each surveillance 
method may have missed recognised cases and mild undiagnosed cases, these 
observations demonstrate the importance of multiple sources to maximize the 
completeness of ascertainment.   
 
7.4 Comparison of IR with other studies  
While accepting that there was probably a degree of under-ascertainment, the age-
standardized incidence (4.1 per million per year aged 0-14 years) is comparable with 
other national studies in France and Denmark (5.0 and 5.4) and reports from the German 
and Swiss Cancer registries (6.0 and 4.3).  The variation may reflect different methods 
of ascertainment or the small number of cases.  
 
The biggest differences in rates are likely to be due to differences in methods of 
ascertainment. The French study, estimated at 97% complete, used two sources of 
ascertainment while the Danish study used various complementary sources. The 
importance of multiple sources has been discussed; those studies using a single source 
generally reported lower rates than those using several sources (section 2.3.1) [119, 
120]. All studies were retrospective except for the LCH-Belgian Survey, which reported 
an IR of 8.3 per million per year (aged <20 years) based on both retrospective and 
prospective data collection. Interestingly, this rate is among the highest of those 
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reported.  It is also, one of the most recently reported.  Differences in IRs may also be 
due to the time period in which cases were diagnosed.  Improved diagnostic techniques, 
changes in the classification of disease and recording of cases may have an effect on 
identification of cases as discussed by Alston et al in their study over a 40-year period 
[2]. Another explanation is that incidence may increase over time. However, none was 
reported by Alston et al; the LCH-Belgian Survey reported stable incidence over six 
years and the earliest incidence rate, reported in Denmark for 1975-1989, is comparable 
with more recent IRs [1, 2, 44].  
 
Incidence declined with age from 9.9 in infants to 1.8 per million per year in children 
aged 10-14 years. These rates were similar to those in the Northeast and Northwest of 
England where the IRs for those aged less than one year were 9.0 and 8.0 per million 
per year and 4.6 and 3.2 for those aged 1-4 years respectively.  However our rates for 
older age groups were higher suggesting better ascertainment of bone disease in these 
children. The downward trend has been reported in other studies although national rates 
in infants in France and Germany were much higher than in the UK (15.3 and 23 per 
million per year respectively – table 2.7).  A possibility for this variation may be due to 
differences in referral patterns or more aggressive diagnosis in young children. 
Comparisons of diagnostic times are discussed further below (section 7.5.1).   
 
Overall, the incidence in children with SS disease was twice as high as those with MS 
disease (2.9 versus 1.1 per million per year) which is comparable with recent French 
and Swedish studies [3, 28]. However, the reverse was the case in infants (3.3 SS versus 
6.6 MS cases per million per year). This differs from the French study in which the rates 
of disease in infants were 8.2, 2.4 and 4.7 for UF, MF and MS RO+ disease 
respectively. The high rate of SS disease in infants in their study was due to a large 
number of UF skin cases [3]. The spectrum of disease is discussed further below. 
 
Our incidence rate for those aged 0-14 years is higher than the 2.5 per million per year 
(42 cases from 1968-1995), the 2.6 per million per year (101 cases from 1954-1998) and 
the 3.0 per million per year (13 cases from 1980-1984) reported by children‟s cancer 
registries in the Northeast, Northwest and West Midlands of England [2, 25, 33].  ASRs 
for these regions were 3.7, 5.0 and 4.2 per million per year respectively, which taken 
with the overall rate may suggest a degree of under-reporting or under-diagnosis in the 
previous reports. The age-specific rate for the Southwest region, 3.2 per million per 
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year, was comparable with a rate of 3.4 per million per year, calculated from a recent 
report (16 cases from 2002-2006 aged 0-15 years).   No significant difference in 
regional incidence rates was found; there were too few cases and too little data to 
indicate any further geographic analyses.  
 
7.5 Comparisons of spectrum of disease 
7.5.1 Symptoms and presentation 
Patients presented mainly to a GP (80%), the most common symptoms being pain and 
swellings, which reflect the number of cases with bone disease.  Similarly in France, in 
77% of cases, the initial presentation involved bone [3]. The low frequency of rare 
diseases may result in delay in recognition and diagnosis and thus possibly increase the 
risk of complications and poor outcome. However, diagnostic delay is difficult to define 
since there may be variations in both patient delay and referral delay.  As might be 
expected, there was wide variation in the time from symptoms to diagnosis although 
there was a no significant difference between any subgroup. A significant difference 
between unisystem and MS groups was found in a study in Ireland but further details 
were not reported [115]. The shortest median time of 9.2 weeks (range 3.1-26.7) was for 
patients with RO+ disease.  The longest median interval, 28 weeks (range 6.7-37) was 
reported for the six children with “other” disease (two each of SS lymph node, skin and 
diabetes insipidus).  In a US study, the mean age at diagnosis of neonates with skin 
lesions was 14 weeks [72]. These times are longer than those reported in France; the 
median time between symptoms and diagnosis was seven weeks for MF or MS disease, 
and 11 and 17 weeks respectively for cases of skin and endocrine disease [88].  The 
time from symptoms to diagnosis was even shorter in Stockholm, the median time being 
one month [28]. Stein et al reported some misdiagnoses in their US study but 
differences in health systems may account for the shorter times to diagnosis in some 
European countries since infants and young children may present to paediatricians 
rather than GPs. 
 
7.5.2 Spectrum of disease  
The proportion of those with SS disease was 73% which is a little higher than the 69% 
reported in Stockholm, 67% in Denmark and 60% in France [1, 3, 28].  In common with 
other studies, the most frequent site of disease at diagnosis was bone (83%) [3, 28, 58, 
64].  The proportion of those with MF bone disease (16%) was similar to previous 
  165 
reports (range 15-30%) as was the proportion of MS cases with bone involvement 
(60%) [3, 59]). Of those with SS bone disease, skull was the most common site (25%). 
However, this was lower than that reported in Stockholm (55%) and by a multi-
institutional European study of 178 cases of SS disease (40%) [28, 58].  18% of cases 
had skin disease at diagnosis compared with 11% in the European study, 12% in Japan 
and 34% in Stockholm [28, 58, 64].  The median age at diagnosis of all those with skin 
involvement was 0.8 years, with only three children older than one year.  Although 
there were only two cases of SS skin disease, it was present in all seven MS RO+ cases 
and in over half the MS RO- cases. In common with the findings of other studies, skin 
disease is found predominantly among young children. In France, 78% of all children 
under one year of age had skin disease and in Japan, the median age at diagnosis was six 
months [3, 64]. 
 
In contrast with our study, 56% of cases in the Northwest of England were MS, the 
frequency of bone and skin disease being 67% and 37% respectively [2]. The 
differences may reflect the differences in ascertainment of older children (described 
above) and consequently the number of cases of SS bone disease.   
 
Overall, the median age at diagnosis was 5.5 years which is higher than several previous 
reports where the medians were between 2-4.8 years although comparable with the 
Swiss Registry (5.8 years) [1-3, 28, 29, 64]. Again, this may be explained by the higher 
proportion of older children with SS bone disease in our study (median age 6.7 years).  
 
The sex ratio was 1.5:1 which is similar to other national reports (range 1.2:1-2.2:1). As 
in France, male predominance was not observed in those under one year of age (1.1:1). 
The sex ratio in this study was highest (2.7:1) in the 10-14 years age group which had a 
high proportion of bone cases (87%). 
 
7.6 Possible associations with LCH  
7.6.1 Seasonality 
Infectious agents vary themselves by season. If they are involved in the aetiology of 
childhood LCH then seasonal variation in birth dates or dates of onset of the disease 
may be apparent. An association with date of birth may suggest a prenatal infectious 
agent; an agent acting during childhood with a short incubation period from infection to 
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clinical disease may be more apparent if there is an association with the onset of 
symptoms (or date of diagnosis as a proxy for the onset of first symptoms). Seasonality 
may also be apparent if diagnosis occurs more often at some times of the year than 
others.  
 
Although there have been seasonality studies of leukaemias and other neoplasms (with 
conflicting results) [209, 212, 229] there have been very few in relation to LCH.  A 
study in Stockholm reported more cases diagnosed during the autumn and winter 
months (22/29) with a median time between onset of symptoms and diagnosis of only 
one month suggesting that an infectious agent prevalent in the autumn or another 
environmental factor may be implicated [28]. Other studies have reported a higher 
incidence in wet regions or during periods of high rainfall [119, 153]. Seasonality may 
be more pronounced within types of LCH or within particular age-groups. Although no 
studies of such subgroups have been conducted, Stalemark et al noted that all MS cases 
in their Stockholm study group and 3/5 SS patients who later developed MS disease 
were diagnosed in the winter months.  In this study, the only association found was with 
the month of diagnosis with a peak in spring; a higher number of cases than expected 
were diagnosed from March to May (p=0.04). However, the test used in this analysis 
(Edwards test) is known to be unreliable for small and medium samples and the result 
should be treated with caution.  In addition, the month of diagnosis is a poor proxy for a 
childhood infection since even small variations in the lag period between first 
symptoms and diagnosis could make a difference to the analyses. In this study, 
symptoms may have developed several months before diagnosis given that the median 
time from symptoms to diagnosis was 11.5 weeks.  The result appears anomalous since 
no association was found with the month of first symptoms (which more plausibly 
suggests a childhood infectious agent) although fewer dates of first symptoms were 
available for the analysis. Seasonal patterns in diagnosis can often be attributed to 
holiday patterns with more patients being seen before or after a major holiday period, 
which in this case may have been the Easter holidays. The finding of an association with 
month of diagnosis is therefore tenous and likely to be due either to chance or a 
statistical artifact. 
 
A recent seasonality study of cancers and LCH in Northern England found no 
seasonality in the month of birth or month of diagnosis of 71 LCH cases (unpublished 
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data) between 1968-2005 and no seasonal associations were reported in the Northwest 
of England over four decades [2, 230].   
 
7.6.2 Ethnicity 
While the majority of LCH studies have described white children with LCH, this may 
be due to a bias in reporting. The proportion of non-Caucasian children was 14% which 
was similar to that reported by McClelland et al (13%) in a study at Great Ormond 
Street Hospital. Compared with the 7.9% of ethnic minorities in the whole population, 
the proportion of mixed or other ethnicity children was significantly different from the 
general population (p=0.027). However, ethnicity was not reported in six cases and 
although the proportion of ethnic minorities as a whole is reported to be 7.9%, it should 
be noted that some non-white groups in the UK and Ireland have a younger age 
structure than white groups, especially those of mixed ethnicity (9/13 cases in this 
study) [231, 232]. This result does, however, provide evidence of a possible association 
with ethnic origin which might be investigated in a larger study. The percentage of non-
white Caucasians in our study is lower than the 27% in Stockholm County although the 
latter may not have been representative of Sweden as a whole. 
 
7.6.3 Birth and familial factors  
Gestational ages and birth weights were not significantly different from those in the 
general population (p=0.13 and p=0.26 respectively) although the proportions of pre-
term and lower birth weight children in the cohort were slightly higher. There were no 
differences in birth weights or gestational ages of MS or SS cases. Birth weight data 
were missing for a third of cases but the findings are in keeping with Carstensen and 
Ornvold‟s study and two large US case control studies which investigated a large 
number of factors surrounding pregnancy and birth [1, 141, 142].  Unlike the study in 
the Northwest region which reported no congenital cases of LCH, there were four (4%) 
in this study [2]. All had had prominent symptoms from birth although the median time 
to diagnosis was 8 weeks and one case was only diagnosed post mortem.  This is higher 
than the 2% of cases reported by the Austrian/German/Swiss/Netherlands LCH Study 
Group and the 5/258 cases in France [3, 54].  However, these studies only included 
cases diagnosed within four weeks of birth. It was thought that the incidence of neonatal 
LCH was underestimated since there is evidence that although the condition is present 
at birth, as in this study, it is not diagnosed until later [54].  Minkov et al also reported 
that the rate of spontaneous regression in neonates with SS skin disease was 56% (5/9 
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cases) which may represent a group which are generally under-reported and under-
diagnosed. 
 
Both monozygotic and dizygotic twins have been reported to be concordant for LCH. 
Three children were reported to be twins although there was no information about their 
siblings. Prior to this study commencing, the Childhood Cancer Research Group in 
Oxford noted that there were three sibling pairs on their registry. However, the data 
were old (1964-1972) and it was thought likely that they were actually cases of HLH 
[233].  Two children were reportedly born after IVF treatment which is similar to the 
proportion of artificial reproductive technology (ART) births in the UK population 
(1.3%). However, the study questionnaire was not designed specifically to capture 
information on either siblings or IVF (or other forms of ART births) and the cases 
reported were volunteered.  No other epidemiological LCH studies have included 
siblings and, given the conflicting findings of an association with ART by Kallen et al, 
further studies with larger cohorts may be warranted [160, 161]. 
 
In the two US publications on risk factors, LCH was (inconsistently) associated with 
maternal urinary tract infections, parental solvent exposure, feeding problems and 
medications during infancy, a family history of thyroid disease and infections in the 
postnatal period [141, 142]. However, only one mother in this study had a reported 
thyroid condition and only single cases of infections or other conditions were reported.  
Interestingly, one mother had Darier‟s disease, a genetic skin disorder, which has been 
included in the differential diagnosis of LCH.   
 
7.6.4 Cancer and co-morbidities  
Congenital anomalies have been associated with an increased risk of both LCH and 
cancer [158, 234]. In a study of 39 cases over three decades by Shiels et al, 18% of 
those with LCH had major congenital anomalies compared to 3% and 8% in control 
groups. These cases were also more likely to have MS disease.   In contrast, only two 
cases had a congenital disorder – one with partial Trisomy 3 had MF bone disease and a 
child with congenital LCH (RO+) who died in infancy had multiple intestinal stenoses. 
Although there have been cases reports of gastrointestinal LCH, it is rare and there has 
only been one case of intestinal atresia previously published [235].  Few other co-
morbidities were reported (section 6.8.2).   
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One child had a related histiocytic disease, juvenile xanthogranuloma, and two children 
had medulloblastoma, one of which was diagnosed before LCH. The LCH-Malignancy 
Registry has recorded over 90 cases of malignancy and LCH, most frequently solid 
tumours which tended to occur after the diagnosis of LCH (in 62% of cases) [236]. In 
13/20 cases, tumours had arisen in the radiotherapy field given to treat LCH.  However, 
radiotherapy is no longer used to treat LCH patients and further details of the 
medulloblastoma cases in this study are unknown.  The reported association of LCH 
with both congenital anomalies and cancers may suggest a common genetic 
predisposition.  
 
A female, diagnosed aged 13 years with MF bone disease, was reported to have 
developed Crohn‟s disease. There has been one report of an adult case with both 
diseases [237] although Crohn‟s disease, a chronic inflammatory disease of the 
intestine, has been reported with paediatric cases of HLH, rheumatoid arthritis and other 
auto-immune inflammatory diseases [238, 239]. Given the evidence of over-production 
of inflammatory cytokines in LCH [133], this may be indicative of some subtle but 
mutual abnormality of the immune system. 
 
7.7 Follow up  
7.7.1 Treatment and reactivation 
The study found that 40% of cases had been treated on LCH protocol, 40% had had a 
biopsy, curettage or surgery, 12% received no treatment and 5% had „other‟ treatment.  
Similarly, in France (2000-2004), 30% were enrolled on a clinical trial and in 
Stockholm (1992-2001) 45% had systemic treatment. However, 43% of French and 
31% of Swedish cases were „wait and see‟ [3, 28].  The difference between studies may 
be due simply to the way in which treatments had been categorized; in this study, the 
surgery group included cases that had had a biopsy only and no other treatment. All 
those with active disease at the end of follow up were cases that had been diagnosed ‟at 
risk of reactivation‟ and consequently were receiving or had received treatment on LCH 
protocol. 
 
At the end of the first year of follow up (median 1.3 years from diagnosis) no deaths had 
occurred and 87% cases had no active disease. Few cases (eleven) had active disease (7 
MS and 4 SS bone); compared with those without disease, there were significant 
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differences by disease type (p=0.01) and treatment with a higher than expected number 
of MS cases and those treated on LCH protocol. The probability of disease-free survival 
was 68% in SS cases, 55% in MS cases and 100% in MF bone cases (p=0.03). This 
differs from event-free survival in a study by Jubran et al which was 89% for SS bone, 
24% for MS and 58% for MF bone cases with a longer follow up time (median of 
5.5.years) [94].  In the present study, there was a borderline difference in disease-free 
survival by time from the first symptoms to diagnosis (p=0.06); those diagnosed 
between 12 and 25 weeks had a lower probability of being disease-free than those 
diagnosed more quickly suggesting that delay in diagnosis gives a poorer prognosis. 
However, the prognosis improved in those whose took longer than 26 weeks to 
diagnose.  All except one of the cases diagnosed between 12-25 weeks were MS cases, 
including one with RO+ disease, although there was no pattern in the sites of disease 
involved. More prompt treatment in those diagnosed early and less severe disease in 
those who took longer to diagnose may account for the better prognosis in these cases. 
However, dates of first symptoms were missing in some cases and the finding may be of 
interest to explore in a larger study. 
 
Comparisons of disease-free survival between the two follow ups are difficult to make 
since there were differences in both the number and the composition of cases assessed 
(as described in section 6.11).  At the end of the second follow up (median 3.5 years 
from diagnosis) 91% cases had no active disease.  No significant differences were found 
between those with and without active disease except by type of disease and treatment 
type. The most severe cases with active disease at follow up had all received or were 
receiving treatment on LCH protocol. This is to be expected since these cases generally 
have the poorest outcome regardless of treatment. Some patients do not respond to 
treatment and the aim of the latest protocol (LCH IV) is to reduce reactivation and 
progression of disease, particularly CNS disease, while continuing to improve survival. 
 
 In each follow up, the number of cases with active disease was very small and the 
addition of one or two cases can make a large difference to disease-free survival 
estimates. The overall probability of disease-free survival combining data from both 
follow ups was 61% (median 3.1 years, range 0.2-6.2 years); there were only eight cases 
with active disease and the confidence intervals were very wide. (CI: 29%-82%).  In a 
study by Willis et al, event free survival was 30% 15 years after diagnosis, (estimated at 
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50% at 3 years for comparison with this study) and it did not reach a plateau until 16 
years after diagnosis [101]. 
 
Reactivation is not directly comparable with other reports since in this study only a 
snapshot of the patient‟s disease status was obtained at two time-points after diagnosis. 
A short-coming of the study is that details of when reactivation or progression occurred 
were not obtained and it is not known whether there were any periods of complete 
disease resolution in those with active disease at diagnosis. Clinicians reported 
reactivation in the original site of disease or, in some cases, progression of the disease to 
additional sites in space provided on the follow up questionnaires for additional 
information.  Eighteen cases (20% of survivors) had active disease or reported previous 
reactivation at one of the follow ups.  These comprised 50% of MS cases (10 MS RO-, 
1 MS RO+) and 10% of SS cases (6 SS bone, and 1 SS skin). The shortest time to first 
recurrence of disease has been reported in those with MS or MF disease, and those with 
MF bone disease have a higher risk of reactivation compared to SS bone disease [94, 
96, 101]. However, in this study none of the MF bone cases had active disease or a 
report of reactivation at follow up.  In a study of 278 cases with SS disease, there was 
no difference in disease reactivation between those with UF and MF bone disease (18% 
in each), and it was suggested that early systemic therapy may have restricted 
reactivation in MF cases [58]. In this study, 6/10 MF bone cases had been treated on 
LCH protocol lending some credence to this theory. 
 
Of those where reactivation had been reported (in 12% of surviving cases), eight 
children had reactivated disease at the first follow up and six at the second follow up, 
with three cases recurring.  In studies in Stockholm, California and Argentina the 
proportions were higher – 18%, 49% and 30% respectively although the follow up 
periods were longer [96, 97, 101]. In line with other reports, the majority of 
reactivations were in cases with MS disease, except for one SS skin case, and their 
median age at diagnosis was 1.8 years [94, 101]. In a large study of 300 cases in 
Argentina the reactivation rate was 48% for MS cases, comparable with 41% MS in this 
study. However, the SS rate was much higher in Argentina [96] (17% versus 2%) 
although in the present study there was a larger proportion of SS cases. Similarly, 17% 
of paediatric bone cases in a Scottish study had progression of disease [107]. In contrast, 
Jubran et al found a low rate of reactivation in SS bone cases – 7.6% [94]. As in other 
reports, reactivation occurred mainly in existing sites of skin and bone [96], although it 
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developed in new sites in six cases – spleen (1), bone (3), skin (1), diabetes insipidus 
(5).  
 
Three cases progressed, including one from SS bone to MS RO-, an event which is 
reportedly rare [58].  However, Bernstrand et al reported progression in 12/49 cases (6 
SS and 6 MS), 75% of which, unlike the cases in this study, changed stage within six 
months of diagnosis [97].   
 
The time from disease resolution to first reactivation is reported to be very variable, 
ranging from a few months to 27 years [58, 96-98, 101]. In addition, although 
reactivation often occurs within two years after no active disease, attaining resolution 
may also take considerable time.  The range was 1 month to 7.5 years for MS cases in 
an International LCH Registry study, with 88% achieving resolution within two years 
after diagnosis [98].  With the relatively short duration of follow up in this study, it is 
likely that some cases will continue to experience reactivation or progression. Since 
reactivation is associated with increased risk of permanent consequences (as discussed 
below) further follow ups would be valuable to obtain comparable reactivation data and 
better estimations of disease-free survival.   
 
7.7.2 Permanent consequences  
At the first follow up, 20 cases (23%) had sequelae, and 16 cases (21%) had sequelae at 
the second. The proportions were similar in a national study in Denmark (27%) and 
multicentre study in France (22%) although lower than in Argentina (38%) [1, 56, 96].  
However, only 11 cases with sequelae were reported at both follow ups. The 
differences, described in section 6.11.3, were mainly due to changes in reports of 
orthopaedic cases and the loss of a MS case who developed DI post-diagnosis.  The 
probability of sequelae-free survival (excluding those diagnosed with diabetes 
insipidus) was 64% (CI: 37-82%) at 5 years, the addition of one case having the effect 
of reducing this to 21% (CI: 12-59%) at the maximum follow up period (6.2 years).  
Those with the lowest probability of being sequelae-free at five years were MS cases 
(42%), those treated on LCH protocol (40%) and those who took longest to diagnose, 
i.e. more than 6 months (29%).  However, the number of cases in each of these 
subgroups was extremely small.  As might be expected in cases with more extensive 
disease and treatment, previous studies have reported that MS and MF bone cases were 
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most at risk although only one MF bone case in this study had permanent consequences 
[58, 96, 101, 102].  
 
Diabetes insipidus was the main permanent consequence in 12 cases (13%) cases which 
is comparable with other studies [56, 73, 96, 97] although reports by a French 
nationwide study and the Histiocyte Society were higher (both 24%).  It is more 
common in MS cases [73, 97, 102], as was found in this study – 9/12 cases had MS 
disease. 
 
DI developed after the original diagnosis in five cases and was the only permanent 
consequence in six. There is up to a 50% higher risk of DI if the skull or facial bones are 
involved [73, 102, 240]. 40% of the study group had skull, mandible, facial or orbit 
bone involvement at diagnosis (22 SS, 1MF and 14 MS RO-).  However, only four of 
these had DI at diagnosis, two developing DI later on (i.e. 16% of those with skull 
involvement); this is comparable with Jubran et al (20%) but lower than other studies 
[94, 96, 102]. 
 
Of the five cases that developed DI post-diagnosis, two were reported to have DI at the 
first follow up and three cases were reported at the second follow up. All five had been 
treated on LCH protocol – four had MS disease and one had localised special site 
involvement (table 2.3) [74]. There has been conflicting evidence and debate as to 
whether systemic treatment will prevent progression to DI (and neurodegenerative 
disease which may not develop until many years later) [240-242].  In this study, 
treatment was not preventative. In addition, all five cases had reactivated disease in 
existing or new sites as well as DI, including other hormone deficiencies (2), bone 
lesions (3), skin (1) and lymph (1), and consequently received further treatment.  New 
treatments may emerge when more is known about the mechanism of brain damage 
following inflammation elsewhere in the body, a topic which was the subject of this 
year‟s Nikolas Symposium (an annual think-tank of LCH scientists and doctors) [106]. 
 
As described above, endocrine and neurological problems have been associated with 
both DI and facial or skull bone involvement [96, 102, 241]. In keeping with these 
findings, all seven cases with growth failure or hormone deficiencies had DI; of three 
children with neurological problems, two had DI and the third had disease of the ears 
and nervous system.  There were few orthopaedic sequelae (two cases) compared with 
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other reports (range 20%-42%) but as expected, very small numbers of other permanent 
consequences (table 6.20) [58, 101, 102]. Two bone cases had resolved spontaneously 
and five others had been discharged.  The small number reported with orthopaedic 
sequelae may be due to the loss of ten SS bone cases in the final follow up.  On the 
other hand it might be expected that any orthopaedic problems would have been brought 
to the attention of the treating clinician and sequelae consequently would have been 
reported.  
 
Reactivation has been found to increase the risk of permanent consequences 
significantly [96, 98] and in this study 7/10 cases with sequelae (which were not present 
at diagnosis) had reported reactivation of disease.   
 
The differences in rates and types of sequelae between the studies may be due to the 
length of follow up which increases the chance of finding permanent consequences. The 
median length of the final follow up was quite short (3.5 years) and as with reactivation, 
sequelae may develop long after the original diagnosis [102, 240, 242]. In a study by 
Bernstrand et al, at a median follow up time of 16 years, 42% had permanent 
consequences [97].  
 
7.8 Deaths, survival and mortality 
Three children (3.2%) with MS RO+ disease all died during the case ascertainment 
period and there were no further deaths during the follow up period.  In France, the two-
year survival rate among 258 cases was 99%, and in a Swedish study, 100% survival 
was reported in 29 cases with a median follow-up period of six years [3, 28]. In the 
Northwest of England over a 40-year period the 5-year survival rate was 71%. 
However, the rate improved over time, the 3-year survival rate (1985-1998) being 95%. 
The survival rate increased with age from 51% in those aged <1 year to 95% in those 
aged 5-15 years, those with liver or spleen disease having a higher risk [2].  In this 
study, the three children who died all had liver disease although in one case this was 
only identified microscopically post mortem. Jubran et al found that those aged <1 year 
with MS RO+ disease were at most risk of death, as was the case in this study [94]. 
Deaths over a 30 year period at GOSH and in Dublin were 13% and 21% respectively.  
Survival has improved over time due to international co-operation in clinical trials and 
implementation of treatment, and shared expertise.  
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Of the three deaths identified during the study period, only one was confirmed by ONS.  
All deaths in the UK should be registered between 5-14 days [243]. A lag in registration 
or loss may have occurred for unknown reasons although incomplete registration of 
neonatal deaths has been reported previously [244]. Anonymised deaths data from the 
RoI required further checking by the CSO.  Three deaths notified were coded with an 
ICD-9 code which can be used for conditions other than LCH.  On further examination 
of the text of the cause of death, only one of the three deaths was confirmed. (The other 
two deaths were from “Complex V mitochondrial disorder” and “Inherited defect in 
urea cycle metabolism”.) In a recent study in France, which identified LCH deaths 
based on ICD codes, it was stated that the text of the cause of death was also checked 
[168]. This underlines the importance of obtaining textual information for the cause of 
death to avoid over-reporting. 
 
In addition to the two unregistered deaths found in this survey, a further 18 deaths with 
LCH on the death certificate were identified over a 10-year period (1996-2005); all 
were under five years old. The sex ratio was 1.8:1. This is a little higher than in a study 
by Glass et al, of 270 deaths (1960-1964) of children with disseminated disease, in 
which the ratio was 1.4:1.   
 
The age-standardized mortality rate was 1.91 per 10 million per year, aged 0-14 years. 
In France, the rate was comparable, decreasing from 1.0 per million per year between 
1980-90, to 0.5 and 0.1 per million per year between 1990-99 and 1999-2005 
respectively [168].  The decrease in mortality in children was thought to be due to more 
aggressive therapy over the years. In the UK and RoI, the highest number of deaths per 
year was four in 1999. Thereafter the number dropped to one per year from 2002 which 
may be consistent with this suggestion.  In France, deaths data were obtained from the 
French national death certification centre and from the French LCH Registry. The 
difference in ASRs may be due to the different methods of ascertainment or the small 
number of cases. 
 
7.9 Limitations of the data and questionnaires 
The number of cases identified by this two-year survey was small because of the rarity 
of the disease. Consequently, this made meaningful interpretation of analyses difficult, 
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especially for follow ups.  A longer survey period would have provided a larger cohort 
for analysis although would have been costly to obtain.  In addition, the questionnaires 
varied in their completeness.  For example, data on birth weights and the patient‟s first 
consultation were missing for a third of cases thus introducing the possibility of bias.  
However, there were relatively few inconsistencies and contradictory responses were 
readily resolved.  
 
Inevitably there are aspects of the questionnaire design which could have been tackled 
differently with hindsight.  For example, small improvements in the design of the 
questionnaire using closed questions for some questions, e.g. symptoms and 
investigations, may have helped both completion and analysis. Similarly, a single closed 
question on ethnicity using 2001 census criteria (which incorporates a mixed ethnicity 
group) may have been helpful. In addition, inclusion of a simple tick box in neonatal 
history may have clarified information, e.g., about twins, since the data on the three 
known twins was volunteered not requested.   However, although there are advantages 
and disadvantages with both open and closed questions, valuable information was 
provided by clinicians in the open questions and additional text fields. 
 
The amount and type of data collected by questionnaire in this survey was limited by 
the BPSU surveillance methods, mainly because they do not allow patient consent to be 
sought (because it would introduce delay and possible reporting bias). The questionnaire 
was designed to capture sufficient information to identify cases in the survey and 
although it was hoped that the results might give some indications for future studies it 
was not designed to look for risk factors.  It was, therefore, a compromise. For example, 
the BPSU were reluctant to include questions on environmental exposures (section 
3.7.2) which have been included in the Canadian paediatric survey [46].  However, 
although it would have been of interest to collect such information, the questionnaire 
was already several pages long and the burden of completion by clinicians was a 
consideration.   
 
With hindsight it may have been wiser to have conducted a single follow up two years 
after diagnosis since one year allows too little time for sequelae to develop and to assess 
mortality, and is too short for meaningful outcomes.  With regard to the follow up  
questionnaires, a snapshot of the disease status only was obtained.  Information on 
whether patients had attained complete resolution of their disease would have been 
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desirable as the distinction between those with refractory and reactivated disease cannot 
be made nor comparisons made with other studies.  In addition, although the change in 
format of the two year follow up questionnaire was designed to prompt speedy replies 
from clinicians – a strategy described in section 7.2.1 – the information received may 
have been less informative.  A single, more detailed follow up questionnaire sent two 
years after diagnosis may have elicited better data. 
 
The results obtained have, however, generated ideas for future studies which are 
outlined in the final chapter. 
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Chapter 8. Conclusions and recommendations 
 
8.1 What the study adds 
The epidemiology of LCH is under-studied and thus any information about the disease 
may be regarded as novel.  This is the first study to report the incidence and mortality 
rates of LCH in children in the UK and Ireland.  It is also the first national study of 
incidence to have used a well-established prospective method of surveillance with 
additional sources of ascertainment, the importance of which were demonstrated.  In 
addition, the spectrum of disease among the population was described, and event-free 
survival and mortality were assessed.   
 
8.2 Summary of strengths and weaknesses 
The study benefited from using three sources of cases to maximize ascertainment, and 
although probably incomplete, it was comparable with other studies.  The study was 
particularly effective in collecting cases of SS bone disease.  The prospective method of 
ascertainment and active follow up may also have been beneficial as data on newly 
ascertained cases are readily available. However, responses from clinicians were 
incomplete in terms of both questionnaire returns and questionnaire completion. The 
difficulty in diagnosis of some cases (the longest interval was 170 weeks) may have 
contributed to the incidence being under-estimated. The study may also have failed to 
identify a small number of those with milder forms, 16-17 year olds, and possibly, very 
young cases with skin disease thereby introducing a bias in case ascertainment. The 
number of cases and incomplete questionnaire data also has implications for meaningful 
interpretation of analyses.  
 
8.3 Recommendations  
In line with other authors it is recommended that registries and incidence studies record 
all sources of cases and include estimates of completeness of ascertainment, as well as 
incidence rates, in their publications [45, 187].  Specific registers for LCH have been 
established in France, Belgium and Germany, and several other European cancer 
registries register LCH cases, as described above. It would be desirable if all UK cancer 
registries consistently recorded cases of LCH.  However, given that only one form of 
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the disease is regarded (coded) as a malignancy this seems unlikely, and thus it is 
recommended that a registry of all LCH cases in the UK should be established building 
on the work in this thesis. 
 
8.3.1 UK LCH registry  
Registries of diseases have recently come into focus in connection with concern over 
the lack of information and services for rare diseases.  The Chief Medical Officer 
(CMO) reported the urgent need for more specialists, awareness and funding for rare or 
orphan conditions (i.e., those which affect <5 per 10,000 per year) [245]. There are over 
6000 such conditions in the UK and the numbers of cases combined (estimated at three 
million) contribute significantly to morbidity and mortality in childhood.  The CMO‟s 
report included a proposal for national registers to improve surveillance, planning and 
research.  In June 2009, EU Health Ministers adopted a European Council 
Recommendation calling on Member States to develop and implement strategies for the 
treatment of rare diseases. In the light of both these recommendations, it is to be hoped 
that a national plan will emerge. 
 
In the rest of Europe the plight of those with rare diseases has been recognised for 
several years. Projects with EU/French funding such as the Orphanet database and 
Professional Encyclopedia of expert services, Eurordis, and European rare disease 
conferences, have been initiated to improve awareness of orphan drugs, research, 
policy, funding, patient associations and events.  At present,“specialised Centres of 
Reference (CR) for diagnoses or procedures of particular conditions” exist within the 
NHS, and there are also regional specialist services for genetic diseases [246]. The UK 
branch of Orphanet is based in Manchester. Rare Diseases UK, initiated by patient 
organisations of those affected by genetic disorders, has also been formed to develop 
and strengthen support for those with rare diseases.  By including LCH on these and 
other web-sites such as cure4kids, the National Organization for Rare Disorders 
(NORD) and the US National Institute of Health Office of Rare Disease Research, 
access to good quality information has become easier.  
 
In the UK, as well as the BPSU, other groups, such as the British Orphan Lung Disease 
Registry, have been established to carry out surveillance of rare diseases.  Registries for 
numerous rare conditions have also been set up, e.g., for Fanconi anaemia, Wolf-
Hirschhorn syndrome and Evans syndrome [247].   As well as describing patterns of 
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disease, registers with detailed case information can answer important questions for 
parents, such as their child‟s survival prospects, expected quality of life and 
reproductive prospects. They can also be used to develop more detailed aetiological 
epidemiology studies. 
 
A UK registry may also include HLH and other histiocytoses since the incidence of 
these related diseases is currently unknown. An additional benefit of setting up a 
registry of all histiocytoses would be the contribution to two international databases of 
LCH and associated syndromes, Euro-Histio-Net and the Rare Histiocytic Disorders 
Registry in Toronto. Given the recent dissolution of the CCLG, it is unclear how UK 
cases would otherwise be contributed. 
 
A number of adult cases of LCH were notified during this survey and it is likely that 
there are at least as many adults as children with LCH in the UK.  An adult LCH 
registry is being established in Germany but the only national incidence data currently 
available are from the Belgian LCH Registry (IR 2.2 per million per year). A UK 
registry of all histiocytic cases would provide a sufficient number of cases and a range 
of information for further childhood LCH studies and allow long-term follow up. It 
would also enable the incidence of LCH to be estimated in adults, and the patterns of 
disease to be described. There have been no population-based studies of LCH in adults 
and publications have been mainly from single specialty clinics. Most children with 
LCH are seen by paediatric oncologists and services are well-established. However, 
adults may present to many different disciplines and services are less well co-ordinated.  
As highlighted by the CMO and others, there is a need for better awareness and 
management of adults with rare diseases cases, and for adolescents making the 
transition to adult services [49, 246].   
 
Case ascertainment could be both retrospective and prospective, as in the Belgian LCH 
survey. Retrospective data collection, e.g. from 2003 (the start of this study) would 
provide a comparison with the incidence rate estimated in this study.  New cases could 
be sought prospectively based on methods and experience gained in this survey. To 
ascertain adult cases, sources could be expanded to include, for example, adult 
orthopaedic hospitals, bone tumour registries, lung transplant centres and societies of 
dermatologists and endocrinologists.  Patient identifiable data would be required to 
avoid duplication, for cross-checking or linkage with other sources and for follow up. 
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Although many registries have an exemption from NIGB, patient consent may be 
required to enable fuller data (and tissue samples for other studies) to be collected.  A 
mandatory minimum dataset for Euro-Histio-Net has been proposed but there are 
guidelines for much more extensive data collection (a form over 40 pages long).   
 
A UK registry would ensure systematic collection of standardized data which would be 
compatible with children‟s cancer registries and Euro-Histio-Net.  The objectives of the 
registry would have to be clearly established and justified since other kinds of data 
collection may suffice for different applications, e.g. ad hoc surveys, such as this study, 
or clinical trials. However, a major reason for creating any registry is to carry out long-
term follow up.  Establishment of a registry is complex. In addition to ascertainment of 
cases, consideration would need to be given to the regulatory issues of ethical approval, 
patient consent, confidentiality and data security, as well as data validation, follow up 
procedures, statistical analyses, access to medical records, dissemination of information 
and data sharing, plus continuous staffing and funding.  
 
8.3.2 Further studies 
The study has generated several ideas for future studies, assuming that larger numbers 
and more detailed information are available.  
 
Risk factors 
The two large US case-control studies, although not consistent in their findings, 
described several associations with LCH (section 2.5.1) [141, 142].  They used clinical 
notes and a 22-page questionnaire which was comprehensive in its coverage of potential 
risk factors.  It may be difficult and of limited usefulness to try to replicate these studies 
but they made other interesting observations which may warrant further investigation.  
For example, in the study by Bhatia et al, although adjusting for the higher 
socioeconomic status of the LCH cases (all parents were members of The Histiocytosis 
Association), the possibility of selection bias could not be ruled out.  Only part of the 
postcode was obtained in this study, to aid identification of cases. However, the full 
postcode would have enabled an assessment of socioeconomic status (by obtaining 
Townsend scores linked to postcodes and wards).  It is possible that lower social class 
patients are less likely to present early and may be associated with diagnostic delay and 
more advanced disease which may affect the long-term outcome [248]. Full postcode 
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data would also allow geographic factors such as urban and rural differences to be 
investigated, and with sufficient numbers and a long timescale, cluster analysis. 
 
In addition, it was noted in the study by Hamre et al that the offspring of all five 
mothers who gave birth aged over 41 years were diagnosed with disseminated disease 
under two years of age [142]. Examination of parental ages would therefore be of 
interest, as would parental occupations, smoking and other environmental factors.  It is 
notable that these factors are included in the Canadian Paediatric Surveillance of LCH 
(begun 2009) which is based on this study.   
 
Several studies have pointed to both genetic and environmental factors in the aetiology 
of LCH.  As has been suggested, an epigenetic mechanism – an environmental factor 
causing a heritable change in gene function (though not a change in DNA code) – would 
support familial cases and spontaneous regression as well as LCH being an abnormal 
immune response to an infection [146]. A large study collecting data on maternal and 
childhood illnesses and infections may be warranted, as well as data on twins and those 
conceived via ART, as mentioned in section 7.6.3.  As discussed in sections 7.6.1 and 
7.6.2,  any possible associations with seasonality and ethnicity may also be confirmed in 
with a larger cohort. 
 
Follow up studies  
The outcome of the disease is the main concern of parents of children with LCH. 
Survival data from UK clinical trials are available for those with the more severe forms 
of the disease. However, long-term follow up of all types of cases would provide more 
accurate information on co-morbidities, disease activity and permanent consequences, 
particularly since the latter events may be protracted.   
 
Quality of life studies on patients with LCH have been carried out and there is some 
expertise in this area in the UK [100, 110, 249].  Although these studies have mainly 
concentrated on physical and cognitive function and behaviour, children with LCH have 
been found to have more anxiety and depression when compared with normative data 
[249].  A large study of children in the UK remains to be carried out and could 
additionally examine the reasons why some areas of quality of life are affected in this 
patient group.  
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Since little is known about the outcome of LCH in adolescents as they move to adult 
services, a study of young adults would also be of interest. Super et al described two 
teenage cases highlighting several issues in treating adolescents, including the need for 
appropriate information, confidentiality, support groups, smoking and compliance 
[250]. Long-term follow up of this group may usefully inform parents and teenagers of 
other patients‟ experiences as well as assess clinical outcome. Data on a national scale 
would be needed as the incidence rate reported in the Northern Region was 0.3 per 
million per year, aged 15-24 years [25]. Cases could be cross-checked with the TYA 
database at the Christie Hospital in Manchester.  
 
Collaborative studies 
Collaboration with other groups, in addition to providing larger numbers for analysis, 
may also give clues to the aetiology of LCH by comparing patterns of disease.  For 
example, as referred to in section 2.5.4, for unknown reasons, the occurrence of liver 
and lung disease is much higher in South America. There are, however, reportedly 
higher rates of other lung diseases in urban areas of South America which may indicate 
ethnic or environmental differences [251, 252].  
 
In the absence of a UK registry, further studies may be conducted using data from the 
Northern Region Young Person‟s Malignancy Disease Registry (NRYPMDR), based in 
Newcastle, and other children‟s cancer registries in the UK. The NRYPMDR registered 
70 cases between 1968-2009, the Northwest registry registered 101 cases between 1954-
1998, the West Midlands registry has registered 133 cases since 1954 and the Southwest 
registry has 16 cases from 2002-2006  [2, 21, 25, 253]. There is a fifth children‟s cancer 
registry – the Yorkshire Specialist Register of Cancer in Children and Young People – 
however, only LCH cases coded as a malignancy have been registered [254]. 
 
Finally, one of the objectives of this study was that it would contribute to a wider 
investigation involving Canada and the Netherlands.  As mentioned above, a survey is 
underway in Canada and it is hoped that data will be combined in due course.
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Appendix A WHO classification of diseases (ICD-10) – LCH in relation to 
cancers, leukaemias and other haematopoietic disorders 
 
C00-C97 MALIGNANT NEOPLASMS  
C00-C75 Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, 
haematopoietic and related tissue 
C75-C81 Malignant neoplasms of ill-defined, secondary and unspecified sites; stated or presumed to be  
primary,of lymphoid, haematopoietic and related tissue; of independent (primary) multiple 
sites 
C81-C96 Malignant neoplasms of lymphoid, haematopoietic and related tissue   
C81  Hodgkin‟s Disease 
C82 Follicular [nodular] non-Hodgkin's lymphoma 
C83 Diffuse non-Hodgkin's lymphoma 
C84 Peripheral and cutaneous T-cell lymphomas 
C85 Other and unspecified types of non-Hodgkin's lymphoma 
C88 Malignant immunoproliferative diseases 
C90 Multiple myeloma and malignant plasma cell neoplasms 
C91 Lymphoid leukaemia 
C92 Myeloid leukaemia 
C93 Monocytic leukaemia 
C94 Other leukaemias of specified cell type 
C95 Leukaemia of unspecified cell type 
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic 
and related tissue 
C96.0  Letterer-Siwe disease  
C96.1  Malignant histiocytosis 
C96.2  Malignant mast cell tumour 
C96.3  True histiocytic lymphoma 
C96.7  Other specified malignant neoplasms of lymphoid, haematopoietic and related 
tissue  
C96.9  Malignant neoplasm of lymphoid, haematopoietic and related tissue, 
unspecified 
 
D00-D48 IN SITU AND BENIGN NEOPLASMS AND NEOPLASMS OF UNCERTAIN OR UNKNOWN BEHAVIOUR 
 
D50-D89 DISEASES OF THE BLOOD AND BLOOD-FORMING ORGANS AND CERTAIN DISORDERS INVOLVING THE 
IMMUNE MECHANISM   
D50-D70 Nutritional, haemolytic, aplastic anaemias; Coagulation defects, purpura, other haemorrhagic 
conditions 
D70-D77 Other diseases of blood and blood-forming organs 
D70  Agranulocytosis 
D71  Functional disorders of polymorphonuclear neutrophils  eg Chronic granulomatous  
disease 
D72 Other disorders of white blood cells eg Eosinophilia 
D73 Diseases of spleen 
D74  Methaemoglobinaemia 
D75  Other diseases of blood and blood-forming organs 
D76  Certain diseases involving lymphoreticular tissue and reticulohistiocytic 
system 
D76.0  Langerhans' cell histiocytosis, not elsewhere classified – 
             Eosinophilic granuloma; Hand-Schüller-Christian disease; Histiocytosis X 
(chronic) 
D76.1 Haemophagocytic lymphohistiocytosis 
D76.2  Haemophagocytic syndrome, infection-associated 
D76.3  Other histiocytosis syndromes; Reticulohistiocytoma; Sinus histiocytosis; 
Xanthogranuloma 
D77  Other disorders of blood and blood-forming organs in diseases classified  
 elsewhere 
D80 -D89 Certain disorders involving the immune mechanism
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Appendix B Literature research strategy 
 
A computerised search of the literature from 1950-2010 was carried out using SCOPUS, 
Medline, PubMed and ZETOC with no language restriction. In addition, selected 
medical journals, in particular, Paediatric Blood and Cancer, were reviewed as were 
abstracts of the proceedings of the annual meetings of the Histiocyte Society and 
publications by key authors in the field. 
 
Keywords included all forms of the disease – Langerhans cell histiocytosis, eosinophilic 
granuloma, Hand-Schuller-Christian disease, Letterer-Siwe disease, Histiocytosis X, 
infantile acute reticuloendotheliosis, Hashimoto–Pritzker disease and Langerhans cell 
granulomatosis. Using the link word „AND‟ keywords were searched with the following 
MESH (Medical Subject Heading) terms: classification, congenital, diagnosis, drug 
therapy, epidemiology, aetiology, genetics, history, immunology, mortality, pathology, 
physiopathology, radiotherapy, surgery, therapy, virology. Variations in spellings were 
taken into account by using free text terms as well as MESH terms. 
 
Keywords were also combined with other search terms including: child, adult, infant, 
incidence, prevalence, risk factor, follow up, morbidity, reactivation, recurrence, 
neoplasm, registries, cancer registry, treatment, sequelae, in vitro fertilisation, diabetes 
insipidus. 
 
The titles of all retrieved articles were reviewed and the full texts of relevant 
publications were obtained. Reference lists from the selected publications were checked 
for any papers of interest not previously identified.   
 
Further information, electronic reports and data were obtained from the web-sites of 
various organisations and institutions such as the Department of Health, ONS, Orphanet 
and Rare Diseases Taskforce.  
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Appendix C Methods flowchart 
 
 
 
  
Reporting 
Reporting 
Paediatricians Orange card 
cards 
 
BPSU 
Study team 
notified  
Study team 
contact specialists 
not on BPSU list 
Send clinician a LETTER 
and QUESTIONNAIRE 
Questionnaire 
returned 
Reminder 
NO 
YES 
Send Follow up 
LETTER and 
QUESTIONNAIRE 
Questionnaire 
returned 
DATA ENTRY 
Reminder 
YES 
NO 
RESULTS, 
REPORT 
DATA ENTRY 
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Appendix D BPSU response form
 
 
Professor L Parker 
Sir James Spence Institute - RVI 
Queen Victoria Road 
Newcastle-upon-Tyne 
NE1 4LP 
 
Notification of Case Reported 
 
BPSU Case Ref: LC/0506/08  Respondent Ref: 9511RU 
   
Date: 01/07/2004  Reported by:  
  Dr  
Royal United Hospital 
Coombe Park 
Bath 
BA1 3NG 
 
Please complete the result follow up section below as soon as you have the information 
requested, save this document and return it by reattaching the saved version to an email to 
Jennifer.Ellinghaus@rcpch.ac.uk or via post to the address listed above.  If you have any queries, 
please contact the BPSU Research Administrator.   
 
 
Result of Follow Up LC/0506/08       9511RU   
Please mark the appropriate box with an X: 
 
 Case confirmed (C) 
 Possible (P) 
 Already known (R) (please give source at * below) 
 Duplicate confirmed (DP) (please give previous case ref. at * below) 
 Duplicate not confirmed (DN) (please give previous case ref. at * below) 
 No case / error (E) (please give details at * below) 
 Unable to follow up (UF) (please give details at * below) 
 
* Please give details here: 
 
 
 
Any additional comments: 
 
 
 
Regards 
Jennifer Ellinghaus 
BPSU  Research Administrator 
British Paediatric Surveillance Unit 
50 Hallam Street, London W1 6DE 
Tel: 020 7323 7912 Fax: 020 7323 7901 
Email: Jennifer.Ellinghaus@rcpch.ac.uk 
 
 
 
  188 
Appendix E List of sources for compilation of Newcastle mailing list 
 
Children‟s Cancer and Leukaemia Group (formerly UK Children‟s Cancer Study 
Group) members list 
 
British Paediatric Rheumatology Group 
 
British Society for Paediatric Dermatology 
 
British Association for Paediatric Nephrology 
 
Royal College of Pathologists 
 
The Medical Directory 2000, Informa Healthcare, Informa Publishing Group 2000 
 
Irish Medical Directory, 7
th
 Edition.  Medical Information Systems 2000  
 
Hospital and institution web pages 
 
www. specialistinfo.com 
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Appendix F Letter and form used in Newcastle survey 
 
Dear Dr 
 
Surveillance of Langerhans Cell Histiocytosis (LCH) in the UK and Ireland 
 
We are carrying out the above two year study in association with the British Paediatric 
Surveillance Unit of the Royal College of Paediatrics and Child Health (RCPCH).  The 
study has been approved  by the London Multi-centre Research Ethics Committee and a 
copy of the approval letter is enclosed.  
 
We are aware that clinicians who may not be members of RCPCH may come across adults 
and children with this disease.  We would like to ascertain as many cases as possible and 
are therefore writing to ask you to inform us of any newly-diagnosed cases of Langerhans 
Cell Histiocytosis (LCH) that you have seen during 1.6.03 - 30.11.03.  I enclose a leaflet 
about the disease for your information. 
I should be very grateful if you would complete the slip at the bottom of this letter and 
return it to me in the enclosed pre-paid envelope.   If you have seen a newly-diagnosed case 
of LCH during this period, we will send you a questionnaire to obtain further details. 
 
Please do not hesitate to contact me if you have any questions about the study. If you need 
any clinical advice regarding the eligibility of a particular case for inclusion in the study, 
please contact Dr Vasanta Nanduri or Dr Kevin Windebank (telephone numbers and 
addresses are shown on the leaflet).  
 
We will contact you again in six months time. My apologies for any cross-posting. 
 
With many thanks for your help, 
Yours sincerely, 
 
 
 
Prof Louise Parker 
Professor in Paediatric Epidemiology  E-mail:louise.parker@ncl.ac.uk 
 
 
 
 
<Doctor ID> SURVEY OF LANGERHANS CELL HISTIOCYTOSIS – 1.6.03 - 30.11.03 
       
I have/have not seen a new case of LCH.      Number of definite cases 
  
             Number of probable cases           Adult cases YES/NO 
 
 
Signed: …………………………………………………………………     Date: …………………. 
 
 
Name: ………………………………………………………………………….. 
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Appendix G Letter to reporting clinicians for further information 
Dear Dr 
 
Re: Surveillance of Langerhans Cell Histiocytosis (LCH) in the United Kingdom and Ireland in 
association with the British Paediatric Surveillance Unit. 
 
Thank you for notifying a case for this study through the British Paediatric Surveillance Unit of the Royal 
College of Paediatrics and Child Health.  
 
I am now writing to gather further information about this case, using the enclosed questionnaire. I should 
be very grateful if you could complete it and return it to me in the enclosed reply paid envelope. Please 
return the questionnaire, even if there are some sections you are unable to complete.  
 
The following information is sought: 
- demographic details 
- referral pattern  
- clinical presentation and diagnosis 
 
I will not be contacting your patient or his/her family at any time. Minimum identifying information is 
sought on your patient to avoid duplication. All information provided by you will be treated in strict 
confidence. The study has been approved by the London MREC (copy of approval attached). 
 
Please do not hesitate to contact me if you have any questions about the questionnaire, or any aspect of 
the study. If you need any clinical advice regarding the eligibilityof a particular case for inclusion in the 
study please contact Dr Vasanta Nanduri or Dr Kevin Windebank (telephone numbers and addresses 
below).  
 
I am grateful to you for reporting to the BPSU and for taking the time to provide further information 
about your patient(s). I will also ensure that you are sent a copy of the final report of the study. 
 
With many thanks for your help, 
Yours sincerely 
 
 
Prof Louise Parker 
Professor in Paediatric Epidemiology 
Dept of Child Health, Sir James Spence Institute 
Royal Victoria Infirmary, Victoria Road 
Newcastle upon Tyne, NE1 4LP 
Tel: 0191 202 3037 
Email: louise.parker@ncl.ac.uk 
 
Contact details 
Dr Vasanta Nanduri 
Consultant Paediatrician and Oncologist 
Watford General Hospital 
Vicarage Road, Watford WD1 8HB 
Tel: 01923 217992 
Email:   v_nanduri@hotmail.com 
 vasanta.nanduri@whht.nhs.uk 
 
Dr Kevin Windebank 
Consultant Paediatric Oncologist and Senior Lecturer 
Dept of Child Health, Sir James Spence Institute 
Royal Victoria Infirmary, Victoria Road 
Newcastle upon Tyne, NE1 4LP 
 
Tel: 0191 202 3037 
E mail: k.p.windebank@ncl.ac.uk 
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Appendix H Questionnaire to reporting clinicians 
 
 
 
 
 
Sir James Spence Institute, Newcastle upon Tyne           
British Paediatric Surveillance Unit, London 
 
SURVEY OF LANGERHANS CELL HISTIOCYTOSIS (LCH) IN  
THE UNITED KINGDOM AND IRELAND 
 
 
 
 
 
 
For office Use 
 
 
Study Number ____________      
 
 
BPSU Number  ____________ 
 
 
Questionnaire completed by   __________________________________ 
 
 
 
Consultant in charge, if not above  ______________________________ 
 
  
 
Hospital / Institution  ________________________________________ 
 
 
 
Date of completion  __________________________________________ 
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SECTION A: PATIENT IDENTIFICATION DATA  
 
HOSPITAL NUMBER:   __/__/__/__/__/__/__/__/__/__   
NHS NUMBER:    __/__/__/__/__/__/__/__/__/__   
DATE OF BIRTH (DD / MM / YY):  ___ / ___ / ___ 
GENDER:    MALE / FEMALE  
POST CODE of current address (first half):   ___ ___ ___ ___ 
 
SECTION B: FAMILY HISTORY 
1. Country of Birth (Please tick)   2. Ethnic Origin (Please tick)  
 England       White 
 Scotland      Black - Caribbean 
 Wales       Black - African 
 Northern Ireland     Black - other 
 Irish Republic     Please specify ………………………. 
 Elsewhere      Indian   
Please specify ……………………….   Pakistani 
        Bangladeshi 
        Chinese 
        Any other ethnic group 
        Please specify ………………………. 
 
3. Parental consanguinity    Yes    No     Not known  
 
4. Associated conditions 
   
 a. Maternal history of thyroid disease  Yes    No     Not known  
   b. Family history of LCH   Yes    No     Not known  
       If yes, relationship to patient and any other relevant details  
…………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………                    
SECTION C: PREGNANCY, DELIVERY AND NEONATAL HISTORY 
 
1. Maternal health during pregnancy  
 Hypertension      
 Serious infection (requiring IV antibiotics, hospitalisation) 
 Any other medical problems, please specify………………………………………. 
………………………………………………………………………………………………. 
2. Gestational age …………………………….  
3. Birth weight …………………………….. 
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SECTION D: DIAGNOSIS 
DATE OF DIAGNOSIS (DD /MM / YY):    ___ / ___ / ___  
(Date of biopsy or of clinical/ radiological diagnosis upon which management decisions were 
based.) 
HISTOLOGY: Tissue …………………………………………..     
 H&E  S100 ATPase P.Lectin αMann CD1A Birbeck 
Positive        
Negative        
Not done        
 
 
SECTION E: REFERRAL HISTORY 
  
1. Date of 1
st
 symptom (DD/MM/YY)  ___ / ___ / ___      a. Age at 1
st
 symptom  ……… 
2. Presenting symptom(s) (e.g. rash, lump, pain, fever, ear discharge, other)              
…………………………………………………………………………………………………  
………………………………………………………………………………………………… 
………………………………………………………………………………………………… 
 
3. Date of 1
st
 visit to GP with initial symptoms  DD/MM/YY    ___ / ___ / ___ 
    Details…….………………………………………………………………………………… 
4. Date of first referral to hospital  (DD/MM/YY)  ___ / ___ / ___              Not known 
5. Date first seen in hospital (DD/MM/YY)   ___ / ___ / ___ 
6. Referred to tertiary centre    Yes      No         Not known  
    If yes, details…………………………………………………………………………………. 
7. Date seen at specialist / tertiary centre  (DD/MM/YY) ___ / ___ / ___    
8. Specialties referred to for LCH-related problems  (Please tick all boxes that apply) 
 Yes Date, if known No Not known 
Orthopaedic     
Paediatrics     
Dermatology     
Oncology     
ENT     
Ophthalmology     
Respiratory     
Endocrinology     
Other (specify)     
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SECTION F: SYSTEM/S INVOLVED AND DIAGNOSTIC PROCEDURES (PLEASE TICK ALL THAT APPLY) 
 
 At diagnosis At any time Diagnostic procedure e.g. X ray, scan, biopsy, relevant positives/negatives 
Bone 
Y N N/K Y N N/K Y N N/K DETAILS 
Skin           
Ears           
Oral mucosa           
Bone marrow           
Liver           
Spleen           
Lymph node           
Lungs           
Gut           
Diab. Insipidus           
Ant. pituitary           
Genital mucosa           
Nervous system           
Other,  specify           
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SECTION G: STATUS 
Does this child have any associated malignant disease (or has he/she had one in the past)? 
    Yes    No      Not known   
 
If yes, please specify ……………………………………………………………………….. 
 
Date of last follow up   (DD/MM/YY) ___ / ___ / ___ 
 
Status at last follow up   
 
  Alive, with no active disease      Alive, with active disease        Dead  
  
If dead, date of death (DD/MM/YY)   ___ / ___ / ___ 
 
 
Is the patient registered with UKCCSG?    Yes   No     Not known  
  
 
Any other comments you wish to make 
……………………………………………………………………………………………………………… 
 
……………………………………………………………………………………………………………… 
 
……………………………………………………………………………………………………………… 
 
……………………………………………………………………………………………………………… 
 
 
Thank you for your help 
 
Please return in the reply paid envelope provided to Prof. Louise Parker, at the address below, 
who can be contacted by email  or telephone if necessary: 
 
Email: Louise.Parker@ncl.ac.uk   Tel: 0191 202 3037 
 
Prof. Louise Parker 
Professor in Paediatric Epidemiology 
School of Clinical Medical Sciences (Child Health) 
University of Newcastle 
Sir James Spence Institute  
Royal Victoria Infirmary 
Queen Victoria Road  
Newcastle upon Tyne 
NE1 4LP 
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Appendix I Structure of the database 
 
 
 
 
Questionnaire tables are truncated.  
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Appendix J First year follow up questionnaire 
 
 
 
 
 
 
 
Sir James Spence Institute, Newcastle-upon-Tyne           
British Paediatric Surveillance Unit, London 
 
SURVEY OF LANGERHANS CELL HISTIOCYTOSIS (LCH) IN  
THE UNITED KINGDOM AND IRELAND - 1 year follow up  
 
 
 
 
 
For office Use 
 
Study Number  ____________      
 
 
BPSU Number  ____________ 
 
 
Questionnaire completed by ___________________________________ 
Consultant in charge, if not above  _______________________________ 
HOSPITAL / INSTITUTION   ______________________________________ 
Date of completion  ____________________________________________ 
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SECTION A: PATIENT IDENTIFICATION DATA  
 
1. HOSPITAL NUMBER: __/__/__/__/__/__/__/__/__/__   
2. NHS NUMBER:    __/__/__/__/__/__/__/__/__/__ 
3. DATE OF BIRTH (DD/MM /YY): ___ / ___ / ___ 
4. GENDER:   MALE / FEMALE  
5. POST CODE of current address:   ___ ___ ___  Ist 3 characters only 
 
SECTION B: CURRENT STATUS 
 
 Alive, no active disease    
 Alive, active disease   
 Active disease, on treatment  
 Dead    
If dead, date of death (DD / MM / YY): ___ / ___ /___ 
 
 
SECTION C: TREATMENT 
 
1. Wait and see     Yes      No      Not Known  
2. Curettage/surgery     Yes      No      Not Known 
3. LCH protocol     Yes      No      Not Known 
4. Other     Yes      No      Not Known 
Details………………………………………………………………………………………………………
………………………………………………………………………………….. 
 
SECTION D: SEQUELAE / PERMANENT CONSEQUENCES 
1. Diabetes insipidus:   Yes      No      Not Known   
2. Growth failure:    Yes      No      Not Known   
3. Anterior pituitary dysfunction:  
a. GH deficiency:   Yes      No      Not Known  
b. TSH deficiency:   Yes      No      Not Known  
c. FSH / LH deficiency:   Yes      No      Not Known  
d. ACTH deficiency    Yes      No      Not Known  
4. Hearing loss:    Yes      No      Not Known   
Conductive  /   Sensori-neural 
 
 
5. Ophthalmologic problems  Yes      No      Not Known 
 
If yes, specify________________________________________________ 
6. Tooth loss     Yes      No      Not Known  
 
 
7.Orthopaedic disabilities  Yes      No      Not Known 
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If yes, specify________________________________________________ 
8. Neurological consequences   Yes      No      Not Known 
 If yes, specify________________________________________________ 
9. Chronic liver disease  Yes      No      Not Known 
 If yes, specify________________________________________________ 
10.Chronic lung disease   Yes      No      Not Known 
 If yes, specify________________________________________________ 
  
Any other comments you wish to make 
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
……………………………………………… 
 
 
Thank you for your help 
 
Please return in the reply paid envelope provided to Prof. Louise Parker, at the address below, 
who can be contacted by email  or telephone if necessary :  
 
Email Louise.Parker@ncl.ac.uk Tel 0191 202 3023 
 
Prof. Louise Parker 
Professor in Paediatric Epidemiology 
Dept of Child Health 
University of Newcastle upon Tyne 
Royal Victoria Infirmary 
Queen Victoria Road  
Newcastle, NE1 4LP     
  200 
Appendix K Second year follow up questionnaire 
 
SURVEY OF LANGERHANS CELL HISTIOCYTOSIS (LCH) IN THE UK AND IRELAND - 
Follow up - 2007 
 
Consultant name Hospital name 
  
PATIENT   
Hospital Number  
NHS Number  
Date Of Birth   
Gender Male/Female 
Post Code of Current Address (First Half)  
 
 
CURRENT STATUS Please tick and give date of last follow up 
Alive, no active disease  
Alive, active disease  
Active disease, on treatment  
Dead.  If dead, date of death  
Not known  
 
TREATMENT STRATEGY Please tick 
Wait and see  
Curettage/ surgery  
LCH protocol  
Other.  Please give details  
 
 
 
 
SEQUELAE Please tick and/or circle 
Growth failure  
Anterior pituitary dysfunction Deficiency - GH    TSH    FSH/LH    ACTH 
Post pituitary dysfunction  
Hearing loss  
Ophthalmic problems  
Tooth loss  
Orthopaedic disabilities  
Neurological consequences  
Chronic liver disease  
Chronic lung disease  
 
Any other comments you wish to make: 
 
 
 
 
 
 
 
Completed by:    _________________________   Date of completion: __________ 
(if not name above) 
 
Thank you for your help 
Please return in the reply paid envelope provided to Dr Kevin Windebank, at the address below: 
School of Clinical Medical Sciences (Child Health), University of Newcastle,  
Sir James Spence Institute, Royal Victoria Infirmary, Queen Victoria Road,  
Newcastle upon Tyne  NE1 4LP  
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Appendix L Results of ascertainment using Epidat 
 
Table 1. Two sources 
 
 
Missing 
cases 
Total 
no. of 
cases CI Exhaustivity (%) 
    BPSU NCL CCLG Total 
BPSU versus NCL 14 102 91-113 67.48 56.72 - 86.06 
BPSU versus CCLG 2 86 83-89 80.03 - 86.99 97.43 
NCL versus CCLG 8 96 89-104 - 60.12 77.74 91.21 
 
 
 
 
 
Table 2. Three sources – eight models 
 
 Hypothesis 
Estimate 
of xˆ  
Estimate 
of  Nˆ  
CI 
(95.0%) 
G² df BIC 
1 A, B and C independent    2 96 93-99 15.93 3 7.81 
2 A and B independent of C  2 96 93-100 15.93 2 10.52 
3 A and C independent of B  7 101 94-109 2.32 2 -3.09 
4 B and C independent of A  1 95 93-98 14.35 2 8.94 
5 A independent of B        6 100 92-110 2.26 1 -0.45 
6 A independent of C        1 95 93-98 14.28 1 11.58 
7 B independent of C        20 114 83-145 0.00 1 -2.71 
8 A, B and C dependent      20 114 75-153 0.00 0 0.00 
 
Where A= CCLG, B= NCL, C= BPSU 
 xˆ   Estimation of the cases not notified by any registry 
  Estimation of the total cases 
 df     degrees of freedom 
 G²    Likelihood ratio statistic (goodness of fit) 
 BIC   Bayesian information criterion 
 
 
Compared with figure 4.3 (Hook and Regal) 
Models 2-4 are equivalent to two independent sources  
Models 5-7 are equivalent to two independent subsets, e.g. model 5 is subset CCLG-BPSU 
independent of subset NCL-BPSU 
 
 
 
 
 
Nˆ
  202 
Appendix M LCH cases and their inclusion in follow ups 
Case 
ID 
Sex Type of disease Date of birth 
Date of 
diagnosis 
1st Follow 
up 
2nd 
Follow 
up 
4 M SS Bone 09/10/1992 03/06/2003 Y Y 
5 M SS Bone 12/11/2002 11/06/2003 Y Y 
6 M SS Bone 04/06/1997 18/07/2003 Y Y 
7 M SMF Bone 02/12/1998 17/07/2003 Y Y 
17 M MS RO- 16/03/1994 17/09/2003 Y Y 
20 F SS Bone 27/09/1996 08/07/2003 Y Y 
21 M MS RO- 24/08/2001 10/10/2003 Y Y 
23 F SS Bone 27/01/2001 25/11/2003 Y Y 
26 M SS Lymph 09/07/1993 15/07/2003 Y Y 
28 M SS Bone 26/02/2000 08/12/2003 Y Y 
30 F MS RO- 24/05/1997 18/09/2003 Y Y 
31 M SS Bone 15/04/1995 14/10/2003 Y Y 
34 F SS Bone 05/05/1995 03/07/2003 Y Y 
38 F SS Bone 22/07/2002 27/11/2003 Y Y 
40 M SS Skin 05/11/2002 23/10/2003 Y Y 
41 F SS Bone 22/10/1997 26/01/2004 Y Y 
42 M SS Bone 27/05/1996 10/10/2003 Y Y 
43 F MS RO- 26/09/2003 23/01/2004 Y Y 
44 F MS RO+ 01/06/2003 25/02/2004 Y Y 
45 M MS RO- 26/01/1994 11/09/2003 Y Y 
46 F SS Bone 30/11/1995 15/09/2003 Y Y 
47 M SS Bone 20/08/2000 18/06/2003 Y Y 
48 F SS Bone 09/05/1993 20/01/2004 Y Y 
49 M MS RO+ 23/12/2003 27/01/2004 Dead Dead 
50 F MS RO- 08/05/2002 23/03/2004 Y Y 
51 F SS Bone 22/10/2003 11/03/2004 Y Y 
52 M SMF Bone 01/10/2002 02/05/2004 Y Y 
53 M SS Bone 10/05/1993 09/02/2004 Y Y 
55 M SS Bone 16/07/2000 21/04/2004 Y Y 
56 M SMF Bone 11/09/1994 26/03/2004 Y Y 
57 M SS Bone 19/04/2001 28/08/2003 Y 
Lost to 
FUP 
58 M SS Bone 15/01/1995 27/05/2004 Y Y 
59 M MS RO+ 26/05/2003 21/04/2004 Y Y 
61 M SS Bone 31/05/1994 10/12/2003 Y Y 
62 M MS RO+ 22/09/2002 04/06/2003 Dead Dead 
63 M MS RO- 04/04/2000 30/04/2004 Y 
Lost to 
FUP 
64 F SS Bone 01/03/1993 31/03/2004 Y 
Changed 
diagnosis 
65 F MS RO- 21/08/2003 01/04/2004 Y Y 
66 F SS Bone 25/10/1998 23/06/2004 Y Y 
67 M MS RO- 06/02/2003 07/04/2004 Y Y 
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69 M MS RO- 01/03/2002 09/07/2004 Y Y 
70 F SMF Bone 15/10/1990 04/06/2004 Y Y 
71 F SS Bone 20/10/1994 28/06/2004 Y Y 
74 M MS RO+ 03/03/2004 20/08/2004 Y Y 
75 M SMF Bone 02/02/1999 14/06/2004 Y Y 
76 M MS RO- 09/08/2003 20/08/2004 Y Y 
77 M SS Bone 09/01/2000 20/08/2004 Y 
Lost to 
FUP 
78 M MS RO- 21/01/2004 09/09/2004 Y Y 
80 F SS Bone 12/06/2003 07/05/2004 Y Y 
81 F MS RO- 07/10/2003 14/10/2004 Y Y 
82 M SS DI 26/08/1995 10/11/2004 Y Y 
85 M SS Bone 08/11/1988 15/01/2004 Y Y 
86 M SS Bone 01/03/2002 21/10/2004 Y Y 
88 M SS Bone 27/11/1994 02/02/2005 Y Y 
89 M SS Bone 25/10/2000 20/12/2004 Y Excluded 
90 M SS Bone 27/11/2003 11/01/2005 Excluded Excluded 
91 M SS Bone 29/06/1998 15/03/2005 Y Y 
92 F SS Bone 05/10/1995 09/03/2005 Y Y 
93 F MS RO+ 31/03/2004 04/01/2005 Y Y 
94 M SS Bone 12/07/1998 13/08/2003 Y 
Lost to 
FUP 
95 M SS Bone 08/02/1990 30/12/2004 Y Y 
96 M SS Bone 22/05/1995 15/09/2003 Excluded 
Lost to 
FUP 
97 M SS Bone 23/10/1997 03/03/2005 Y 
Lost to 
FUP 
98 M MS RO- 06/07/1995 15/03/2005 Y Y 
99 M MS RO+ 22/02/2004 12/01/2005 Dead Dead 
101 M SS Bone 13/12/1990 01/09/2004 Y Y 
102 M MS RO- 25/11/1995 08/02/2005 Y Y 
103 M SS Bone 04/03/1992 27/03/2004 Y Y 
104 F SS Lymph 27/02/1995 13/01/2004 Y Y 
105 M MS RO- 23/02/1999 15/04/2005 Y Y 
106 F SS Bone 02/11/1994 06/04/2005 Y Y 
107 M SS Bone 18/05/1994 29/03/2005 Y Y 
118 M SMF Bone 12/07/2000 02/12/2004 Y Y 
119 F SMF Bone 25/02/2002 06/01/2005 Y Y 
120 M SS Bone 06/01/1998 11/03/2005 Y Y 
121 M SS DI 18/07/1996 20/05/2005 Y Y 
122 M SS Bone 17/08/1992 10/05/2005 Y Y 
130 M MS RO- 05/08/1990 25/05/2005 Y Y 
131 F SMF Bone 21/03/2000 18/05/2005 Y Y 
132 F SS Skin 15/10/2004 01/12/2004 Y Y 
133 F SS Bone 11/05/2002 03/03/2005 Y Y 
135 F SS Bone 15/03/2001 21/06/2004 Y Y 
136 M SS Bone 11/05/2000 11/10/2004 Y Y 
140 F SMF Bone 23/04/2000 06/05/2005 Y Y 
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141 F SMF Bone 02/10/2001 04/05/2005 Y Y 
142 F SS Bone 06/02/1997 03/05/2005 No reply Y 
143 M SS Bone 04/10/1991 19/01/2005 Excluded 
Lost to 
FUP 
144 F SS Bone 24/10/1994 01/06/2004 Y 
Lost to 
FUP 
145 F SS Bone 29/11/1995 28/02/2005 Y 
Lost to 
FUP 
146 F SS Bone 01/03/2003 14/04/2005 Excluded 
Lost to 
FUP 
147 F SS Bone 19/03/2001 20/04/2005 Y 147 
149 F SS Bone 03/01/1997 27/05/2005 Y 149 
150 M SS Bone 19/07/1998 01/05/2004 Y 150 
151 F MS RO- 01/05/1999 24/07/2003 Y 151 
Number of cases 94 86 78 
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